AU724857C - SCARECROW gene, promoter and uses thereof - Google Patents

Description

SCARECROW GENE. PROMOTER AND USES THEREOF

This application is a continuation-in-part of co-pending Application No. 08/638,617, filed April 26, 1996, the disclosure of which is incorporated by reference in its entirety.

This invention was made with government support under grant number: GM43778 awarded by the National Institute of Health. The government may have certain rights in the invention.

1. INTRODUCTION The present invention generally relates to the SCARECROW (SCR) gene family and their promoters. The invention more particularly relates to ectopic expression of members of the SCARECROW gene family in transgenic plants to artificially modify plant structures. The invention also relates to utilization of SCARECROW promoter for tissue and organ specific expression of heterologous gene products.

2. BACKGROUND OF THE INVENTION Asymmetric cell divisions, in which a cell divides to give two daughters with different fates, play an important role in the development of all multicellular organisms. In plants, because there is no cell migration, the regulation of asymmetric cell divisions is of heightened importance in determining organ morphology. In contrast to animal embryogenesis, most plant organs are not formed during embryogenesis. Rather, cells that form the apical meristems are set aside at the shoot and root poles. These reservoirs of stem cells are considered to be the source of all post- embryonic organ development in plants. A fundamental question in developmental biology is how meristems function to generate plant organs. 2.1. ROOT DEVELOPMENT

Root organization is established during embryogenesis. This organization is propagated during postembryonic development by the root meristem. Following 5 germination, the development of the postembryonic root is a continuous process, a series of initials or stem cells continuously divide to perpetuate the pattern established in the embryonic root (Steeves & Sussex, 1972, Patterns in Plant Development. Englewood Cliffs, NJ: Prentice-Hall, Inc.). 0 Due to the organization of the Arabidopsis root it is possible to follow the fate of cells from the meristem to maturity and identify the progenitors of each cell type (Dolan et al., 1993, Development 119:71-84). The Arabidopsis root is a relatively simple and well characterized organ. 5 The radial organization of the mature tissues in the

Arabidopsis root has been likened to tree rings with the epidermis, cortex, endodermis and pericycle forming radially symmetric cell layers that surround the vascular cylinder (FIG. IA) . See also Dolan et al., 1993, Development 0 119:71-84. These mature tissues are derived from four sets of stem cells or initials: i) the columella root cap initial; ii) the pericycle/vascular initial; iii) the epidermal/lateral root cap initial; and iv) the cortex/endodermal initial (Dolan et al., 1993, Development 25 119:71-84). It has been shown that these initials undergo asymmetric divisions (Scheres et al., 1995, Development 121:53-62). The cortex/endodermal initial, for example, first divides anticlinally (in a transverse orientation) (FIG. IB) . This asymmetric division produces another initial 30 and a daughter cell. The daughter cell, in turn, expands and then divides periclinally (in the longitudinal orientation) (FIG. IB) . This second asymmetric division produces the progenitors of the endodermis and the cortex cell lineages (FIG. IB) . 35 2.2. GENES REGULATING ROOT STRUCTURE Mutations that disrupt the asymmetric divisions of the cortex/endodermal initial have been identified and characterized (Benfey et al., 1993, Development 119:57-70; Scheres et al., 1995, Development 121:53-62). short-root (shr) and scarecrow (ser) mutants are missing a cell layer between the epidermis and the pericycle. In both types of mutants the cortex/endodermal initial divides anticlinally, but the subsequent periclinal division that increases the number of cell layers does not take place (Benfey et al., 1993, Development 119:57-70; Scheres et al., 1995, Development 121:53-62) . The defect is first apparent in the embryo and it extends throughout the entire embryonic axis which includes the embryonic root and hypocotyl (Scheres et al., 1995, Development 121:53-62). This is also true for the other radial organization mutants characterized to date, suggesting that radial patterning that occurs during embryonic development may influence the post-embryonic pattern generated by the meristematic initials (Scheres et al., 1995, Development 121:53-62).

Characterization of the mutant cell layer in shr indicated that two endodermal-specific markers were absent (Benfey et al., 1993, Development 119:57-70). This provided evidence that the wild-type SHR gene may be involved in specification of endodermis identity.

2.3. GEOTROPISM In plants, the capacity for gravitropism has been correlated with the presence of amyloplast sedimentation. See, e.g., Volkmann and Sievers, 1979, Encyclopedia Plant Physiol., N.S. vol 7, pp. 573-600; Sack, 1991, Intern. Rev. Cytol. 127:193-252; Bjόrkmann, 1992, Adv. Space Res. 12:195- 201; Poff et al., in The Physiology of Tropisms, Meyerowitz & Somerville (eds); Cold Spring Harbor Laboratory Press, Plainview, NY (1994) pp. 639-664; Barlow, 1995, Plant Cell Environ. 18:951-962. Amyloplast sedimentation only occurs in cells in specific locations at distinct developmental stages. That is, when and where sedimentation occurs is precisely regulated (Sack, 1991, Intern. Rev. Cytol. 127:193-252). In roots, amyloplast sedimentation only occurs in the central (columella) cells of the rootcap; as these cells mature into peripheral cap cells, the amyloplasts no longer sediment (Sack & Kiss, 1989, Amer. J. Bot. 76:454-464; Sievers & Braun, in The Root Cap: Structure and Function. Wassail et al. (eds.), New York: M. Dekker (1996) pp. 31-49). In stems of many plants, including Arabidopsis, amyloplast sedimentation occurs in the starch sheath (endodermis) especially in elongating regions of the stem (von Guttenberg, Die Phvsioloqischen Scheiden. Handbuch der Pflanzenanatomie; K. Linsbauer (ed.), Berlin: Gebruder Borntraeger, vol. 5 (1943) p. 217; Sack, 1987, Can. J. Bot. 65:1514-1519; Sack, 1991, Intern. Rev. Cytol. 127:193-252; Caspar & Pickard, 1989, Planta 177:185-197; Volkmann et al., 1993,J. PI. Physiol. 142:710-6).

Gravitropic mutants have been studied for evidence that proves the role of amyloplast sedimentation in gravity sensing. However, many gravitropic mutations affect downstream events such as auxin sensitivity or metabolism (Masson, 1995, BioEssays 17:119-127). Other mutations seem to affect gene products that process information from gravity sensing. For example, the lazy mutants of higher plants and comparable mutants in mosses can clearly sense and respond to gravity, but the mutations reverse the normal polarity of the gravitropic response (Gaiser & Lomax, 1993, Plant Physiol. 102:339-344; Jenkins et al., 1986, Plant Cell Environ 9:637- 644) . Other mutations appear to affect gravitropism of specific organs. For example, sgr mutants have defective shoot gravitropism (Fukaki et al., 1996, Plant Physiol. 110:933-943; Fukaki et al., 1996, Plant Physiol. 110:945-955; Fukaki et al., 1996, Plant Res. 109:129-137).

Citation or identification of any reference herein shall not be construed as an admission that such reference is available as prior art to the present invention. 3. SUMMARY OF THE INVENTION The structure and function of a regulatory gene, SCARECROW (SCR) , is described. The SCR gene is expressed specifically in root progenitor tissues of embryos, and in certain tissues of roots and stems. SCR expression controls cell division of certain cell types in roots, and affects the organization of root and stem. The invention relates to the SCARECROW (SCR) gene (which encompasses the Arabidopsis SCR gene and its orthologs and paralogs) , SCR gene products, (including but not limited to transcriptional products such as mRNAs, antisense and ribozyme molecules, and translational products such as the SCR protein, polypeptides, peptides and fusion proteins related thereto) , antibodies to SCR gene products, SCR regulatory regions and the use of the foregoing to improve agronomically valuable plants.

The invention is based, in part, on the discovery, identification and cloning of the gene responsible for the scarecrow phenotype. In contrast to the prevailing view that the SCR gene was likely to be involved in the specification of endodermis, the inventors have determined that the mutant cell layer in roots of ser mutants has differentiated characteristics of both cortex and endodermis. This is consistent with a role for SCR in the regulation of the asymmetric cell division rather than in specification of the identity of either cortex or endodermis. The inventors have also determined that SCR expression affects the gravitropism of plant aerial structures such as the stem.

One aspect of the invention relates to the heterologous expression of SCR genes and related nucleotide sequences, and specifically the Arabidopsis SCR genes, in stably transformed higher plant species. Modulation of SCR expression levels can be used to advantageously modify root and aerial structures of transgenic plants and enhance the agronomic properties of such plants. Another aspect of the invention relates to the use of promoters of SCR genes, and specifically the use of Arabidopsis SCR promoter to control the expression of protein and RNA products in plants. Plant SCR promoters have a variety of uses, including but not limited to expressing heterologous genes in the embryo, root, root nodule, and stem of transformed plants. The invention is illustrated by working examples described infra which demonstrate the isolation of the Arabidopsis SCR gene using insertion mutagenesis. More specifically, T-DNA tagging of genomic and cDNA clones of the Arabidopsis SCR gene are described. Additional working examples include the isolation of SCR sequences from plant genomes using PCR amplification in combination with screening of genomic libraries, and heterologous gene expression in transgenic plants using SCR promoter expression constructs. Structural analysis of the deduced amino acid sequence of Arabidopsis SCR protein indicates that SCR encodes a transcription factor. Northern analysis, in situ hybridization analysis and enhancer trap analysis show highly localized expression of Arabidopsis SCR in embryos and roots. Genetic analysis shows SCJ? expression also affects gravitropism of aerial structures (e . g. , stems). This indicates that SCR is also expressed in those structures.

Computer analysis of the deduced amino acid sequence of Arabidopsis SCR protein with those of Expressed Sequence Tag (EST) sequences in GenBank reveals the existence of at least thirteen SCR genes in Arabidopsis, one SCR gene in maize, four SCR genes in rice, and one SCR gene in Brassica. A further aspect of the invention relates to the use of such EST sequences to obtain larger and/or complete clones of the corresponding SCR gene. The various embodiments of the claimed invention presented herein are by the way of illustration and are not meant to limit the invention.

3.1. DEFINITIONS As used herein, the terms listed below will have the meanings indicated. 35S cauliflower mosaic virus promoter for the 35S transcript

CDNA complementary DNA cis-regulatory element = A promoter sequence 5' upstream of the TATA box that confers specific regulatory response to a promoter containing such an element. A promoter may contain one or more cis- regulatory elements, each responsible for a particular regulatory response coding sequence sequence that encodes a complete or partial gene product (e .g. , a complete protein or a fragment thereof)

DNA deoxyribonucleic acid

EST expression tagged functional portion a functional portion of a promoter is any portion of a promoter that is capable of causing transcription of a linked gene sequence, e .g. , a truncated promoter

gene fusion a gene construct comprising a promoter operably linked to a heterologous gene, wherein said promoter controls the transcription of the heterologous gene gene product the RNA or protein encoded by a gene sequence gene sequence sequence that encodes a complete gene product (e . g . , a complete protein)

GUS 1,3-β-Glucuronidase gDNA genomic DNA heterologous gene = In the context of gene constructs, a heterologous gene means that the gene is linked to a promoter that said gene is not naturally linked to. The heterologous gene may or may not be from the organism contributing said promoter. The heterologous gene may encode messenger RNA (mRNA) , antisense RNA or ribozymes homologous promoter a native promoter of a gene that selectively hybridizes to the sequence of a SCR gene described herein mRNA messenger RNA operably linked A linkage between a promoter and gene sequence such that the transcription of said gene sequence is controlled by said promoter ortholog = related gene in a different plant (e . g. , maize ZCARECROW gene is an ortholog of the Arabidopsis SCR gene) paralog related gene in the same plant (e . g . , Arabidopsis SRPal is a paralog of Arabidopsis SCR gene)

RNA ribonucleic acid

RNase ribonuclease

SCR SCARECROW gene or gene product, encompasses (italic) SCR and ZCR genes and their orthologs and paralogs

SCR SCARECROW protein scr scarecrow mutant (e .g. , scrl )

(lower case) ZCR = maize ZCARECROW gene, a paralog of, for example, the Arabidopsis SCR gene

SCR protein means a protein containing sequences or a domain substantially similar to one or more motifs (i.e., Motif I-VI) , preferably MOTIF III (VHIID) , of Arabidopsis SCR protein as shown in FIGS. 13A-F and FIGS. 15A-S. SCR proteins include SCR ortholog and paralog proteins having the structure and activities described herein.

SCR polypeptides and peptides include deleted or truncated forms of the SCR protein, and fragments corresponding to the SCR motifs described herein.

SCR fusion proteins encompass proteins in which the SCR protein or an SCR polypeptide or peptide is fused to a heterologous protein, polypeptide or peptide. SCR gene, nucleotides or coding sequences means nucleotides, e.g., gDNA or cDNA encoding SCR protein, SCR polypeptides or peptides, or SCR fusion proteins.

SCR gene products include transcriptional products such as mRNAs, antisense and ribozyme molecules, as well as translational products of the SCJ? nucleotides described herein including but not limited to the SCR protein, polypeptides, peptides and/or SCR fusion proteins.

SCJ? promoter means the regulatory region native to the SCR gene in a variety of species, which promotes the organ and tissue specific pattern of SCJ? expression described herein.

4. BRIEF DESCRIPTION OF THE FIGURES FIGS. 1A-B. Schematic of Arabidopsis root anatomy.

FIG. IA. Transverse section showing the four tissues, epidermis, cortex, endodermis and pericycle that surround the vascular tissue. In the longitudinal section, the epidermal/lateral root cap initials and the cortex/endodermal initials are shown at the base of their respective cell files. FIG. IB. Schematic of division pattern of the cortex/endodermal initial. The initial expands then divides anticlinally to reproduce itself and a daughter cell. The daughter then divides periclinally to produce the progenitors of the endodermis and cortex cell lineages. Abbreviations: C, cortex; Da, daughter cell; E, endodermis; In, initial.

FIGS. 2A-F. Phenotype of scr mutant plants. FIG. 2A. Shown left to right are 12-day scr-2, scr-1 and wild-type seedlings grown vertically on nutrient agar medium. FIG. 2B. 21-day scr-2 mutant plants in soil. FIG. 2C.

Transverse section through primary root of 7-day scr-2. FIG. 2D. Transverse section through primary root of 7-day wild- type (WT) . FIG. 2E. Transverse section through lateral root of 12-day scr-1 mutant seedling. FIG. 2F. Transverse section through root regenerated from scr-l callus. Bar, 50 μm. Abbreviations: C, cortex; En, endodermis; Ep, epidermis; M, mutant cell layer; P, pericycle; V, vascular tissue. FIGS. 3A-F. Characterization of the cellular identity of the mutant cell layer. FIG. 3A. Endodermis- specific Casparian band staining of transverse sections through the primary root of 7-day scr-1 mutant. (Note: the histochemical stain also reveals xylem cells in the vascular cylinder.) FIG. 3B. Casparian band staining of transverse sections through the primary root of 7-day wild-type (WT) . FIG. 3C. Immunostaining with the endodermis (and a subset of vascular tissue) specific JIM13 monoclonal antibodies on transverse root sections of scr-2 mutant. FIG. 3D.

Immunostaining with JIM13 monoclonal antibodies on transverse root sections of WT. FIG. 3E. Immunostaining with the JIM7 monoclonal antibody that stains all cell walls on transverse root sections of scr-2 mutant. FIG. 3F. Immunostaining with JIM7 monoclonal antibodies on transverse root sections of WT. Bar, 25 μm. Abbreviations are same as those for description of FIGS. 2A-2F and: Ca, casparian strip.

FIGS. 4A-F. Immunostaining. FIG. 4A. Immunostaining with the cortex (and epidermis) specific CCRC- M2 monoclonal antibodies on transverse root sections of scr-1 mutant. FIG. 4B. Immunostaining with CCRC-M2 antibodies on transverse root sections of scr-2 mutant. FIG. 3C. Immunostaining with CCRC-M2 antibodies on transverse root sections of wild-type (WT) . FIG. 4D. Immunostaining with the CCRC-M1 monoclonal antibodies (specific to a cell wall epitope found on all cells) on transverse root sections of scr-1. FIG. 4E. Immunostaining with CCRC-M1 antibodies on transverse root sections of scr-2 . FIG. 4F. Immunostaining with CCRC-M1 antibodies on transverse root sections of WT. Bar, 30 μm. Abbreviations are same as those for description Of FIGS. 2A-2F.

FIG. 5A-E. Structure of the Arabidopsis SCARECROW gene. FIG. 5A. Nucleic acid sequence and deduced amino acid sequence of the Arabidopsis SCR genomic region (SEQ ID NO:l) and (SEQ ID N0:2), respectively. Regulatory sequences including: (i) TATA box, (ii) ATG start codon, and (iii) potential polyadenylation sequence are underlined. Within the deduced amino acid sequence homopolymeric repeats are ^•underlined. FIG. 5B. Schematic diagram of genomic clone indicating possible functional motifs, T-DNA insertion sites and subclones used as probes. Abbreviations: Q,S,P,T, region with homopolymeric repeats of these amino acids; b, region with similarity to the basic region of bZIP factors; I and II, regions with leucine heptad repeats; E, acidic region. FIG. 5C. Comparison of the charged region found in Arabidopsis SCR protein with that found in bZIP transcription factors, SCR bZIP-like domain (SEQ ID NO:3), GCN4 (SEQ ID

NO:4), TGAl (SEQ ID N0:5), C-Fos (SEQ ID NO:6), C-JUN (SEQ ID NO:7), CREB (SEQ ID NO:8), Opaque-2 (SEQ ID NO:9), OBF2 (SEQ ID NO:10), RAF-1 (SEQ ID NO:11). FIG. 5D. Translations of EST clones encoding putative peptide having similarities to the VHIID domain region of Arabidopsis SCR protein (SEQ ID NO:12), F13896 (SEQ ID N0:13), Z37192 (SEQ ID NO:14), and Z25645 (SEQ ID NO:15) are from Arabidopsis, T18310 (SEQ ID NO:17) is from maize and D41474 (SEQ ID NO:16) is from rice. FIG. 5E. The deduced amino acid sequence of the Arabidopsis SCARECROW gene (SEQ ID NO:2).

FIGS. 6A-B. Expression of the Arabidopsis SCARECROW gene. FIG. 6A. Northern blot of total RNA from wild-type siliques (Si) , roots (R) , leaves (L) and whole seedlings (Sd) hybridized with Arabidopsis SCR probe a and with a probe from the Arabidopsis glutamine dehydrogenase (GDH) gene (Melo-Oliveira et al., 1996, Proc. Natl. Acad. Sci. USA 93:4718-4723) as a control for RNA integrity. (GDH expression is lower in siliques than in vegetative tissues.) The 1.6 kb band corresponds to the GDH gene and the approximately 2.5 kb band corresponds to SCR. Ribosomal RNA is shown as a loading control. FIG. 6B. Northern blot of Arabidopsis wild-type, scr-1 and scr-2 total RNA, probed with Arabidopsis SCR probe "a" corresponding to a cDNA sequence shown in FIG. 5B, and with the GDH probe. In scr-2 mutant additional bands of 4.1 kb and 5.0 kb were detected.

FIGS. 7A-G. In situ hybridization and enhancer trap analyses of Arabidopsis SCR expression. FIG. 7A. SCR RNA expression detected by in situ hybridization of SCJ? antisense probe to a longitudinal section through the root meristem. FIG. 7B. In_ situ hybridization of SCR antisense probe to a transverse section in the meristematic region. FIG. 7C. In situ hybridization of SCJ? antisense probe to late torpedo stage embryo. FIG. 7D. Negative control in situ hybridization using a SCR sense probe to a longitudinal section through the root meristem. FIG. 7E. GUS expression in a whole mount in the enhancer trap line, ET199 in primary root tip. FIG. 7F. GUS expression in the ET199 line in transverse root section in the meristematic region. FIG. 7G. GUS expression in ET199 detected in a section through the root meristem. GUS expression is observed in the cortex/endodermal initial, and in the first cell in the endodermal cell lineage but not in the first cell of the cortex lineage. Expression in two endodermal layers is observed higher up in the root because the section was not median at that point. Bar, 50 μm. Abbreviations are same as those in the description of FIGS. 2A-2F. FIG. 8. Partial nucleotide sequence (SEQ ID NO:18) and deduced amino acid sequence (SEQ ID NO:19) of the Arabidopsis SRPa4 gene.

FIG. 9. Partial nucleotide sequence (SEQ ID NO:20) and deduced amino acid sequence (SEQ ID NO:21) of the Arabidopsis SRPa3 gene.

FIG. 10. Partial nucleotide sequence (SEQ ID NO:22) of the Arabidopsis SRPal gene.

FIG. IIA. Nucleotide sequence (SEQ ID NO:24) and deduced amino acid sequence (SEQ ID NO:25) of the maize Zm- Sell fragment.

FIG. IIB. Partial nucleotide sequence (SEQ ID NO:25) and deduced amino acid sequence (SEQ ID NO:26) of the maize SRPml gene (Zm-Scl2) .

FIG. 12A-B. Nucleotide sequence of rice SRPo3 EST clone. FIG. 12A. Sequence of 5' end of EST clone (SEQ ID N0:28) . FIG. 12B. Sequence of 3' end of EST clone (SEQ ID N0:29) . FIGS. 13A-F. Comparison of the amino acid sequence of members of the SCARECROW family of genes. Conserved Motifs I through VI are indicated by dashed line above the aligned sequences. Consensus sequences are shown in bold. See Table 1 for the identity and sequence identifier number of each of the sequences shown in this Figure. Hu-scr-1 = Human SCR paralog (SEQ ID NO:40).

FIG. 14. Restriction map of the approximately 8.8 kb Eco RI insert DNA of lambda clone, t643, containing the Arabidopsis SCR gene. The locations of the approximately 5.6 kb Hindlll-Sacl fragment subcloned in plasmid LIG l-3/SAC+MoB₂ 1SAC, and the SCJ? coding region are indicated below the restriction map. The location of the translational initiation site of the SCR gene is at the Nco I site at the left end of the indicated coding region. The SCR coding sequence begins at the translation initiation site and extends approximately 1955 nucleotides to its right. E. coli DH5α containing plasmid pLIGl-3/SAC+MoB₂ 1SAC, has the ATCC accession number 98031. FIGS. 15A-S. Comparison of the partial and complete amino acid sequences of several plant members of the SCARECROW family of genes. The amino acid sequences are aligned in a manner that maximizes amino acid sequence similarity and identity among SCR family members. Each sequence shown is continuous except where noted otherwise; the dots are inserted between two sequence segments in order to align homologous segments. "X" in the middle of a sequence indicates ambiguity in the corresponding nucleotide sequence and, possible termination of the ORF at the ^MX" residue site. "X" at the end of a sequence indicates termination of the ORF at the "X" residue site. The numbering of the amino acid residues is shown at the bottom of each figure and is based on the Arabidopsis SCR amino acid sequence. Conserved Motifs I through VI are indicated by the various dashed lines above the figures. The new and old names of the family members are shown in FIG. 15A. The sequences of SCR, Tfl and Tf4 are of the complete SCR protein. See Table l for the identity and the sequence identifier number of each sequence shown in these figures.

FIGS. 16A-M. The partial nucleotide sequences of several plant members of the SCARECROW family of genes. ^MN" indicates an unknown base. See Table 1 for the identity and the sequence identifier number of each sequence shown in these figures.

FIG. 17A. The partial nucleotide sequence (SEQ ID NO:66) of the maize ZCR gene. FIG. 17B. The partial amino acid sequence (SEQ ID

NO:67) of the maize ZCJ? gene. The underlined sequence shares approximately 80% sequence identity with a corresponding sequence of Arabidopsis SCR protein.

FIG. 18. Comparison of the partial amino acid sequences of several SCR ortholog sequences amplified from the genomes of carrot, soybean and spruce. The SRPdl and SRPpl sequences each were obtained by PCR amplification using a combination of IF and IR primers. The SRPgl sequence was obtained by PCR amplification using a combination of IF and WP primers. The amino acid sequences are aligned in a manner that maximizes amino acid sequence identity and similarity amongst these sequences. Each sequence shown is continuous except where noted otherwise; the dashes are inserted between two sequence segments in order to allow alignment of homologous segments. "x" in the middle of a sequence indicates ambiguity in the corresponding nucleotide sequence and, possible termination of the ORF or existence of an intron at the "x" residue site. See Table 1 for the identity and the sequence identifier number of each sequence shown in this figure.

FIG. 19. Comparison of promoter activities in transgenic lines and roots. Panel a. A stably transformed line containing four copies of the B2 subdomain of the 35S promoter of CaMV upstream of GUS (Benfey et al., 1990). GUS is expressed in the root tip. Panel b. Roots emerging from callus transformed with four copies of the B2 subdomain of the 35S promoter fused to GUS. GUS expression can be seen in the emerging root tips (arrows) . Panel c. Higher magnification of a root emerging from the callus in panel b. GUS is clearly restricted to the root tip. The morphology of roots regenerated from calli often appears abnormal. Panel d. A transgenic plant regenerated from the calli and roots shown in panel b. GUS expression in this plants appears to be similar to that of the original line shown in panel a. Panel e. ET199, a stably transformed line that contains an enhancer trapping construct with a minimal promoter fused to the GUS coding region inserted 1 kb upstream from the SCR coding region. GUS expression is primarily in the endodermal layer of the root. Panel f. Roots emerging from calli transformed with the SCR promoter::GUS construct. Expression of the GUS gene appears to be limited to an internal layer (arrows). Panel g. SCR promoter::GUS transformed root in liquid culture. Roots shown in panel f were excised and transferred to liquid cultures. GUS expression is primarily found in the endodermal layer as in ET199. The expression of GUS in the quiescent center, as seen here, is also sometimes observed in ET199. Bar, 50μm.

FIG. 20. Analysis of SCJ? promoter activity in the scr mutant background. Panel a. Roots emerging from scr calli transformed with the SCR promoter::GUS construct. Roots regenerated from scr calli are very short. GUS expression appears to be limited to an internal layer of the root (arrows) . Panel b. Root regenerated from transformed scr calli and transferred to liquid culture. The scr phenotype, a single layer between the epidermis and pericycle, is easily seen. GUS expression is limited to this mutant layer. E, Epidermis. M, Mutant Layer. P, Pericycle. Bar, 50μm.

FIG. 21. Molecular Complementation of the scr mutant. Panels a, c and e. scr transformed with the SCR promoter::GUS construct. Panels b, d and f. scr transformed with the SCR promoter: :SCR coding region construct. Panels a and b. Roots emerging from scr calli. Arrows point to several very short roots among many fine root hairs in the scr calli transformed with the SCR promoter: :GUS construct. In contrast, roots from scr calli transformed with the SCR promoter:: SCR coding region construct appeared to be wild-type in length, suggesting molecular complementation by the transgene. Panels c and d. Transgenic roots in liquid culture. The scr roots transformed with the SCJ? promoter::GUS construct appeared short, while those transformed with the SCR promoter::SCJ? coding region construct appeared of wild-type length. Panels e and f. Transverse sections through roots emerging from calli. Whereas there is only a single cell layer between the epidermis and stele in the SCR promoter: :GUS transformed root, the radial organization of the root transformed with the SCJ? promoter: :SCJ? coding region appeared identical to wild-type, with both cortex and endodermal layers. E, epidermis. M, mutant layer. C, cortex. En, Endodermis. P, Pericycle. Bar, 50μm

FIG. 22. Expression of ZCR in maize root tips. Left Panel. Expression of ZCR is in the endodermal layer and extends down through the region of the quiescent center. Right Panel. Higher magnification showing expression in a single cell layer through the quiescent center.

5. DETAILED DESCRIPTION OF THE INVENTION

The invention relates to the SCAJ?J?CJ?CW (SCR) gene, SCR gene products, including but not limited to transcriptional products such as mRNAs, antisense and ribozyme molecules, and translational products such as the SCR protein, polypeptides, peptides and fusion proteins related thereto; antibodies to SCR gene products; SCR regulatory regions; and the use of the foregoing to improve agronomically valuable plants.

In summary, the data described herein show the identification of SCJ?, a gene involved in the regulation of a specific asymmetric division, in controlling gravitropic response in aerial structures, and in controlling pattern formation in roots. Sequence analysis shows that the SCR protein has many hallmarks of transcription factors. In situ and marker line expression studies show that SCJ? is expressed in the cortex/endodermal initial of roots before asymmetric division occurs, and in quiescent center of regenerating roots. Together, these findings indicate that SCR gene regulates key events that establish the asymmetric division that generates separate cortex and endodermal cell lineages, and that affect tissue organization of roots. The establishment of these lineages is not required for cell differentiation to occur, because in the absence of division the resulting cell acquires mature characteristics of both cortex and endodermal cells. However, it is possible that SCR functions to establish the polarity of the initial before cell division, or that it is involved in generating an external polarity that has an effect on asymmetric cell division.

Genetic analysis indicates that SCR expression affects gravitropism of plant stems and hypocotyls. This indicates that SCR is also expressed in these aerial structures of plants.

The SCR genes and promoters of the present invention have a number of important agricultural uses. The SCR promoters of the invention may be used in expression constructs to express desired heterologous gene products in the embryo, root, root nodule, and starch sheath layer in stem of transgenic plants transformed with such constructs. For example, SCR promoters may be used to express disease resistance genes such as lysozymes, cecropins, maganins, or thionins for anti-bacterial protection or the pathogenesis- related (PR) proteins such as glucanases and chitinases for anti-fungal protection. SCR promoters also may be used to express a variety of pest resistance genes in the aforementioned plant structures and tissues. Examples of useful gene products for controlling nematodes or insects include Bacillus thuringiensis endotoxins, protease inhibitors, collagenases, chitinase, glucanases, lectins, and glycosidases.

Gene constructs that express or ectopically express SCJ?, and the SCJ?-suppression constructs of the invention may be used to alter the root and/or stem structure, and the gravitropism of aerial structures of transgenic plants. Since SCR regulates root cell divisions, overexpression of SCJ? can be used to increase division of certain cells in roots and thereby form thicker and stronger roots. Thicker and stronger roots are beneficial in preventing plant lodging. Conversely, suppression of SCR expression can be used to decrease cell division in roots and thereby form thinner roots. Thinner roots are more efficient in uptake of soil nutrients. Since SCR affects gravitropism of aerial structures, overexpression of SCR may be used to develop "straighter" transgenic plants that are less susceptible to lodging.

Further, SCR gene sequence may be used as a molecular marker for a qualitative trait, e . g . , a root or gravitropism trait, in molecular breeding of crop plants. For purposes of clarity and not by way of limitation, the invention is described in the subsections below in terms of (a) SCR genes and nucleotides; (b) SCJ? gene products; (c) antibodies to SCJ? gene products; (d) SCJ? promoters and promoter elements; (e) transgenic plants which ectopically express SCR; (f) transgenic plants in which endogenous SCR expression is suppressed; and (g) transgenic plants in which expression of a transgene of interest is controlled by SCR promoter.

5.1. SCR GENES

The SCARECROW genes and nucleotide sequences of the invention include: (a) a gene listed below in Table 1 (hereinafter, a gene comprising any one of the nucleotide sequences shown in FIG. 5A, FIG. 8, FIG. 9, FIG. 10, FIGS.

11A-B, FIGS. 12A-B, FIGS. 16A-M, or FIG. 17A, or a segment Of such nucleotide sequences) , or as contained in the clones described herein and deposited with the ATCC (see Section 13, infra) ; (b) nucleotide sequence that encodes a protein comprising any one of the amino acid sequences shown in FIG. 5A, FIG. 5D, FIG. 5E, FIG. 8, FIG. 9, FIGS. 11A-B, FIGS. 13A- F, FIGS. 15A-S, FIG. 17B or FIG. 18 or a segment of such amino acid sequences, or that is encoded by any one of the genes and/or nucleotide sequences listed by their sequence identifier numbers in Table 1, or any segment of such genes and/or nucleotide sequences, or contained in any one of the clones described herein and deposited with the ATCC (see Section 13, infra); (c) any gene comprising nucleotide sequence that hybridizes to the complement of any one of the genes and/or nucleotide sequences listed by their sequence identifier numbers in Table 1, or any segment of such genes and/or nucleotide sequences, or as contained in any one of the clones described herein and deposited with the ATCC, under highly stringent conditions, e .g. , hybridization to filter-bound DNA in 0.5 M NaHP0₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in O.lxSSC/0.1% SDS at 68°C (Ausubel F.M. et al. , eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and that encodes a gene product functionally equivalent to SCR gene product encoded completely or partly by any one of the genes and/or sequences listed in Table 1 or any segment of such genes and nucleotide sequences, or as contained in any one of the clones deposited with the ATCC; (d) any gene comprising nucleotide sequence that hybridizes to the complement of any one of the sequences listed by their sequence identifier numbers in Table 1, or any segment of such nucleotide sequences, or as contained in any one of the clones described herein and deposited with the ATCC, under less stringent conditions, such as moderately stringent conditions, e . g . , washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, supra) , and which encodes a functionally equivalent SCJ? gene product; (e) any gene comprising nucleotide sequence that hybridizes to the complement of any one of the sequences listed by their sequence identifier numbers in Table 1 or any segment of such nucleotide sequences, or as contained in any one of the clones described herein and deposited with the ATCC, under the following low stringency conditions: pre- hybridization in hybridization solution (HS) containing 43% formamide, 5xSSC, 1% SDS, 10% dextran sulfate, 0.1% sarkosyl, 2% block (Genius kit, Boehringer-Mannheim) , followed by hybridization overnight at 30 to 33°C using as a probe a DNA molecule of approximately 1.6 kb of SEQ ID NO:l at a concentration of 20 ng/ml, followed by washing in 2xSSC/0.1% SDS two times for 15 minutes at room temperature and then two times at 50°C, and which encodes a functionally equivalent SCJ? gene product; and/or (f) any gene comprising nucleotide sequence that encodes a polypeptide or protein containing the consensus sequence for SCR (i.e., MOTIF III or VHIID) shown in FIGS. 13B-D or a segment of such polypeptide or protein. The partial and complete nucleotide and amino acid sequences of SCR genes and encoded proteins and polypeptides included in the invention are listed in Table 1 below.

Table 1. SCR ORTHOLOGS AND PARALOGS

SEQ ID NOs

New Name Old Name EST Clone¹ Nucleotide³ Amino Acid

ARABIDOPSIS

SRPal 1110 Z25645/33772 22 23

SRPa2 Tf4 Z34599 — 35^*

SRPa3 3935 Z37192/1 20 21 N96166

SRPa4 4818 F13896/7 18 19

SRPaδ 4871 F13949 45 46

SRPaβ 12398 R29793 51 52

SRPa7 3635 T21627 55 56 H76979 N96767

SRPa8 Tfl T46205 (9468) — 34^* N96653 (21711)

SRPa9 10964 T78186 47 48 T44774

SRPalO 11261 T76483 49 50

SRPal 1 18652 N37425 53 54

SRPal2 23196 W43803 57 58

W435138

AA042397

SRPal3 33/08 T46008 — 41

SCR Scr N.A.² 1⁺ 2^*

RICE

SJ?Pol 713 D15490 — 43

SRPo2 2504 D40482 44 D40607 D40800 D41389

SRPo3 3989 D41474 — 36

SRPo4 11846 C20324 — 59 MAIZE

SRPJJII 18310 T18310 — 37 BRASSICA

SRPbl 174 H74669 —_ 42 Table 1. (Continued;

SEQ ID NOs

New Name Old Name Nucleotide³ Amino Acid

CARROT

SRPdl N.A. N.A. 60 61

SOYBEAN

SRPgl N.A. N.A. 62 63

SPRUCE

SRPpl N.A. N.A. 64 65

Each EST clone is identified by its GenBank accession number. Each EST clone corresponds to a deposit of a cDNA sequence that matches a part of the nucleotide sequence of the corresponding SCJ? ortholog or paralog.

N.A. = not applicable.

The partial or complete nucleotide sequence of the SCR orthologs and paralogs listed here are shown in FIGS. 5A, 8, 9, 10, 11A-B, 12A-B, 16A-M and 17A.

Contains the complete coding sequence of Arabidopsis SCR gene.

Contains the complete amino acid sequence of Arabidopsis SRPa2 , SRPa8 , or SCR protein.

Functional equivalents of the SCR gene product include any plant gene product that regulates plant embryo or root development, or, preferably, that regulates root cell division or root tissue organization, or affects gravitropism of plant aerial structures (e.g., stems and hypocotyls) . Functional equivalents of the SCR gene product include naturally occurring SCR gene products, and mutant SCJ? gene products, whether naturally occurring or engineered.

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of the nucleotide sequences (a) through (f) , in the first paragraph of this section. Such hybridization conditions may be highly stringent, less highly stringent, or low stringency as described above. In instances wherein the nucleic acid molecules are oligonucleotides ("oligos") , highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos) , and 60°C (for 23-base oligos) . These nucleic acid molecules may act as SCR antisense molecules, useful, for example, in SCR gene regulation and/or as antisense primers in amplification reactions of SCR gene and/or nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for SCR gene regulation. Still further, such molecules may be used as components in probing methods whereby the presence of a SCARECROW allele may be detected.

The invention also includes nucleic acid molecules, preferably DNA molecules, which are amplified using the polymerase chain reaction under conditions described in Section 5.1.1., infra, and that encode a gene product functionally equivalent to a SCR gene product encoded by any one of the genes and sequences listed in Table 1 or as contained in any one of the clones described herein and deposited with the ATCC.

The invention also encompasses (a) DNA vectors that contain any of the foregoing gene and/or coding sequences and/or their complements (i.e., antisense or ribozyme molecules) ; (b) DNA expression vectors that contain any of the foregoing gene and/or coding sequences operatively associated with a regulatory element that directs the expression of the gene and/or coding sequences; and (c) genetically engineered host cells that contain any of the foregoing gene and/or coding sequences operatively associated with a regulatory element that directs the expression of the gene and/or coding sequences in the host cell. As used herein, regulatory elements include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression.

The invention also encompasses nucleotide sequences that encode mutant SCJ? gene products, peptide fragments of the SCJ? gene product, truncated SCJ? gene products, and SCR fusion proteins. These gene products include, but are not limited to, nucleotide sequences encoding mutant SCR gene products; polypeptides or peptides corresponding to one or more of the Motifs I-VI as shown in FIGS. 13A-F and FIGS. 15A-S, or the bZIP, VHIID, or leucine heptad domains of the SCR, or portions of these motifs and domains; truncated SCR gene products in which one or more of the motifs or domains is deleted, e.g., a truncated, nonfunctional SCR lacking all or a portion of the Motifs I-VI as shown in FIGS. 13A-F and FIGS. 15A-S, or the bZIP, VHIID, or leucine heptad domains of the SCR. Nucleotides encoding fusion proteins may include but are not limited to full length SCR, truncated SCR or peptide fragments of SCR fused to an unrelated protein or peptide, such as for example, an enzyme, fluorescent protein, or luminescent protein which can be used as a marker.

In particular, the invention includes, for example, fragments of SCR genes encoding one or more of the following domains as shown in FIG. 5E: amino acids 1-264, 265-283, 287- 316, 410-473, 436-473, and 473-653.

In addition to the gene and/or coding sequences described above, homologous SCJ? genes, and other genes related by DNA sequence, may be identified and may be readily isolated, without undue experimentation, by molecular biological techniques well known in the art. More specifically, such homologs include, for example, paralogs (i.e., members of the SCR gene family occurring in the same plant) as well as orthologs (i.e., members of the SCR gene family which occur in a different plant species) of the Arabidopsis SCR gene.

A specific embodiment of a SCR gene and coding sequence of the invention is Arabidopsis SCR (FIGS. 5A and 5E) . Other specific embodiments include the various SCR genes and coding sequences listed in Table 1, supra . Methods for isolating SCR genes and coding sequences are described in detail in Section 5.2, below. SCR genes share substantial amino acid sequence similarities at the protein level and nucleotide sequence similarities in their encoding genes. The term "substantially similar" or "substantial similarity" when used herein with respect to two amino acid sequences means that the two sequences have at least 75% identical residues, preferably at least 85% identical residues and most preferably at least 95% identical residues. The same term when used herein with respect to two nucleotide sequences means that the two sequences have at least 70% identical residues, preferably at least 85% identical residues and most preferably at least 95% identical residues. Determining whether two sequences are substantially similar may be carried out using any methodologies known to one skilled in the art, preferably using computer assisted analysis. For example, the alignments showed herein were initially accomplished by a BLAST search (NCBI using the BLAST network server) . The final alignments of SCJ? family members were done manually. Moreover, SCR genes show highly localized expression in embryos and, particularly, roots. Such expression patterns may be ascertained by Northern hybridizations and in situ hybridizations using antisense probes.

5.1.1. ISOLATION OF SCJ? GENES

The following methods can be used to obtain SCJ? genes and coding sequences from a wide variety of plants, including but not limited to Arabidopsis thaliana , Zea mays , Nicotiana tabacum , Daucus carota , Oryza , Glycine max, Lemna gibba , and Picea abies .

Nucleotide sequences encoding an SCR gene or a portion thereof may be obtained by PCR amplification of plant genomic DNA or cDNA. Useful cDNA sources include "free" cDNA preparations (i.e., the products of cDNA synthesis) and cloned cDNA in cDNA libraries. Root cDNA preparations or libraries are particularly preferred.

The amplification may use, as the 5'-primer (i.e., forward primer) , a degenerate oligonucleotide that corresponds to a segment of a known SCR amino acid sequence, preferably from the amino-terminal region. The 3'-primer (i.e., reverse primer) may be a degenerate oligonucleotide that corresponds to a distal segment of the same known SCR amino acid sequence (i.e., carboxyl to the sequence that corresponds to the 5'-primer) . For example, the amino acid sequence of the Arabidopsis SCR protein (SEQ ID NO:2) may be used to design useful 5' and 3' primers. Preferably, the primers corresponds to segments in the Motif III or VHIID domain of SCR protein (see FIGS. 13B-D and FIGS. 15K-L) . The sequence of the optimal degenerate oligonucleotide probe corresponding to a known amino acid sequence may be determined by standard algorithms known in the art. See for example, Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Vol 2 (1989). Further, for amplification from cDNA sources, the 3'-primer may be an oligonucleotide comprising an 3' oligo(dT) sequence. The amplification may also use as primers nucleotide sequences of SCJ? genes or coding sequences (e .g. , any one of the scr sequences and EST sequences listed in Table 1) .

PCR amplification can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp") . One can choose to synthesize several different degenerate primers for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the degenerate primers and the corresponding sequences in the cDNA library. One of ordinary skill in the art will know that the appropriate amplification conditions and parameters depend, in part, on the length and base composition of the primers and that such conditions may be determined using standard formulae. Protocols for executing all PCR procedures discussed herein are well known to those skilled in the art, and may be found in references such as Gelfand, 1989, PCR Technology. Principles and Applications for DNA Amplification. H.A. Erlich, ed. , Stockton Press, New York; and Current Protocols In Molecular Biology. Vol. 2, Ch. 15, Ausubel et al., eds 1988, New York, Wiley & Sons, Inc.

A PCR amplified sequence may be molecularly cloned and sequenced. The amplified sequence may utilized as a probe to isolate genomic or cDNA clones of a SCR gene, as described below. This, in turn, will permit the determination of a SCJ? gene's complete nucleotide sequence, including its promoter, the analysis of its expression, and the production of its encoded protein, as described infra .

In a preferred embodiment, PCR amplification of SCR gene and/or coding sequences can be carried out according to the following procedure: PRIMERS:

Forward:

Name: SCR5AII (23-mer, 2 inosines, 64-mix)

A.A. code: HFTANQAI DNA Sequence: 5' CAT/C TTT/C ACI GCI AAT/C CAA/G GCN AT 3'

Name: SCR5B (29-mer, 1 inosine, 144-mix)

A.A. code: VHIID(L/F)D

DNA Sequence: 5' ACGTCTCGA GTI CAT/C ATA/C/T ATA/C/T GAT/C TTN GA 3'

Name: IF

A.A. code: LQCAEAV

DNA Sequence: (T/C)TI CA(A/G) TG(T/C GCI GA(A/G) GCN GT

Reverse:

Name: SCR3AII (23-mer, 2 inosines, 128-mix)

A.A. code: PGGPP(H/N/K) (V/L/F)R' DNA Sequence: 5' CG/T CCA/C GTG/T TGG IGG ICC NCC NGG 3'

Name: IR

A.A. code: AFQVFNGI

DNA Sequence: AT ICC (A/G)TT (A/G)AA IAC (C/T)TG (A/G)AA NGC

Name: 4R

A.A. code: QWPGLFHI

DNA Sequence: AT (A/G)TG (A/G)AA IA(A/G) NCC IGG CCA (C/T)TG

I = inosine N = A/C/G/T

Useful primer combinations include the following: SCR5AII+SCR3AII; SCR5B+SCR3AII; IF+IR; and IF+4R

PCR:

Reaction mixture (volume 50 μl) :

-5 μl 10X amplification buffer containing Mg (Boehringer-

Mannheim) -1 μl 10 mM dNTP's

-1 μl forward primer (stock concentration: 80 pmol/μl) -1 μl reverse primer (80 pmol/μl) -DNA (100-300 ng) .

Begin reaction with "hot start" in which the enzyme is added to the mix only after a brief denaturation at a high temperature (80°C)

Cycles: 94°C 30 sec - brief denaturation (to prevent non-specific priming)

80°C 5 min - apply the enzyme to the tubes (30 tubes/round at maximum)

94°C 5 min - thorough denaturation

2 times: 94°C 1 min

64°C 5 min 72°C 2 min

2 times: 94°C 1 min 62°C 5 min 72°C 2 min 2 times: 94°C 1 min 60°C 5 min 72°C 2 min

(reduce the annealing temperature 2°C in every second round), until 44°C is reached after that:

40 times: 94°C 20 sec 48°C l min 72°C 2 min finally, let cool down to 15°C.

A SCR gene coding sequence may also be isolated by screening a plant genomic or cDNA library using a SCR nucleotide sequence (e.g., the sequence of any of the SCR genes and sequences and EST clone sequences listed in Table 1.) as hybridization probe. For example, the whole or a segment of the Arabidopsis SCJ? nucleotide sequence (FIG. 5A) may be used. Alternatively, a SCJ? gene may be isolated from such libraries using as probe a degenerate oligonucleotide that corresponds to a segment of a SCR amino acid sequence. For example, degenerate oligonucleotide probe corresponding to a segment of the Arabidopsis SCR amino acid sequence (FIG. 5E) may be used. In preparation of cDNA libraries, total RNA is isolated from plant tissues, preferably roots. Poly(A)+ RNA is isolated from the total RNA, and cDNA prepared from the poly(A)+ RNA, all using standard procedures. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual. 2d ed., Vol. 2 (1989). The cDNAs may be synthesized with a restriction enzyme site at their 3'-ends by using an appropriate primer and further have linkers or adaptors attached at their 5'-ends to facilitate the insertion of the cDNAs into suitable cDNA cloning vectors. Alternatively, adaptors or linkers may be attached to the cDNAs after the completion of cDNA synthesis. In preparation of genomic libraries, plant DNA is isolated and fragments are generated, some of which will encode parts of the whole SCR protein. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis, column chromatography and sucrose gradient centrifugation.

The genomic DNA or cDNA fragments can be inserted into suitable vectors, including but not limited to, plasmids, cosmids, bacteriophages lambda or T₄, and yeast artificial chromosome (YAC) [See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual. 2d ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); Glover, D.M(ed.), DNA Cloning: A Practical Approach. MRL Press, Ltd., Oxford, U.K., Vols. I and II (1985)].

The SCJ? nucleotide probe, DNA or RNA, should be at least 17 nucleotides, preferably at least 26 nucleotides, and most preferably at least 50 nucleotides in length. The nucleotide probe is hybridized under moderate stringency conditions and washed under moderate, preferably high stringency conditions. Clones in libraries with insert DNA having substantial homology to the SCR probe will hybridize to the probe. Hybridization of the nucleotide probe to genomic or cDNA libraries is carried out using methods known in the art. One of ordinary skill in the art will know that the appropriate hybridization and wash conditions depend on the length and base composition of the probe and that such conditions may be determined using standard formulae. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Vol. 2, (1989) pp 11.45-11.57 and 15.55- 15.57.

The identity of a cloned or amplified SCR gene sequence can be verified by comparing the amino acid sequences of its three open reading frames with the amino acid sequence of a SCR gene (e.g., Arabidopsis SCR protein [SEQ ID No:2]). A SCR gene or coding sequence encodes a protein or polypeptide whose amino acid sequence is substantially similar to that of a SCR protein or polypeptide (e.g., the amino acid sequence of any one of the SCR proteins and/or polypeptides shown in FIG. 5A, 5E, FIG. 8, FIG. 9, FIGS. 11A-B, FIGS. 15A-S, FIG. 17B and FIG. 18). The identity of the cloned or amplified SCR gene sequence may be further verified by examining its expression pattern, which should show highly localized expression in the embryo and/or root of the plant from which the SCR gene sequence was isolated.

Comparison of the amino acid sequences encoded by a cloned or amplified sequence may reveal that it does not contain the entire SCJ? gene or its promoter. In such a case the cloned or amplified SCR gene sequence may be used as a probe to screen a genomic library for clones having inserts that overlap the cloned or amplified SCR gene sequence. A complete SCR gene and its promoter may be reconstructed by splicing the overlapping SCJ? gene sequences.

5.1.2. EXPRESSION OF SCR GENE PRODUCTS

SCR proteins, polypeptides and peptide fragments, mutated, truncated or deleted forms of SCR and/or SCR fusion proteins can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in assays, the identification of other cellular gene products involved in regulation of root development; etc. SCR translational products include, but are not limited to those proteins and polypeptides encoded by the SCR gene sequences described in Section 5.1, above. The invention encompasses proteins that are functionally equivalent to the SCR gene products described in Section 5.1. Such a SCR gene product may contain one or more deletions, additions or substitutions of SCR amino acid residues within the amino adid sequence encoded by any one of the SCJ? gene sequences described, above, in Section 5.1, but which result in a silent change, thus producing a functionally equivalent SCR gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylaianine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. "Functionally equivalent", as utilized herein, refers to a protein capable of exhibiting a substantially similar in vivo activity as the endogenous SCJ? gene products encoded by the SCR gene sequences described in Section 5.1, above. Alternatively, "functionally equivalent" may refer to peptides capable of regulating gene expression in a manner substantially similar to the way in which the corresponding portion of the endogenous SCR gene product would.

The invention also encompasses mutant SCR proteins and polypeptides that agree not functionally equivalent to the gene products described in Section 5.1. Such a mutant SCR protein or polypeptide may contain one or more deletions, additions or substitutions of SCR amino acid residues within the amino acid sequence encoded by any one the SCR gene sequences described above in Section 5.1., and which result in loss of one or more functions of the SCR protein (e.g., recognition of a specific nucleic sequence, binding of an transcription factor, etc.), thus producing a SCJ? gene product not functionally equivalent to the wild-type SCR ^• protein.

While random mutations can be made to SCJ? DNA (using random mutagenesis techniques well known to those skilled in the art) and the resulting mutant SCRs tested for activity, site-directed mutations of the SCR gene and/or coding sequence can be engineered (using site-directed mutagenesis techniques well known to those skilled in the art) to generate mutant SCRs with increased function, (e.g., resulting in improved root formation) , or decreased function (e.g., resulting in suboptimal root function). In particular, mutated SCR proteins in which any of the domains shown in FIGS. 13A-F are deleted or mutated are within the scope of the invention. Additionally, peptides corresponding to one or more domains of the SCR (e.g., shown in FIGS. 13A- F) , truncated or deleted SCRs, as well as fusion proteins in which the full length SCR, a SCR polypeptide or peptide fused to an unrelated protein are also within the scope of the invention and can be designed on the basis of the SCR nucleotide and SCR amino acid sequences disclosed in Section 5.1. above.

While the SCR polypeptides and peptides can be chemically synthesized (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co. , N.Y.) large polypeptides derived from SCR and the full length SCR may advantageously be produced by recombinant DNA technology using techniques well known to those skilled in the art for expressing nucleic acid sequences.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing SCR protein coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Sambrook et al., 1989, supra, and Ausubel et al., 1989, supra . Alternatively, RNA capable of encoding SCR protein sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed. , IRL Press, Oxford. A variety of host-expression vector systems may be utilized to express the SCR gene products of the invention. Such host-expression systems represent vehicles by which the SCJ? gene products of interest may be produced and subsequently recovered and/or purified from the culture or plant (using purification methods well known to those skilled in the art) , but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the SCR protein of the invention in situ . These include but are not limited to microorganisms such as bacteria (e.g., E. coli , B . subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing SCR protein coding sequences; yeast (e.g., Saccharomyces , Pichia ) transformed with recombinant yeast expression vectors containing the SCR protein coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the SCR protein coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing SCJ? protein coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter; the cytomegalovirus promoter/enhancer; etc.) .

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the SCR protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not 5 limited, to the E. coli expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the SCR coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-

10 3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503- 5509) ; and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with gluta¬ thione S-transferase (GST) . In general, such fusion proteins are soluble and can easily be purified from lysed cells by

15 adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene protein can be released from the GST moiety.

20 In one such embodiment of a bacterial system, full length cDNA sequences are appended with in-frame Bam HI sites at the amino terminus and Eco RI sites at the carboxyl terminus using standard PCR methodologies (Innis et al. , 1990, supra) and ligated into the pGEX-2TK vector (Pharmacia,

25 Uppsala, Sweden) . The resulting cDNA construct contains a kinase recognition site at the amino terminus for radioactive labelling and glutathione S-transferase sequences at the carboxyl terminus for affinity purification (Nilsson, et al., 1985, EMBO J. 4: 1075; Zabeau and Stanley, 1982, EMBO J. 1:

30 1217.

The recombinant constructs of the present invention may include a selectable marker for propagation of the construct. For example, a construct to be propagated in bacteria preferably contains an antibiotic resistance gene,

35 such as one that confers resistance to kanamycin, tetracycline, streptomycin, or chloramphenicol. Suitable vectors for propagating the construct include plasmids, cosmids, bacteriophages or viruses, to name but a few.

In addition, the recombinant constructs may include plant-expressible, selectable, or screenable marker genes for isolating, identifying or tracking plant cells transformed by these constructs. Selectable markers include, but are not limited to, genes that confer antibiotic resistance, (e.g., resistance to kanamycin or hygromycin) or herbicide resistance (e.g., resistance to sulfonylurea, phosphinothricin, or glyphosate) . screenable markers include, but are not be limited to, genes encoding β- glucuronidase (Jefferson, 1987, Plant Mol. Biol. Rep. 5:387- 405), luciferase (Ow et al., 1986, Science 234:856-859), B protein that regulates anthocyanin pigment production (Goff et al., 1990, EMBO J 9:2517-2522).

In embodiments of the present invention which utilize the Agrobacterium tumefacien system for transforming plants (see infra) , the recombinant constructs may additionally comprise at least the right T-DNA border sequences flanking the DNA sequences to be transformed into the plant cell. Alternatively, the recombinant constructs may comprise the right and left T-DNA border sequences flanking the DNA sequence. The proper design and construction of such T-DNA based transformation vectors are well known to those skilled in the art.

5.1.3. ANTIBODIES TO SCR PROTEINS AND POLYPEPTIDES Antibodies that specifically recognize one or more epitopes of SCR, or epitopes of conserved variants of SCR, or peptide fragments of the SCR are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs) , humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. For the production of antibodies, various host animals may be immunized by injection with the SCR protein, an SCR peptide (e.g., one corresponding to a functional domain of the protein) , a truncated SCR polypeptide (SCR in which one or more domains has been deleted) , functional equivalents of the SCR protein, or mutants of the SCR protein. Such SCR proteins, polypeptides, peptides or fusion proteins can be prepared and obtained as described in Section 5.1.2. supra . Host animals may include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete) , mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum . Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals. Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (Nature 256:495-497 [1975]; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al. , 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77- 96) . Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo . Production of high titers of mAbs in vivo makes this the presently preferred method of production. In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452- 454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

In addition, techniques have been developed for the production of humanized antibodies. (See, e.g., Queen, U.S. Patent No. 5,585,089.) An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarily determining regions (CDRs) . The extent of the framework' region and CDRs have been precisely defined (see, "Sequences of Proteins of Immunological Interest", Kabat, E. et al., U.S. Department of Health and Human

Services (1983) . Briefly, humanized antibodies are antibody molecules from non-human species having one or more CDRs from the non-human species and a framework region from a human immunoglobulin molecule. Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against SCR proteins or polypeptides. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a SCR protein and/or polypeptide can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" SCR, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5) :437-444; and Nissinoff, 1991, J. Immunol. 147(8) :2429-2438) .

5.1.4. SCR GENE OR GENE PRODUCTS AS

MARKERS FOR QUALITATIVE TRAIT LOCI

Any of the nucleotide sequences (including EST clone sequences) described in §§ 5.1 and 5.1.1. and/or listed in Table 1, and/or polypeptides and proteins described in §§ 5.1.2. and/or listed in Table 1, can be used as markers for qualitative trait loci in breeding programs for crop plants. To this end, the nucleic acid molecules, including but not limited to full length SCR coding sequences, and/or partial sequences (ESTs) , can be used in hybridization and/or DNA amplification assays to identify the endogenous SCR genes, scr mutant alleles and/or SCR expression products in cultivars as compared to wild-type plants. They can also be used as markers for linkage analysis of qualitative trait loci. It is also possible that the SCR gene may encode a product responsible for a qualitative trait that is desirable in a crop breeding program. Alternatively, the SCR protein, peptides and/or antibodies can be used as reagents in immunoassays to detect expression of the SCR gene in cultivars and wild-type plants. 5.2. SCR PROMOTERS

According to the present invention, SCJ? promoters and functional portions thereof described herein refer to regions of the SCR gene which are capable of promoting tissue-specific expression in embryos and/or roots of an operably linked coding sequence in plants. The SCR promoter described herein refers to the regulatory elements of SCR genes, i .e . , regulatory regions of genes which are capable of selectively hybridizing to the nucleic acids described in Section 5.1, or regulatory sequences contained, for example, in the region between the translational start site of the Arabidopsis SCJ? gene and the Hindlll site approximately 2.5 kb upstream of the site in plasmid pLIGl-3/SAC+Mob21SAC (see FIGS. 5A and 14) in hybridization assays, or which are homologous by sequence analysis (containing a span of 10 or more nucleotides in which at least 50 percent of the nucleotides are identical to the sequences presented herein) . Homologous nucleotide sequences refer to nucleotide sequences including, but not limited to, SCR promoters in diverse plant species (e.g., promoters of orthologs of Arabidopsis SCR) as well as genetically engineered derivatives of the promoters described herein.

Methods which could be used for the synthesis, isolation, molecular cloning, characterization and manipulation of SCJ? promoter sequences are well known to those skilled in the art. See, e.g., the techniques described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd. ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1989). According to the present invention, SCR promoter sequences or portions thereof described herein may be obtained from appropriate plant or mammalian sources from cell lines or recombinant DNA constructs containing SCR promoter sequences, and/or by chemical synthetic methods. SCR promoter sequences can be obtained from genomic clones containing sequences 5' upstream of SCJ? coding sequences. Such 5' upstream clones may be obtained by screening genomic libraries using SCR protein coding sequences, particularly those encoding SCR N-terminal sequences, from SCR gene clones obtained as described in Sections 5.1. and 5.2. Standard methods that may used in such screening include, for example, the method set forth in Benton & Davis, 1977, Science 196:180 for bacteriophage libraries; and Grunstein & Hogness, 1975, Proc. Nat. Acad. Sci. U.S.A. 72:3961-3965 for plasmid libraries.

The full extent and location of SCR promoters within such 5' upstream clones may be determined by the functional assay described below. In the event a 5' upstream clone does not contain the entire SCR promoter as determined by the functional assay, the insert DNA of the clone may be used to isolate genomic clones containing sequences further 5' upstream of the SCR coding sequences. Such further upstream sequences can be spliced on to existing 5' upstream sequences and the reconstructed 5' upstream region tested for functionality as a SCR promoter (i.e., promoting tissue- specific expression in embryos and/or roots of an operably linked gene in plants) . This process may be repeat until the complete SCR promoter is obtained.

The location of the SCJ? promoter within genomic sequences 5' upstream of the SCR gene isolated as described above may be determined using any method known in the art. For example, the 3'-end of the promoter may be identified by locating the transcription initiation site, which may be determined by methods such as RNase protection (e.g., Liang et al., 1989, J. Biol. Chem. 264:14486-14498), primer extension (e.g., Weissenborn & Larson, 1992, J. Biol. Chem. 267:6122-6131), and/or reverse transcriptase/PCR. The location of the 3'-end of the promoter may be confirmed by sequencing and computer analysis, examining for the canonical AGGA or TATA boxes of promoters that are typically 50-60 base pairs (bp) and 25-35 bp 5'-upstream of the transcription initiation site. The 5'-end promoter may be defined by deleting sequences from the 5'-end of the promoter containing fragment, constructing a transcriptional or translational fusion of the resected fragment and a reporter gene, and examining the expression characteristics of the chimeric gene in transgenic plants. Reporter genes that may be used to such ends include, but are not limited to, GUS, CAT, luciferase, /3-galactosidase and Cl and R gene controlling anthocyanin production.

According to the present invention, a SCR promoter is one that confers to an operably linked gene in a transgenic plant tissue-specific expression in roots, root nodules, stems and/or embryos. A SCJ? promoter comprises the region between about -5,000 bp and +1 bp upstream of the transcription initiation site of SCR gene. In a particular embodiment, the Arabidopsis SCJ? promoter comprises the region between positions -2.5 kb and +1 in the 5' upstream region of the Arabidopsis SCR gene (see FIGS. 5A and 14).

5.2.1. CIS-REGULATORY ELEMENTS OF SCR PROMOTERS According to the present invention, the cis- regulatory elements within a SCR promoter may be identified using any method known in the art. For example, the location of cis-regulatory elements within an inducible promoter may be identified using methods such as DNase or chemical footprinting (e.g., Meier et al., 1991, Plant Cell 3:309-315) or gel retardation (e.g., Weissenborn & Larson, 1992, J. Biol. Chem. 267-6122-6131; Beato, 1989, Cell 56:335-344; Johnson et al., 1989, Ann. Rev. Biochem. 58:799-839). Additionally, resectioning experiments may also be employed to define the location of the cis-regulatory elements. For example, an inducible promoter-containing fragment may be resected from either the 5' or 3'-end using restriction enzyme or exonuclease digests.

To determine the location of cis-regulatory elements within the sequence containing the inducible promoter, the 5'- or 3'-resected fragments, internal fragments to the inducible promoter containing sequence, or inducible promoter fragments containing sequences identified by footprinting or gel retardation experiments may be fused to the 5'-end of a truncated plant promoter, and the activity of the chimeric promoter in transgenic plant examined. Useful truncated promoters to these ends comprise sequences starting at or about the transcription initiation site and extending to no more than 150 bp 5' upstream. These truncated promoters generally are inactive or are only minimally active. Examples of such truncated plant promoters may include, among others, a "minimal" CaMV 35S promoter whose 5' end terminates at position -46 bp with respect to the transcription initiation site (Skriver et al. , Proc. Natl. Acad. Sci. USA 88:7266-7270); the truncated "-90 35S" promoter in the X-GUS-90 vector (Benfey & Chua, 1989, Science 244:174-181); a truncated "-101 nos" promoter derived from the nopaline synthase promoter (Aryan et al., 1991, Mol. Gen. Genet. 225:65-71); and the truncated maize Adh-1 promoter in pADcat 2 (Ellis et al. , 1987, EMBO J. 6:11-16).

According to the present invention, a cis- regulatory element of a SCR promoter is a sequence that confers to a truncated promoter tissue-specific expression in embryos, stems, root nodules and/or roots.

5.2.2. SCR PROMOTER-DRIVEN EXPRESSION VECTORS The properties of the nucleic acid sequences are varied as are the genetic structures of various potential host plant cells. In the preferred embodiments of the present invention, described herein, a number of features which an artisan may recognize as not being absolutely essential, but clearly advantageous are used. These include methods of isolation, synthesis or construction of gene constructs, the manipulation of the gene constructs to be introduced into plant cells, certain features of the gene constructs, and certain features of the vectors associated with the gene constructs.

Further, the gene constructs of the present invention may be encoded on DNA or RNA molecules. According to the present invention, it is preferred that the desired, stable genotypic change of the target plant be effected through genomic integration of exogenously introduced nucleic acid construct(s) , particularly recombinant DNA constructs. Nonetheless, according to the present invention, such genotypic changes can also be effected by the introduction of episomes (DNA or RNA) that can replicate autonomously and that are somatically and germinally stable. Where the introduced nucleic acid constructs comprise RNA, plant transformation or gene expression from such constructs may proceed through a DNA intermediate produced by reverse transcription.

The present invention provides for use of recombinant DNA constructs which contain tissue-specific and developmental-specific promoter fragments and functional portions thereof. As used herein, a functional portion of a SCR promoter is capable of functioning as a tissue-specific promoter in the embryo, stem, root nodule and/or root of a plant. The functionality of such sequences can be readily established by any method known in the art. Such methods include, for example, constructing expression vectors with such sequences and determining whether they confer tissue- specific expression in the embryo, stem, root nodule and/or root to an operably linked gene. In a particular embodiment, the invention provides for the use of the Arabidopsis SCR promoter contained in the sequences depicted in FIGS. 5A and 14 and the insert DNA of plasmid pGEX-2TK⁺.

The SCR promoters of the invention may be used to direct the expression of any desired protein, or to direct the expression of a RNA product, including, but not limited to, an "antisense" RNA or ribozyme. Such recombinant constructs generally comprise a native SCR promoter or a recombinant SCJ? promoter derived therefrom, ligated to the nucleic acid sequence encoding a desired heterologous gene product.

A recombinant SCJ? promoter is used herein to refer to a promoter that comprises a functional portion of a native SCR promoter or a promoter that contains native promoter sequences that is modified by a regulatory element from a SCR

- AA - promoter. Alternatively, a recombinant inducible promoter derived from the scr promoter may be a chimeric promoter, comprising a full-length or truncated plant promoter modified by the attachment of one or more SCR cis-regulatory elements. The manner of chimeric promoter constructions may be any well known in the art. For examples of approaches that can be used in such constructions, see Section 5.1.2., above and Fluhr et al., 1986, Science 232:1106-1112; Ellis et al., 1987, EMBO J. 6:11-16; Strittmatter & Chua, 1987, Proc. Natl. Acad. Sci. USA 84:8986-8990; Poulsen & Chua, 1988, Mol. Gen. Genet. 214:16-23; Comai et al., 1991, Plant Mol. Biol. 15:373-381; Aryan et al., 1991, Mol. Gen. Genet. 225:65-71.

According to the present invention, where a SCJ? promoter or a recombinant SCJ? promoter is used to express a desired protein, the DNA construct is designed so that the protein coding sequence is ligated in phase with the translational initiation codon downstream of the promoter. Where the promoter fragment is missing 5'leader sequences, a DNA fragment encoding both the protein and its 5' RNA leader sequence is ligated immediately downstream of the transcription initiation site. Alternatively, an unrelated 5' RNA leader sequence may be used to bridge the promoter and the protein coding sequence. In such instances, the design should be such that the protein coding sequence is ligated in phase with the initiation codon present in the leader sequence, or ligated such that no initiation codon is interposed between the transcription initiation site and the first methionine codon of the protein.

Further, it may be desirable to include additional DNA sequences in the protein expression constructs. Examples of additional DNA sequences include, but are not limited to, those encoding: a 3' untranslated region; a transcription termination and polyadenylation signal; an intron; a signal peptide (which facilitates the secretion of the protein) ; or a transit peptide (which targets the protein to a particular cellular compartment such as the nucleus, chloroplast, mitochondria, or vacuole) . 5.3. PRODUCTION OF TRANSGENIC PLANTS AND PLANT CELLS

According to the present invention, a desirable plant or plant cell may be obtained by transforming a plant cell with the nucleic acid constructs described herein. In some instances, it may be desirable to engineer a plant or plant cell with several different gene constructs. Such engineering may be accomplished by transforming a plant or plant cell with all of the desired gene constructs 0 simultaneously. Alternatively, the engineering may be carried out sequentially. That is, transforming with one gene construct, obtaining the desired transformant after selection and screening, transforming the transformant with a second gene construct, and so on. 5 In an embodiment of the present invention, Agrobacterium is employed to introduce the gene constructs into plants. Such transformations preferably use binary Agrobacterium T-DNA vectors (Bevan, 1984, Nuc. Acid Res. 12:8711-8721), and the co-cultivation procedure (Horsch et 0 al., 1985, Science 227:1229-1231). Generally, the Agrobacterium transformation system is used to engineer dicotyledonous plants (Bevan et al., 1982, Ann. Rev. Genet. 16:357-384; Rogers et al., 1986, Methods Enzymol. 118:627- 641) . The Agrobacterium transformation system may also be 5 used to transform, as well as transfer, DNA to monocotyledonous plants and plant cells (see Hernalsteen et al., 1984, EMBO J 3:3039-3041; Hooykass-Van Slogteren et al., 1984, Nature 311:763-764; Grimsley et al., 1987, Nature 325:1677-179; Boulton et al., 1989, Plant Mol. Biol. 12:31-

30 40.; Gould et al., 1991, Plant Physiol. 95:426-434).

In other embodiments, various alternative methods for introducing recombinant nucleic acid constructs into plants and plant cells may also be utilized. These other methods are particularly useful where the target is a

35 monocotyledonous plant or plant cell. Alternative gene transfer and transformation methods include, but are not limited to, protoplast transformation through calcium-, polyethylene glycol (PEG)- or electroporation-mediated uptake of naked DNA (see Paszkowski et al., 1984, EMBO J 3:2717- 2722, Potrykus et al., 1985, Mol. Gen. Genet. 199:169-177; Fromm et al., 1985, Proc. Natl. Acad. Sci. USA 82:5824-5828; Shimamoto, 1989, Nature 338:274-276), and electroporation of plant tissues (D'Halluin et al., 1992, Plant Cell 4:1495- 1505) . Additional methods for plant cell transformation include microinjection, silicon carbide mediated DNA uptake (Kaeppler et al., 1990, Plant Cell Reporter 9:415-418), and microprojectile bombardment (see Klein et al., 1988, Proc. Natl. Acad. Sci. USA 85:4305-4309; Gordon-Kamm et al. , 1990, Plant Cell 2:603-618).

According to the present invention, a wide variety of plants may be engineered for the desired physiological and agronomic characteristics described herein using the nucleic acid constructs of the instant invention and the various transformation methods mentioned above. In preferred embodiments, target plants for engineering include, but are not limited to, crop plants such as maize, wheat, rice, soybean, tomato, tobacco, carrots, peanut, potato, sugar beets, sunflower, yam, Arabidopsis, rape seed, and petunia; and trees such as spruce.

According to the present invention, desired plants and plant cells may be obtained by engineering the gene constructs described herein into a variety of plant cell types, including but not limited to, protoplasts, tissue culture cells, tissue and organ explants, pollen, embryos as well as whole plants. In an embodiment of the present invention, the engineered plant material is selected or screened for transformants (i.e., those that have incorporated or integrated the introduced gene construct(s) ) following the approaches and methods described below. An isolated transformant may then be regenerated into a plant. Alternatively, the engineered plant material may be regenerated into a plant, or plantlet, before subjecting the derived plant, or plantlet, to selection or screening for the marker gene traits. Procedures for regenerating plants from plant cells, tissues or organs, either before or after selecting or screening for marker gene(s) , are well known to those skilled in the art.

A transformed plant cell, callus, tissue or plant may be identified and isolated by selecting or screening the engineered plant material for traits encoded by the marker genes present on the transforming DNA. For instance, selection may be performed by growing the engineered plant material on media containing inhibitory amounts of the antibiotic or herbicide to which the transforming marker gene construct confers resistance. Further, transformed plants and plant cells may also be identified by screening for the activities of any visible marker genes (e.g., the β- glucuronidase, luciferase, B or Cl genes) that may be present on the recombinant nucleic acid constructs of the present invention. Such selection and screening methodologies are well known to those skilled in the art.

Physical and biochemical methods may also be used to identify a plant or plant cell transformant containing the gene constructs of the present invention. These methods include but are not limited to: 1) Southern analysis or PCR amplification for detecting and determining the structure of the recombinant DNA insert; 2) Northern blot, S-l RNase protection, primer-extension or reverse transeriptase-PCR amplification for detecting and examining RNA transcripts of the gene constructs; 3) enzymatic assays for detecting enzyme or ribozyme activity, where such gene products are encoded by the gene construct; 4) protein gel electrophoresis, western blot techniques, immunoprecipitation, or enzyme-linked immunoassays, where the gene construct products are proteins; 5) biochemical measurements of compounds produced as a consequence of the expression of the introduced gene constructs. Additional techniques, such as in situ hybridization, enzyme staining, and immunostaining, may also be used to detect the presence or expression of the recombinant construct in specific plant organs and tissues. The methods for doing all these assays are well known to those skilled in the art.

5.3.1. TRANSGENIC PLANTS THAT ECTOPICALLY

EXPRESS SCJ?

5

In accordance to the present invention, a plant that expresses a recombinant SCR gene may be engineered by transforming a plant cell with a gene construct comprising a plant promoter operably associated with a sequence encoding SCR protein or a fragment thereof. (Operably associated is used herein to mean that transcription controlled by the "associated" promoter would produce a functional messenger RNA, whose translation would produce the enzyme.) The plant promoter may be constitutive or inducible. Useful

„_ constitutive promoters include, but are not limited to, the CaMV 35S promoter, the T-DNA mannopine synthetase promoter, and their various derivatives. Useful inducible promoters include but are not limited to the promoters of ribulose bisphosphate carboxylase (RUBISCO) genes, chlorophyll a/b binding protein (CAB) genes, heat shock genes, the defense responsive gene (e.g., phenylaianine ammonia lyase genes), wound induced genes (e.g., hydroxyproline rich cell wall protein genes), chemically-inducible genes (e.g., nitrate reductase genes, gluconase genes, chitinase genes, PR-1 genes etc . ) , dark-inducible genes (e.g., asparagine synthetase gene (Coruzzi and Tsai, U.S. Patent 5,256,558, October 26, 1993, Gene Encoding Plant Asparagine Synthetase) developmentally regulated genes (e.g., Shoot Meristemless gene) to name just a few.

«_ In yet another embodiment of the present invention, it may be advantageous to transform a plant with a gene construct operably linking a modified or artificial promoter to a sequence encoding SCR protein or a fragment thereof. Typically, such promoters, constructed by recombining

₃₅ structural elements of different promoters, have unique expression patterns and/or levels not found in natural promoters. See, e .g . , Salina et al., 1992, Plant Cell 4:1485-1493, for examples of artificial promoters constructed from combining cis-regulatory elements with a promoter core.

In a preferred embodiment of the present invention, the associated promoter is a strong and root, root nodule, stem and/or embryo-specific plant promoter such that the SCR protein is overexpressed in the transgenic plant. Examples of root- and root nodules-specific promoters include but are not limited to the promoters of SCR genes, SJfJ? genes, legehemoglobin genes, nodulin genes and root-specific glutamine synthetase genes (See e .g. , Tingey et al., 1987, EMBO J. 6:1-9; Edwards et al., 1990, Proc. Nat. Acad. Sci. USA 87:3459-3463) .

In yet another preferred embodiment of the present invention, the overexpression of SCR protein in roots may be engineered by increasing the copy number of the SCR gene. One approach to producing such transgenic plants is to transform with nucleic acid constructs that contain multiple copies of the complete SCR gene (i.e., with its own native scr promoter) . Another approach is repeatedly transform successive generations of a plant line with one or more copies of the complete SCR gene. Yet another approach is to place a complete SCJ? gene in a nucleic acid construct containing an amplification-selectable marker (ASM) gene such as the glutamine synthetase or dihydrofolate reductase gene. Cells transformed with such constructs is subjected to culturing regimes that select cell lines with increased copies of complete SCR gene. See , e . g . , Donn et al., 1984, J. Mol. Appl. Genet. 2:549-562, for a selection protocol used to isolate of a plant cell line containing amplified copies of the GS gene. Because the desired gene is closely linked to the ASM, cell lines that amplified the ASM gene are also likely to have amplified the SCR gene. Cell lines with amplified copies of the SCR gene can then be regenerated into transgenic plants. 5.3.2. TRANSGENIC PLANTS THAT SUPPRESS ENDOGENOUS SCR EXPRESSION

In accordance with the present invention, a desired plant may be engineered by suppressing SCR activity. In one embodiment, the suppression may be engineered by transforming a plant with a gene construct encoding an antisense RNA or ribozyme complementary to a segment or the whole of SCR RNA transcript, including the mature target mRNA. In another embodiment, SCR gene suppression may be engineered by transforming a plant cell with a gene construct encoding a ribozyme that cleaves the SCR mRNA transcript. Alternatively, the plant can be engineered, e .g. , via targeted homologous recombination to inactive or "knock-out" expression of the plant's endogenous SCR. For all of the aforementioned suppression constructs, it is preferred that such gene constructs express specifically in the root, root nodule, stem and/or embryo tissues. Alternatively, it may be preferred to have the suppression constructs expressed constitutively. Thus, constitutive promoters, such as the nopaline, CaMV 35S promoter, may also be used to express the suppression constructs. A most preferred promoter for these suppression constructs is a SCJ? or SHR promoter.

In accordance with the present invention, desired plants with suppressed target gene expression may also be engineered by transforming a plant cell with a co-suppression construct. A co-suppression construct comprises a functional promoter operatively associated with a complete or partial SCJ? gene sequence. It is preferred that the operatively associated promoter be a strong, constitutive promoter, such as the CaMV 35S promoter. Alternatively, the co-suppression construct promoter can be one that expresses with the same tissue and developmental specificity as the scr gene.

According to the present invention, it is preferred that the co-suppression construct encodes a incomplete SCR mRNA, although a construct encoding a fully functional SCR mRNA or enzyme may also be useful in effecting co- suppression.

In accordance with the present invention, desired plants with suppressed target gene expression may also be engineered by transforming a plant cell with a construct that can effect site-directed mutagenesis of the SCR gene. (See, e.g., Offringa et al., 1990, EMBO J. 9:3077-84; and Kanevskii et al., 1990, Dokl. Akad. Nauk. SSSR 312:1505-1507) for discussions of nucleic constructs for effecting site-directed mutagenesis of target genes in plants.) It is preferred that such constructs effect suppression of SCJ? gene by replacing the endogenous SCR gene sequence through homologous recombination with none or inactive SCR protein coding sequence.

5.3.3. TRANSGENIC PLANTS THAT EXPRESS A

TRANSGENE CONTROLLED BY THE SCR PROMOTER

In accordance with the present invention, a desired plant may be engineered to express a gene of interest under the control of the SCJ? promoter. SCJ? promoters and functional portions thereof refer to regions of the nucleic acid sequence which are capable of promoting tissue-specific transcription of an operably linked gene of interest in the embryo, stem, root nodule and/or root of a plant. The SCR promoter described herein refers to the regulatory elements of SCJ? genes as described in Section 5.2.

Genes that may be beneficially expressed in the roots and/or root nodules of plants include genes involved in nitrogen fixation or cytokines or auxins, or genes which regulate growth, or growth of roots. In addition, genes encoding proteins that confer on plants herbicide, salt, or pest resistance may bt engineered for root specific expression. The nutritional value of root crops may also be enhanced through SCJ? promoter driven expression of nutritional proteins. Alternatively, therapeutically useful proteins may be expressed specifically in root crops. Genes that may be beneficially expressed in the stems of plants include those involved in starch lignin or cellulose biosynthesis. _

In accordance with the present invention, desired plants which express a heterologous gene of interest under the control of the SCR promoter may be engineered by transforming a plant cell with SCR promoter driven constructs using those techniques described in Section 5.2.2. and 5.3., supra .

5.3.4. SCREENING OF TRANSFORMED PLANTS FOR THOSE HAVING DESIRED ALTERED TRAITS

It will be recognized by those skilled in the art that in order to obtain transgenic plants having the desired engineered traits, screening of transformed plants (i.e., those having an gene construct of the invention) having those traits may be required. For example, where the plants have been engineered for ectopic overexpression of SCR gene, transformed plants are examined for those expressing the SCR gene at the desired level and in the desired tissues and developmental stages. Where the plants have been engineered for suppression of the SCR gene product, transformed plants are examined for those expressing the SCJ? gene product (e.g., RNA or protein) at reduced levels in various tissues. The plants exhibiting the desired physiological changes, e.g., ectopic SCJ? overexpression or SCR suppression, may then be subsequently screened for those plants that have the desired structural changes at the plant level (e.g., transgenic plants with overexpression or suppression of SCR gene having the desired altered root structure) . The same principle applies to obtaining transgenic plants having tissue-specific expression of a heterologous gene in embryos and/or roots by the use of a SCJ? promoter driven expression construct.

Alternatively, the transformed plants may be directly screened for those exhibiting the desired structural and functional changes. In one embodiment, such screening may be for the size, length or pattern of the root of the transformed plants. In another embodiment, the screening of the transformed plants may be for altered gravitropism or decreased susceptibility to lodging. In other embodiments, the screening of the transformed plants may be for improved agronomic characteristics (e.g., faster growth, greater vegetative or reproductive yields, or improved protein contents, etc.), as compared to unengineered progenitor plants, when cultivated under various growth conditions (e.g., soils or media containing different amount of nutrients, water content) .

According to the present invention, plants engineered with SCR overexpression may exhibit improved vigorous growth characteristics when cultivated under conditions where large and thicker roots are advantageous. Plants engineered for SCJ? suppression may exhibit improved vigorous growth characteristics when cultivated under conditions where thinner roots are advantageous.

Engineered plants and plant lines possessing such improved agronomic characteristics may be identified by examining any of following parameters: 1) the rate of growth, measured in terms of rate of increase in fresh or dry weight; 2) vegetative yield of the mature plant, in terms of fresh or dry weight; 3) the seed or fruit yield; 4) the seed or fruit weight; 5) the total nitrogen content of the plant; 6) the total nitrogen content of the fruit or seed; 7) the free amino acid content of the plant; 8) the free amino acid content of the fruit or seed; 9) the total protein content of the plant; and 10) the total protein content of the fruit or seed. The procedures and methods for examining these parameters are well known to those skilled in the art.

According to the present invention, a desired plant is one that exhibits improvement over the control plant (i.e., progenitor plant) in one or more of the aforementioned parameters. In an embodiment, a desired plant is one that shows at least 5% increase over the control plant in at least one parameter. In a preferred embodiment, a desired plant is one that shows at least 20% increase over the control plant in at least one parameter. Most preferred is a plant that shows at least 50% increase in at least one parameter.

6. EXAMPLE 1: ARABIDOPSIS SCR GENE This example describes the cloning and structure of the Arabidopsis SCR gene and its expression. The deduced amino acid sequence of the Arabidopsis SCR gene product contains a number of potential functional domains similar to those found in transcription factors. Closely related sequences have been found in both dicots and monocots indicating that Arabidopsis SCR is a member of a new protein family. The expression pattern of the SCR gene was characterized by means of in situ hybridization and by an enhancer trap insertion upstream of the SCR gene (described in more detail in Section 7) . The expression pattern is consistent with a key role for Arabidopsis SCR in regulating the asymmetric division of the cortex/endodermis initial which is essential for generating the radial organization of the root.

6.1. MATERIALS AND METHODS

6.1.1. PLANT CULTURE Arabidopsis ecotypes Wassilewskija (Ws) , Columbia (Col) , and Landsberg erecta (Ler) were obtained from Lehle. Arabidopsis seeds were surface sterilized and grown as described previously (Benfey et al., 1993, Development 119:57-70). Generation of the enhancer trap lines is described in Section 7.

6.1.2. GENETIC ANALYSIS

For the scr-1 allele, co-segregation of the mutant phenotype and kanamycin resistance conferred by the inserted T-DNA was determined as described previously (Aeschbacher et al., 1995, Genes & Development 9:330-340). Because kanamycin affects root growth, 1557 seeds from heterozygous lines were germinated on non-selective media, scored for the appearance of the mutant phenotype, and subsequently transferred to selective media. All (284) phenotypically mutant seedlings showed resistance to the antibiotic, whereas 834 of 1273 phenotypically wild-type seedlings showed resistance to kanamycin, respectively. Phenotypically wild type plants (83) were also transferred to soil and allowed to set seeds. The progeny of these plants were plated on selective and non- selective media, and scored for the co-segregation of the mutant phenotype and antibiotic resistance. A majority (48) of the plants segregated for the mutant phenotype and for kanamycin resistance, whereas 35 were wild-type and sensitive to kanamycin. Due to a mis-identified cross, scr-2 was originally thought to be non-allelic and was named pinocchio (Scheres et al., 1995, Development 121:53-62). Subsequent mapping results placed it in an identical chromosomal location as scr-1. The original scr-2 line contained at least two T-DNA inserts. Co-segregation analysis revealed a lack of linkage between the antibiotic resistance marker carried by the T-DNA and the mutant phenotype. Antibiotic sensitive lines were identified that segregated for mutants. These lines were crossed to scr-1. All Fl antibiotic resistant progeny exhibited a mutant phenotype. All F2 progeny (from independent lines) were mutant, and there was a 3:1 segregation for antibiotic resistance indicating that the two mutations were allelic. Antibiotic sensitive lines of scr-2 were found to contain a rearranged T-DNA insert as determined by Southern blots and PCR using T-DNA specific probes and primers respectively. The presence of this T-DNA in the SCJ? gene was confirmed by Southern blots using SCJ? probes. A combination of T-DNA and SCJ? specific primers was used to amplify T-DNA/SCJ? junctions. The PCR fragments were cloned using the TA cloning kit (Invitrogen) and sequenced. The insertion points were determined for both 5' and 3' T- DNA/SCJ? junctions. 6.1.3. MAPPING

Mutant plants of scr-2 (WS background) were crossed to Col WT. DNA from mutant F2 individual plants were analyzed for co-segregation with microsatellite (Bell & 5 Ecker, 1994, Genomics 18:137-144) and CAPS markers (Konieczny & Ausubel, 1993, Plant J. 4:403-410). The closest linkage was found to two CAPS markers located at the bottom of chromosome III. Only one out of 238 mutant chromosomes was recombinant for the BGL1 marker (Konieczny & Ausubel, 1993,

10 Plant J. 4:403-410) and one out of 210 chromosomes was recombinant for the cdc2b marker.

A RFLP for the SCR gene was identified between Col and Ler ecotypes with Xho I endonuclease. Genomic DNAs from independent Rl lines (Jarvis et al., 1994, Plant Mol. Biol.

15 24:685-687) were digested with Xho I and blots were hybridized to SCR. Using the segregation data obtained for 25 Rl lines, the SCR gene was mapped relative to molecular markers by CLUSTER. The SCR gene was assigned to the bottom of chromosome III closest to BGL1.

20

6.1.4. PHENOTYPIC ANALYSIS

Morphological characterization of the mutant roots was performed as follows: 7 to 14 days post-germination phenotypically mutant seedlings were fixed in 4.0%

25 formaldehyde in PIPES buffer pH 7.2. After fixation the samples were dehydrated in ethanol followed by infiltration with Historesin (Jung-Leica, Heidelberg, Germany) . Plastic sections were mounted on superfrost slides (Fisher) . The sections were either stained with 0.05% toluidine blue and

30 photographed using Kodak 160T film or used for Casparian strip detection or antibody staining.

Casparian strip detection was performed as described previously (Scheres et al., 1995, Development 121:53-62), with the following modifications. Plastic

35 sections were used and the counterstaining was done in 0.1% aniline blue for 5 to 15 min. The sections were visualized with a Leitz fluorescent microscope with FITC filter. Pictures were taken using a Leitz camera attached to the microscope and Kodak HC400 film. Slides were digitized with a Nikon slide scanner and_ manipulated in Adobe Photoshop.

For antibody staining, sections were blocked for 2 hours at room temperature in 1% BSA in PBS containing 0.1% Tween 20 (PBT) . Samples were incubated with primary antibodies at 4° C in 1% BSA in PBT overnight, and then washed 3 times 5 minutes each with PBT. Samples were incubated for two hours with biotinylated secondary antibodies (Vector Laboratories) in PBT, and washed as above. Samples were incubated with Texas Red conjugated avidin D for 2 hours at room temperature, washed as before, and mounted in Citifluor. Immunofluorescence was observed with a fluorescent microscope equipped with a Rhodamine filter. Staining with the CCRC antibodies was performed as described previously (Freshour et al., 1996, Plant Physiol. 110:1413- 1429) .

6.1.5. MOLECULAR TECHNIQUES Genomic DNA preparation was performed using the

Elu-Quik kit (Schleicher & Schuell) protocol. Radioactive and non-radioactive DNA probes were labeled with either random primed labeling or PCR-mediated synthesis according to the Genius kit manual (Boehringer Mannheim) . E . coli and AgroJbaσteriujn tumefaciens cells were transformed using a BIO- RAD gene pulser. Plasmid DNA was purified using the alkaline lysis method (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York:Cold Spring Harbor Laboratory, 1982) . A probe made from a rescued fragment of 1.2 kb was used to screen a wild-type genomic library made from WS plants. One genomic clone containing an insert of approximately 23 kb was isolated. A 3.0 kb Sac I fragment from the genomic clone, which hybridized to the 1.2 kb probe, was subcloned and sequenced (FIG. 5A) . Comparison of the nucleotide sequence between the genomic clone and the rescued plasmid revealed the site of the T-DNA insertion. Approximately 600,000 plaques from a cDNA library, obtained from inflorescences and siliques (Col ecotype) , and therefore enriched in embryos, were screened with the 1.2 kb probe. Four cDNA clones were isolated. The dideoxy sequencing method was performed using the Sequenase kit (United States Biochemical Corp.). Sequence-specific internal primers were synthesized and used to sequence the Sac I genomic as well the cDNA clones. Total RNA from plant tissues was obtained using phenol/chloroform extractions as described in (Berry et al., 1985, Mol. Cell. Biol. 5:2238-2246) with minor modifications. Northern hybridization and detection were performed according to the Genius kit manual (Boehringer Mannheim) .

To identify the site of insertion of the enhancer- trap T-DNA, genomic DNA from ET199 homozygous plants was amplified using primers specific for the T-DNA left border and the SCR gene. An approximately 2.0 kb fragment was amplified. This fragment was sequenced and the site of insertion was found to be approximately 1 kb from the ATG start codon.

6.1.6. IN SITU HYBRIDIZATION

Antisense and sense SCR riboprobes were labeled with digoxigenin-ll-UTP (Boehringer Mannheim) using T7 polymerase following the manufacturer's protocol. Probes contained a 1.1 kb 3' portion of the cDNA. Probe purification, hydrolysis and quantification were performed as described in the Boehringer Mannheim Genius System user's guide. Tissue samples were fixed in 4 % formaldehyde overnight at 4°C and rinsed two times in PBS (Jackson et al., 1991, PI. Cell 3:115-125). They were subsequently pre- embedded in 1 % agarose in PBS. The fixed tissue was dehydrated in ethanol, cleared in Hemo-De (Fisher Scientific, Pittsburgh, PA) and embedded in ParaplastPlus (Fisher

Scientific) . Tissue sections (lOμm thick) were mounted on SuperfrostPlus slides (Fisher Scientific) . Section pretreatment and hybridization were performed according to (Lincoln et al., 1994, Plant Cell 6:1859-1876) except that proteinase K was used at 30 mg/ml and a two hour prehybridization step was included. Probe concentration of 50 ng/ml/kb was used in the hybridization.

Slides were washed and the immunological detection was performed according to (Coen et al., 1990, Cell 63:1311- 1322) with the following modifications. Slides were first washed 5 h in 5xSSC, 50% formamide. After RNase treatment slides were rinsed three times (20 min each) in the buffer (0.5 M NaCl, 10 mM Tris-HCI pH 8.0, 5.0 mM EDTA). In the immunological detection, antibody was diluted 1:1000, levamisole (240 ng/ml) was included in the detection buffer, and after stopping the reaction in 10 mM Tris, 1 mM EDTA, sections were mounted directly to Aqua-Poly/Mount (Polysciences, Warrington, PA) .

6.2. RESULTS

6.2.1. CHARACTERIZATION OF THE SCJ? PHENOTYPE The scarecrow mutant scr-1 was isolated in a screen of T-DNA transformed Arabidopsis lines (Feldmann, K.A. , 1991, Plant J. 1:71-82), as a seedling with greatly reduced root length compared to wild-type (Scheres et al., 1995, Development 121:53-62) . A second mutant scr-2 with a similar phenotype was subsequently identified among T-DNA transformed lines. Analysis of co-segregation between the mutant phenotype and antibiotic resistance carried by the T-DNA indicated tight linkage for scr-1 and no linkage for scr-2 (see Experimental Procedures) . An antibiotic sensitive line of scr-2 was isolated and crossed with scr-1 . The F2 progeny of this cross were all mutant and segregated 3:1 for antibiotic resistance confirming allelism (see Materials & Methods) . The principal phenotypic difference between the two alleles was that scr-1 root growth was more retarded than that of scr-2 , suggesting that it is the stronger allele (FIG. 2A) . For both alleles the aerial organs appeared similar to wild-type and the flowers were fertile (FIGS. 2A and 2B) . The progeny of backcrosses of scr-1 or scr-2 to wild-type plants segregated 3:1 for the root phenotype for both alleles, indicating that each mutation is monogenic and recessive. Analysis of transverse sections through the primary root of seedlings revealed only a single cell layer between the epidermis and the pericycle (FIG. 2C) instead of the normal radial organization consisting of cortex and endodermis (FIG. 2D) . This radial organization defect was not limited to the primary root, but was also present in secondary roots (FIG. 2E) and in roots regenerated from calli (FIG. 2F) . Occasionally defects were observed in the number of cells in the remaining cell layer (more than the invariant 8 found in wild-type) . Abnormal placement or numbers of epidermal cells were also observed (see FIG. 2E) . These abnormalities were more frequently observed in scr-l than in scr-2. Nevertheless, organization of the mutant root closely resembles that of wild-type except for the consistent reduction in the number of cell layers. Because the endodermis and cortex are normally generated by an asymmetric division of the cortex/endodermal initial, this indicates that the primary defect in scr is disruption of this asymmetric division.

It has been shown that the radial organization defect in scr-1 first appears in the developing embryo at the early torpedo stage and manifests itself as a failure of the embryonic ground tissue to undergo the asymmetric division into cortex and endodermis (Scheres et al., 1995, Development 121:53-62). This defect extends the length of the embryonic axis which encompasses the embryonic root and hypocotyl.

Other embryonic tissues appear similar to wild-type (Scheres et al., 1995, Development 121:53-62). In seedling hypocotyls of the scarecrow phenotype, two cell layers instead of the normal three layers (two cortex and one endodermis) between epidermis and stele were found. This would be the expected result of the lack of the division of the embryonic ground tissue. Similar results were obtained for scr-2. Hence, this mutant identifies a gene involved in the asymmetric division that produces cortex and endodermis from ground tissue in the embryonic root and hypocotyl and from the cortex/endodermal initials in primary and secondary roots.

6.2.2. CHARACTERIZATION OF CELL IDENTITY IN SCR ROOTS

To understand the role of the Arabidopsis SCR gene in regulating this asymmetric division, it was necessary to determine the identity of the mutant cell layer. Tissue- specific markers were used to distinguish between several possibilities. The cell layer could have differentiated attributes of either cortex or endodermis. Alternatively, it could have an undifferentiated, initial-cell identity or it could have a chimeric identity with differentiated attributes of both endodermis and cortex in the same cell.

Transverse sections of scr-1 and scr-2 roots were assayed for the presence of tissue-specific markers. The casparian strip, a deposition of suberin between radial cell walls, is specific to the endodermal cells and is believed to act as a barrier to the entry of solutes into the vasculature (Esau, K. Anatomy of Seed Plants, New York: John Wiley & Sons, 1977, Ed. 2, pp. 1-550). Histochemical staining revealed the presence of a casparian strip in the mutant cell layer (FIG. 3A, compare to wild-type, FIG. 3B) . It is noted that in the vascular cylinder, this histochemical stain also reveals the presence of lignin, indicating the presence of differentiated xylem cells in mutant (FIG. 3A) and wild-type (FIG. 3B) . Another marker of the differentiated endodermis is the arabinogalactan epitope recognized by the monoclonal antibody, JIM13 (Knox et al., 1990, Planta 181:512-521). The mutant cell layer showed staining with this antibody (FIG. 3C, compare with wild-type, FIG. 3B) . As a positive control, the JIM7 antibody that recognizes pectin epitopes in all cell walls was used (FIGS. 3E and 3F) . These results indicate that the cell layer between the epidermis and the pericycle has differentiated attributes of the endodermis. As a marker for the cortex, the CCRC-M2 monoclonal antibody was used. This antibody recognizes a cell wall oligosaccharide epitope, found only on differentiated cortex and epidermis cells. In sections from the differentiation zone of scr-1 and scr-2 , both cortex and epidermal cells showed staining (FIG. 4A and 4B) that was similar to that of wild-type (FIG. 4C) . In scr-1 , staining of both cell types was apparent, but staining of cortex was somewhat weaker than wild-type. The positive control used the CCRC-M1 monoclonal antibody which recognizes an oligosaccharide epitope found on all cells (FIGS. 4D-F) .

With the CCRC-M2 antibody an interesting difference was observed between the staining pattern of the mutants as compared to wild-type. The appearance of this epitope correlates with differentiation in these two cell types. Normally, in sections close to the root tip there is no staining. In sections higher up in the root, atrichoblasts (epidermal cells that do not make root hairs) stain. In sections from more mature root tissue, all epidermal cells as well as cortex cells stain for this epitope. In both scr-1 and scr-2 , sections could be found in which all epidermal cells stained while there was little detectable staining of cortex cells. Although not precisely identical to the wild- type staining pattern, the fact that the mutant cell layer clearly stains for this cortex marker indicates that there are cortex differentiated attributes expressed in these cells.

Taken together, these results indicate that the mutant cell layer has differentiated attributes of both the endodermis and cortex. The possibility that there has been a simple deletion of a cell type, or that the resulting cell type remains in an undifferentiated initial-like stage can be ruled out. This result is consistent with a role for the scr gene in regulating this asymmetric division rather than a role in directing cell specification. 6.2.3. MOLECULAR CLONING OF THE SCR GENE To further elucidate the function of the Arabidopsis SCR gene the inserted T-DNA sequences were used to clone the gene. Plant DNA flanking the insertion site was obtained from scr-1 by plasmid rescue and used to isolate the corresponding wild-type genomic DNA. Several cDNA clones were isolated from a library made from silique tissue. Comparison of the sequence of the longest cDNA and the corresponding genomic region revealed an open reading frame (ORF) interrupted by a single small intron. (FIG. 5A) . A potential TATA box and polyadenylation signal that matched the consensus sequences for plant genes were also identified (Joshi, C.P., 1987, Nucl. Acids Res. 15:6643-6653); Heidecker & Messing, 1986, Ann. Rev. Plant Physiol. 37:439-466); Mogen et al., 1990, Plant Cell 2:1261-1272).

Comparison of the nucleotide sequence between the genomic clone and the rescued plasmid placed the site of the T-DNA insertion in scr-1 at codon 470 (FIGS. 5A and 5B) . For scr-2, although no linkage was found between the mutant phenotype and antibiotic resistance, DNA blot and PCR analysis of antibiotic sensitive lines revealed the presence of T-DNA sequences that co-segregated with the mutant phenotype. The insertion position in scr-2 was determined by cloning and sequencing the PCR products amplified from its genomic DNA using a combination of T-DNA and SCR specific primers at both sides of the insertion (FIG. 5B) . In scr-2 the T-DNA insertion point is at codon 605 (FIG. 5A and 5B) . To verify linkage between the cloned gene and the mutant phenotype, we identified the chromosomal location of both the scr locus and the SCR gene. To map the scr locus, molecular markers were used on F2 progeny of crosses between scr-2 (ecotype Wassilewskija, Ws) and Colombia (Col) WT. These placed the scr locus at the bottom of chromosome III, approximately 0.5 cM away from each of the two closest markers available, cdc2b and BGL1 (Konieczny and Ausubel, 1993, Plant J. 4:403-410). To map the SCR gene, we identified a polymorphism between Col and Landsberg (Ler) ecotypes using the SCR probe b (FIG. 5B) . Southern analysis of 25 recombinant inbred lines (Jarvis et al., 1994, Plant Mol. Biol. 24:685-687) mapped the cloned gene to the same location as the SCR locus on chromosome III. The determination of the molecular defects in two independent alleles and the co-localization of the cloned gene and the mutant locus confirms that we have identified the SCR gene.

6.2.4. THE SCJ? GENE HAS MOTIFS THAT INDICATE IT

IS A TRANSCRIPTION FACTOR

The Arabidopsis SCJ? gene product is a 653 amino acid polypeptide that contains several domains (FIG. 5B) . The amino-terminus has homopolymeric stretches of glutamine, serine, threonine, and proline residues, which account for 44% of the first 267 residues. Domains rich in these residues have been shown to activate transcription and may serve such a role in SCR (Johnson et al., 1993, J. Nutr. Biochem 4:386-398). A charged region between residues 265 and 283 has similarity to the basic domain of the bZIP family of transcriptional regulatory proteins (FIG. 5C) (Hurst, H.C., 1994, Protein Profile 1:123-168). The basic domains from several bZIP proteins have been shown to act as nuclear localization signals (Varagona et al., 1992, Plant Cell 4:1213-1227), and this region in SCR may act similarly. This charged region is followed by a leucine heptad repeat (residues 291-322) . A second leucine heptad repeat is found toward the carboxy-terminus (residues 436 to 473) . As leucine heptad repeats have been demonstrated to mediate protein-protein interactions in other proteins (Hurst, H.C., 1994, Protein Profile 1:123-168), the existence of these motifs suggests that SCR may function as a dimer or a multimer. The second leucine heptad repeat is followed by a small region rich in acidic residues, also present in a number of defined transcriptional activation domains (Johnson et al., 1993, J. Nutr Biochem 4:386-398). While each of these domains has been found within proteins that do not act as transcriptional regulators, the fact that all of them are found within the deduced SCR protein sequence indicates that SCR is a transcriptional regulatory protein.

6.2.5. SCJ? IS A MEMBER OF A NOVEL PROTEIN FAMILY

The Arabidopsis SCR protein sequence was compared with the sequences in the available databases. Eleven expressed sequence tags (ESTs) , nine from Arabidopsis, one from rice and one from maize, showed significant similarity to residues 394 to 435 of the SCR sequence, a region immediately amino-terminal to the second leucine heptad repeat (FIGS. 15K-L) . This region is designated the VHIID domain. Subsequent analysis of these EST sequences has revealed that the sequence similarity extends beyond this region; in fact, the similarity extends throughout the entire known gene products. The combination and order of the motifs found in these sequences do not show significant similarity to the general structures of other established regulatory protein families (i.e., bZIP, zinc finger, MADS-domain, and homeodomain) , indicating that the SCR proteins comprise a novel family.

6.2.6. SCR IS EXPRESSED IN THE CORTEX/ENDODERMAL INITIALS AND IN THE ENDODERMIS

RNA blot analysis revealed expression of SCJ? in Arabidopsis siliques, leaves and roots of wild-type plants (FIG. 6A) . No hybridization was detected to RNA from scr-1 plants (FIG. 6B, lane 2) . This indicates that scr-1 has a reduced level of RNA expression and may represent the null 0 phenotype. Hybridization to RNA species larger than the normal size were detected in sσr-2. This indicates that abnormal SCJ? transcripts are made in this allele, suggesting that functional but possibly altered proteins may be produced. _ To determine if expression was localized to any particular cell type, RNA in situ was hybridization performed on sections of root tissue. In mature roots, expression was localized primarily to the endodermis (FIGS. 7A and 7B) . Expression appeared to start very close to or within the cortex/endodermal initials and continue up the endodermal cell file as far as the section extended. Expression was also detected in late-torpedo stage embryos in the endodermis throughout the embryonic axis (FIG. 7C) . Sense strand controls showed only background hybridization (FIG. 7D) .

To determine whether the localization of SCR RNA was regulated at the transcriptional or post-transcriptional level, enhancer trap (ET) lines were prepared and examined in which the β-glucuronidase (uid-A or GUS) coding sequence with a minimal promoter was expressed in the root endodermis. (See Section 7, infra) . Restriction fragment length polymorphisms were observed when DNA from one of these lines, ET199 and wild-type were probed with SCR. PCR and sequence analysis confirmed that the enhancer-trap construct had inserted approximately 1 kb upstream of the SCR start site and in the same orientation as that of SCR transcription.

In mature roots, expression in ET199 whole mounts showed a similar pattern to that of the in situ hybridizations, with the strongest staining present in endodermal cells (FIG. 7E) . Transverse sections indicated that expression was primarily in endodermal cells in the elongation zone (FIG. 7F) . Longitudinal sections through the meristematic zone revealed that expression could be detected in the cortex/endodermal initial (FIG. 7G) . Of particular interest was the restriction of expression to the endodermal daughter cell after the periclinal division (FIG. 7G) . This indicated that the expression pattern observed in the in situ analysis was not due to post-transcriptional partitioning of SCR RNA. Rather, it suggests that after the periclinal division of the cortex/endodermis initial only one of the two cells is able to transcribe SCR RNA. 6.3. DISCUSSION

6.3.1. THE SCR GENE REGULATES AN ASYMMETRIC DIVISION REQUIRED FOR ROOT RADIAL ORGANIZATION

The formation of the cortex and endodermal layers in the Arabidopsis root requires two asymmetric divisions. In the first, an anticlinal division of the cortex/endodermal initial generates two cells with different developmental potentials. One will continue to function as an initial, while the other undergoes a periclinal division to generate the first cells in the endodermal and cortex cell files. This second asymmetric division is eliminated in the scarecrow mutant, resulting in a single cell layer instead of two. The scr mutation appears to have little effect on any other cell divisions in the root indicating that it is involved in regulating a single asymmetric division in this organ. Several other mutations have been characterized that appear to affect specific cell division pathways in Arabidopsis. These include knolle (kn) in which formation of the epidermis is impaired (Lukowitz et al., 1996, Cell 84:61- 71) , wooden leg (wol ) in which vascular cell division is defective (Scheres et al., 1995, Development 121:53-62) and f ass (fs) in which there are supernumerary cortex and vascular cells (Scheres et al., 1995, Development 121:53-62); Torres Ruiz & Jurgens, 1994, Development 120:2967-2978). Only in the case of scr and short-root (shr) mutants has it been shown that the defect is in a specific asymmetric division.

Mutational analyses in several organisms have revealed that the genes that regulate asymmetric divisions can be specific to a single type of division or can affect divisions that are not clonally related (Horvitz & Herskowitz, 1992, Cell 68:237-255). In most cases, these mutations result in the formation of two identical daughter cells with similar developmental potentials (Horvitz & Herskowitz, 1992, Cell 68:237-255). Both resulting cells have the identity of one or the other of the normal daughter cells, an example of which is the swi^" mutation in S. cerevisiae (Nasmyth et al., 1987, Cell 48:579-587). However, there are also examples of mutations that result in the formation of chimeric cell types such as the ham-1 mutation in C. elegans (Desai et al., 1988, Nature 336:638-646).

6.3.2. SCR INVOLVEMENT IN CELL

SPECIFICATION OR CELL DIVISION

Genes that regulate asymmetric cell divisions can be divided into those that specify the differentiated fates of the daughter cells and those that function to effect the division of the mother cell (Horvitz & Herskowitz, 1992, Cell, 68:237-255). The aberrant cell layer formed in the scr mutant has differentiated features of both endodermal and cortex cells. Thus, scr is in the rare class of asymmetric division mutants in which a chimeric cell type is created. The ability to express differentiated characteristics of cortex and endodermal cells implies that the differentiation pathways for both these cell types are intact and do not require the functional SCR gene. This indicates that SCR is involved primarily in regulating a specific cell division, and that the correct occurrence of this division can be unlinked from cell specification. This is in contrast to the shr mutant, in which the periclinal division of the cortex/endodermal initial also fails to occur and the resulting cell lacks endodermal markers (Benfey et al., 1993, Development 119:57-70) and has cortex attributes. A genetic analysis was used to address the function of SHR and SCR in the asymmetric division of the cortex/endodermal initial. Placing mutants of each of these genes in a fs mutant background asked whether the supernumerary cell divisions characteristic of fs were sufficient to restore normal cell identities (Scheres et al., 1995, Development 121:53-62). In the shr, fs double mutant there were additional cell layers but no endodermal, indicating that the SHR gene has a role in specifying cell identity. In the scr, fs double mutant no alteration in cell identity was observed as compared to fs (Scheres et al., 1995, Development 121:53-62). Taken together with the cell marker analysis presented herein, these results are consistent with a role for SCJ? in generating the division of the mother cell while the SHR gene may be involved in specifying the fate of the endodermal daughter.

6.3.3. A ROLE FOR SCJ? IN EMBRYONIC DEVELOPMENT

At least one additional cell division appears to be affected in the scr mutant. During embryonic development, the ground tissue does not divide to form the endodermal and cortex layers of the embryonic root and hypocotyl. As shown herein, expression of SCR was detected in the endodermal tissue throughout the embryonic axis shortly after this division occurs. Thus, SCJ? may play a direct role in regulating both this division and the division of the cortex/endodermal initial in the root apical meristem. Alternatively, the radial organization established in the embryo may somehow act as a template that directs the division of the cortex/endodermal initial, thus perpetuating the pattern. This is consistent with the finding in the scr mutant that the aberrant pattern established in the embryo iε perpetuated in the primary root. It is also consistent with a recent study in which the daughter cells of the cortex/endodermal initial were laser ablated (van den Berg et al., 1995, Nature 378:62-65). When a single daughter cell was ablated, it was replaced by a cell that followed the normal asymmetric division pattern. When three adjacent daughter cells were ablated, the central initial divided anticlinally but failed to perform the periclinal division (van den Berg et al., 1995, Nature 378:62-65). This provided evidence that information from mature cells is required for the correct division pattern of cortex/endodermal initials suggesting a "top down" transfer of information. However, the absence of a cell layer in lateral roots and callus- derived roots of the scr mutant suggests that embryo events are not unique in their ability to establish radial organization. Rather, these observations implicate SCR in regulating both embryonic and post-embryonic root radial organization.

6.3.4. TISSUE-SPECIFIC EXPRESSION OF SCR IS

REGULATED AT THE TRANSCRIPTIONAL LEVEL

Although not intending to be limited to any theory or explanation regarding the mechanism of SCJ? action, the cloning of the gene and the expression pattern provide some clues as to the role of SCJ? in the regulation of a specific asymmetric division. The SCR gene is expressed in the cortex/endodermal initial, but immediately after division is restricted to the endodermal lineage. A similar pattern is seen in the ET199 enhancer trap line in which SCJ? regulatory elements are in proximity to a GUS gene, indicating that SCJ? restriction to the endodermal cell file is due to differential regulation of expression of the SCR gene in this cell and the first cell in the cortex file. Another marker line in which expression of GUS is detected only in the cortex daughter cell provides a control for differential degradation of GUS RNA or protein. Thus, partitioning of SCR RNA as a means of achieving this segregation of expression can be ruled out. What remains to be determined is whether this difference in transcriptional activity of the two daughter cells is due to internal polarity of the mother cell prior to division such that cytoplasmic determinants are unequally distributed, or to external polarity that influences cell fate after division. Since SCR is expressed prior to cell division, an attractive hypothesis is that it is involved in establishing polarity in the cortex/endodermal initial. The sequence of the SCR protein strongly suggests that it acts as a transcription factor. Hence, it may act to regulate the expression of other genes essential for the establishment of unequal division. Alternatively, it is conceivable that it could play a role in creating an external polarity that provides a signal to divide asymmetrically. Its expression in more mature endodermal cells is consistent with a role in "top-down" signaling.

6.3.5. A NEW FAMILY OF TRANSCRIPTIONAL REGULATORS Analysis of eighteen EST clones found in the

GenBank database reveals that the proteins they encode share a high degree of homology with Arabidopsis SCR protein. See Table 1 and FIGS. 15A-S. Further sequence analysis of the encoded proteins indicate that a high degree of sequence similarity extends from at least the highly conserved VHIID domain to the carboxy-terminus of the gene products. Comparison of the amino termini of these proteins is precluded by the fact that the ESTs are incomplete. The high degree of similarity among these proteins, in combination with the motifs observed in the SCR protein (homopolymeric motifs, two leucine heptad repeats and a bZIP-like basic domain that may also function as a nuclear localization sequence) indicates that these proteins form a novel class of regulatory proteins. The insertion sites of the T-DNA in the two scr mutant alleles raised the possibility that the mutant phenotype was due to the production of truncated proteins. Northern blot analysis indicated SCR RNA is undetectable in scr-l . This suggests that the phenotype is either the null, or due to highly reduced RNA expression. In scr-2, an alteration in RNA size was detected which would be consistent with the presence of a functional and possibly truncated protein. This could provide an explanation for the observation that scr-2 appears to be the weaker allele.

7. EXAMPLE 2: ENHANCER TRAP ANALYSIS OF ROOT DEVELOPMENT An enhancer trap system was used in order to provide a more detailed molecular analysis of gene expression in lateral root patterning and development in Arabidopsis thaliana . A new collection of marker lines that express β- glucuronidase (GUS) activity in a cell-type specific manner in each of the cells of the root was generated. These lines allow differentiation of cells to be monitored based on molecular characteristics. One of these marker lines, ET199, resulted from the integration of the GUS cassette in proximity to an SCR enhancer. The results described below demonstrate that transcriptional activation of the SCR gene plays an important role in root development in Arabidopsis, and that SCR gene transcriptional regulatory elements can express a transgene in a developmentally and tissue specific manner.

7.1. MATERIALS AND METHODS

7.1.1. PLANT GROWTH CONDITIONS:

Arabidopsis seeds from NO-O and Columbia ecotypes were sterilized and sown on MS plates containing 4.5% sucrose. Plates were oriented vertically and maintained under 18 hours light, 6 hours dark cycle.

7.1.2. HISTOLOGY AND GUS STAINING:

For observation of lateral roots, roots were removed from plates and infiltrated in 25% glycerol for several hours to overnight. Roots were then mounted in 50% glycerol. Whole seedlings were stained for GUS activity for up to three days in the following solution: IX GUS buffer, 20% methanol, 0.5 mg/ml X-Glu. Addition of methanol greatly improves the specificity and reproducibility of staining. Staining solution was made fresh from a 10X buffer (1 M Tris pH7.5, 290 mg NaCl, 66 mg K₃Fe(CN)₆) that was stored for no more than one week. Stained roots were cleared in glycerol and mounted as above. All samples were observed using Nomarski optics on a Leitz Laborlux s microscope.

Photographs were taken using a Leitz MPS52 camera, and images were scanned into Adobe Photoshop to create figures. In some cases the intensity of the blue color was increased. 7.1.3. CONSTRUCTION OF ENHANCER TRAP LINES: Plant Cloning Vector (PCV) (Koncz et al., 1994, Specialized vectors for gene tagging and expression studies, in Plant Molecular Biology Manual. Gelvin & Schilperoort, eds., Vol. B2, pp. 1-2, Kluover Academic Press, Dordrecht, The Netherlands) contains a Bam HI site immediately adjacent to the T-DNA right border sequence. The /3-glucuronidase gene fused to the TATA region (-46 to 78) of the CaMV 35S promoter was introduced into this site (Benfey et al., 1990, EMBO J. 9:1677-1684). 350 transgenic lines were generated by

AgroJbacteriujn mediated root transformation (Marton & Browse, 1991, Plant Cell Reports 10:235-239), and 4 independent lines from each transformant were screened for GUS activity in the root.

7.2. RESULTS

7.2.1. DIFFERENTIATION IN THE LRP The marker lines described above reflect patterns of gene expression that are specific to individual root cell types. There are no readily apparent mutant phenotypes in any of these lines. Therefore, they can be used to analyze the differentiation state of the cells during normal development of the lateral root primordial (LRP) . If there are stages at which the pericycle cells proliferate in the absence of patterning, it can be expected that all cells would be identical with none expressing differentiated characteristics. In contrast, organization of the LRP would be reflected in differential patterns of GUS gene expression, with certain cells beginning to turn on transcription from differentiated cell-type specific promoters (i.e., those that drive GUS expression in the enhancer trap lines) .

The process of lateral root formation is divided into the following seven stages: Stage I: The LRP is first visible as a set of pericycle cells that are clearly shorter in length than their neighbors, having undergone a series of anticlinal divisions. Laskowski et al., 1995, Dev. 121:3303-3310 predict that there are approximately 4 founder pericycle cells involved. In the longitudinal plane, these divisions result in the formation of 8-10 small cells, which enlarge in a radial direction.

Stage II: A periclinal division occurs that divides the LRP into two layers (Upper Layer (UL) and Lower Layer (LL) ) . Not all the small pericycle-derived cells appear to participate in this division — typically the most peripheral cells do not divide. Hence, as the UL and LL cells expand radially the domed shape of the LRP begins to appear.

Stage III: The UL divides periclinally, generating a three layer primordium comprised of ULl, UL2 and LL. Again, some peripheral cells do not divide, creating peripheral regions that are one and two cell layers thick. This further emphasizes the domed shape of the LRP.

Stage IV: The LL divides periclinally, creating a total of four cell layers (ULl, UL2, LL1, LL2) . At this stage the LRP has penetrated the parent endodermal layer.

Stage V: The central cells in LL2 undergo a number of divisions that push the overlying layers up and distort the cells in LL1. These divisions are difficult to visualize at this stage, but clearly form a knot of mitotic activity. The LRP at this stage is midway through the parent cortex. The outer layer contains 10-12 cells.

Stage VI: This stage is characterized by several events. The four central cells of ULl divide periclinally. This division is particularly useful in identifying the median longitudinal plane in the enlarging LRP. At this point there are a total of twelve cells in ULl, four in the middle that have undergone the periclinal division and four on either side. In addition, all but the most central cells of UL2 undergo a periclinal.division. At this point the LRP has passed through the parent cortex layer and has penetrated the epidermis. The central cells apparently derived from LL2 have a distinct elongated shape characteristic of vascular elements.

Stage VII: As the primordium enlarges it becomes difficult to characterize the divisions in the internal layers.

However, the cells in the outermost layer can still be seen very clearly. All of these cells undergo a anticlinal division, resulting in 16 central cells (8 cells in each of two layers) flanked by 8-10 cells on each side. We refer to this as the 8-8-8 cell pattern. The LRP appears to be just about to emerge from the parent root.

7.2.2. MARKER LINES

An enhancer trapping cassette was generated by fusing the GUS coding sequence to the minimal promoter of the 35S promoter from CaMV. This minimal promoter does not produce a detectable level of GUS expression. However, its presence allows other upstream elements to direct GUS expression in a developmental and/or cell-specific manner (Benfey et al., 1990, EMBO J. 9:1677-1684). The use of a minimal promoter instead of a promoterless construct allows GUS expression to occur even if the enhancer trap cassette inserts at a distance from the coding region. Since the insert does not have to be within the structural gene, there are often no mutations generated in the enhancer trap lines. The minimal promoter:GUS construct was cloned immediately adjacent to the T-DNA right border sequence of PCV (Koncz et al., supra) and introduced into Arabidopsis. 350 independent lines were generated and analyzed for GUS activity in the root. The following lines most clearly define each cell type. All of the lines were generated through enhancer trapping, as described herein, below, except for CorAX92 (Dietrich et al., 1992, Plant Cell 4:1371-1382) and EpiGL2:GUS (Masucci et al., Dev. 122:1253-1260) which are transgenic plants that contain cell-type specific promoters fused to the GUS gene.

Ste05 - expresses GUS in the stele including the pericycle layer throughout primary and lateral roots. At the root tip, staining becomes weaker in the elongation zone; therefore, it is likely that only differentiated stele cells express GUS activity. Stelar GUS expression is also seen in aerial parts of the plant.

Endl95 - expresses GUS in the endodermis of primary and lateral roots. Staining can be seen most clearly in the cells in the meristematic region of the root, although overstaining shows that more mature cells also express some GUS activity. It appears that there is no staining in the cortex/endodermal initial, but staining is evident in the first daughter cell of this initial. GUS expression is also seen at the base of young leaves and in the stipules.

ET199 - expresses GUS in the endodermis of primary and lateral roots, again most clearly in cells in the meristematic region. Unlike Endl95, staining in ET199 appears to continue down to the cortex/endodermal initial and, in younger roots, even into the cells of the quiescent center. Expression in the aerial parts of the plant is detectable in the young leaf primordia.

CorAX92 - This line was generated by fusing the 5' and 3' sequences from a cortex specific gene isolated from oilseed rape to the GUS reporter gene (Dietrich et al., Plant Cell 4:1371-1382). Expression is limited to the cortex layer, extending to but not including the cortex/endodermal initial. Staining is also apparent in the petioles and leaf blades of expanded leaves. EpiGL2:GUS - This line was generated by fusing the GL2 promoter to the GUS gene (Masucci et al., Dev. 122:1253- 1260) . Expression is seen in the non-hair forming epidermal cells (atrichoblasts) . Staining is seen near the root tip, but it is difficult to determine if it includes the epidermal initial. Staining is also seen in the trichomes, leaf primordia, and the epidermis of the hypocotyl and leaf petioles.

CRC219 - This line shows staining in the columella root cap only.

LRC244 - This line shows staining in the lateral root cap only.

RC162 - This line shows staining in both the lateral and columella root caps.

Two marker lines show differential staining at very early stages of LRP development. One of these, ET199, presents a complex and dynamic pattern of expression. Staining is first apparent at stage II in only the four central cells of the UL. At stage III staining is strongest in the central cells of UL2. As the LRP reaches stage V the staining remains strongest in the central 2-4 cells of UL2. By stage VI staining also begins to extend into the newly formed endodermal layer, and staining in both the central cells and endodermis persists beyond emergence of the lateral root. Another line, LRB10 (lateral root base) , does not express GUS in the primary root tip. Staining in the LRP is seen at stage I, and at stage II all the cells of the UL and LL are stained. However, by stage IV and V only the cells at the periphery of the LRP are still expressing GUS. As the LRP develops, these cells continue to stain, although less intensely, resulting in a ring of GUS expressing cells at the base of the LR. LRB10 and ET199 clearly demonstrate non-identity between the cells at very early stages, stage IV in the case of LRB10 and within the UL at stage II in ET199. In addition, although it is difficult to identify the nature of the cells that correspond to the observed staining pattern in LRB10 and the early staining cells of ET199, post-emergent lateral roots show analogous staining in these lines, suggesting that the stained cells are already expressing markers that reflect their differentiated cell fates. Hence, these observations suggest a very early onset of differentiation in the cells of the LRP.

7.2.3. ET199 PROVIDES EVIDENCE FOR THE ROLE OF SCR IN PLANT DEVELOPMENT Fortuitously, it was discovered that the GUS cassette in ET199 described Section 7.2.2, above, is situated approximately 1 kb upstream from the SCR gene. The SCR cDNA was labelled and used to probe genomic DNA from WT and ET199 plants. The band pattern seen in the Southern was completely consistent with a T-DNA inserted 1 kb upstream of the putative SCARECROW start site. Subsequently, a DNA fragment was PCR amplified using a primer within the T-DNA and a primer within SCARECROW. The size of this fragment was also consistent with the predicted insertion site. Partial sequencing of the PCR fragment confirmed the presence of SCARECROW sequence. Mutants in the SCJ? gene are completely lacking one of the radial layers between the epidermis and pericycle in both primary and lateral roots, due to the absence of specific cell division during embryogenesis and of the cortex/endodermal initial during post-embryonic growth. The expression pattern (described in Section 7.2.2., above) that was observed in the central cells of the developing LRP of ET199 provide strong evidence that the cells in this region are involved in the establishment of the meristematic initials. More importantly, these results demonstrate that transcriptional activation of the SCR gene plays a major role in the development of the Arabidopsis LRP. Furthermore, these results demonstrate that a transgene can be expressed under the control of SCR gene transcriptional regulatory elements in a developmental and tissue-specific manner.

5 8. EXAMPLE 3: ACTIVITY OF ARABIDOPSIS SCR

PROMOTER IN TRANSGENIC ROOTS

The expression pattern of Arabidopsis SCJ? has been determined by analysis of an enhancer trap line, ET199, in which a GUS coding region with a minimal promoter was fortuitously inserted 1 kb upstream of the SCJ? coding region

(see supra) . In ET199 plants, GUS expression is detected in the endodermis, endodermal initials and sometimes in the quiescent center (QC) of the root. See supra and Malamy and

Benfey, 1997, Dev. 124:33-44. This expression pattern of SCR

1 „9_ in the primary root has been confirmed by in situ analysis

(See supra and Di Laurenzio et al., 1996, Cell 86:423-433).

The following experiments demonstrate that 2.5 kb of 5' sequence upstream of the Arabidopsis SCJ? coding region is sufficient to confer SCR expression pattern to a heterologous gene. The 5' sequence used in these studies starts from the Hind III site approximately 2.5 kb upstream of the ATG initiation site and extends 3' downstream to the base pair immediately upstream of the ATG initiation site (see FIG. 14) . This 5' sequence was fused to a GUS coding sequence. The resulting SCJ? promoter::GUS construct was incorporate into an Agrobacterium vector, which was used to transform and generate transgenic roots using standard procedures.

A large number of roots were regenerated. They show GUS staining pattern that is similar to the SCR expression pattern in ET199 plants (Figure 19, Panel f) . Since organs regenerated from callus often have an abnormal morphology, transgenic roots were transferred to liquid culture. Roots grown in liquid culture appeared morphologically normal and showed GUS expression in the endodermis, endodermal initial and QC (Figure 19, Panel g) , similar to the expression pattern of SCR seen in the enhancer trap line ET199. These results indicate that the 2.5 kb region upstream of the SCR start site is sufficient to confer the SCR expression pattern in the root.

The expression of the SCR promoter::GUS construct was also examined in scr mutant background. The scr mutant has an altered root organization (see, supra) . Whereas the wild-type root of Arabidopsis has four distinct cell layers surrounding the vascular tissue, the roots of scr mutant have only three. Transgenic roots of the scr mutant were generated that contained a SCJ? promoter::GUS construct. As in the wild-type, a large number of transgenic roots were formed that had detectable GUS expression (Figure 20, Panel a) . These roots were shorter than wild-type regenerated roots, consistent with the shorter root phenotype of the scr mutant. Additional transgenic root experiments demonstrated that the SCR gene under control of its own promoter can rescue the scr mutant phenotype. Transgenic scr roots were generated that contained the full length SCR gene under the control of its own promoter. The length of transgenic roots containing the construct were longer than those of the scr mutant, indicating that the introduced SCR gene partially rescued the mutant. Whereas scr regenerated roots that carried the SCR promoter::GUS construct were very short (Figure 21, Panel a; and Figure 20, Panel a) , roots transformed with the SCJ? promoter and coding region were noticeably longer (Figure 21, Panel b) . The difference was even more obvious in liquid culture, in which scr mutant roots remained short (Figure 21, Panel c) , while SCR gene complemented scr mutant roots were long and resembled wild- type roots (Figure 21, Panel d) .

Anatomical studies of the regenerated roots confirmed the ability of the SCR promoter:: SCR gene construct to rescue the scr mutant phenotype. Whereas regenerated roots of scr mutant were missing an internal layer (Figure 21, Panel e) , the scr mutant roots that were transformed with the SCJ? promoter:: SCR gene construct had a radial organization that resembled wild-type root (Figure 21, Panel f) .

9. EXAMPLE 4: ISOLATION SCJ? SEQUENCES USING PCR-

> CLONING STRATEGY

Based on the comparison of the sequences of SCR paralogs in Arabidopsis, degenerate primers SCR3AII, SCR5AII and SCR5B were designed and used in PCR amplification of SCR sequences from genomic DNA of various plant species. The

10 amplification was performed according to condition described in Section 5.1.1., supra , using DNA isolated from maize plants grown from a commercial seed mixture. Amplification products (104 bp fragment for the SCR5B+SCR3AII primer combination; 146 bp fragment for the SCR5AII+SCR3AII primer

1,3_ combination) were obtained, and each cloned into a T/A vector

(Invitrogen, San Diego, CA) and sequenced. Two of the three different types of clones obtained had deduced amino acid sequences that were very similar to a part of the Arabidopsis SCR protein (i.e., approximately 90% identity), suggesting that they represent parts from two different alleles of the maize SCR gene (i.e., ZCJ? gene). The two clones each had only two conservative changes in their nucleotide sequence.

The 146 bp amplification product, ZmScll, was subsequently used as a probe for screening of a genomic library generated in lambda BlueSTAR vector (NOVAGEN) from maize (Hill line) genomic DNA. The screening was performed according to the standard procedures described in Genius™ System User's Guide For Membrane Hvbridization (Boehringer- Mannheim) : The probe was a single-strand DNA molecule corresponding to the ZmScll fragment produced by PCR (Genius, Boehringer-Mannheim) . Hybridization was performed according to recommendations of the manufacturer's manual (Boehringer-Mannheim) . Prehybridization was for 2 hr in 50% formamide hybridization solution at 42°C. Hybridization was overnight at 42°C with 200 ng/ml probe concentration. Filters were washed twice at room temperature in 2xSSC, 0.1% SDS for 5 min, and for stringent washing at 65°C in 0.5xSSC,0.1% SDS twice for 15 min.

A positive clone was identified. The clone contained a 13 kb insert, which was subcloned into a plasmid vector. The resulting plasmid was designated pZCR. A 5 kb Eco RI fragment containing the maize SCR (ZCR) sequence was subcloned and sequenced. The nucleotide sequence of the region containing a partial ZCR coding sequence is shown in FIG. 17A and the corresponding deduced amino acid sequence is shown in FIG. 17B. The ZCR protein contain a segment that is highly homologous to a corresponding segment in the Arabidopsis SCR protein (FIG. 17B) . This segment is flanked by segments of low homology. Thus, it is possible that the genomic clone of ZCR is a composite clone, containing sequences that are not ZCR sequences.

The deduced ZCR protein sequence was aligned with that of Arabidopsis SCR protein. The comparison revealed new conserved sites in the SCJ? coding sequence which were used to design new, more specific PCR primers (i.e., IF, IR, and 4R) for use in amplification of SCR sequences from yet other plant species.

Using combinations of primers 1F+1R and 1F+4R, PCR amplification were performed as described in section 5.1.1.. Two DNA of expected size were obtain from soybean: a 247 bp DNA from the 1F+1R primer combination and a 379 bp DNA from the 1F+4R primer combination. A DNA of expected size (247 kb) was obtained from carrot and spruce when their genomic DNA was amplified using 1F+4R primer combination. The nucleotide sequences of the 379 kb soybean DNA (SRPgl) , the 247 kb DNA from carrot (SRPdl ) and spruce (SRPpl ) are shown in FIGS. 16K-M. The corresponding deduced amino acid sequences of these amplified sequences are shown in FIG. 18. Comparison of these partial SCR coding sequences indicate this approach isolated DNA sequences that encode SCR proteins with amino acid sequences that are very similar but not identical to a segment of Arabidopsis SCR protein (see FIG. 18) . 10. EXAMPLE 5. EXPRESSION PATTERN OF MAIZE ZCR GENE IN ROOT TISSUE

These experiments examined the expression pattern of ZCR in the primary root and quiescent centers of maize root. The expression pattern was determined by in situ hybridization using a ZCR RNA probe, corresponding to an amino acid segment region that is highly homologous to a corresponding segment of the Arabidopsis SCR protein. The experiment was carried out as follows. Restriction fragments containing the maize ZCR sequence were isolated from pZCR and subcloned into a pBluescript vector for in vitro transcription. The probe was synthesized using conditions described in the Genius Dig RNA labeling kit. The pBluescript plasmid was linearized, and 1 μg was used as a template to synthesize digoxigenin-labeled RNA using the T7 polymerase. The RNA probe was subjected to mild alkali hydrolysis by heated at 60°C for 1 hr in 100 mM carbonate buffer (pH 10.2) to yield a probe size of approximately 0.15 kb. Probe concentration for hybridization was optimized at 1 μg/ml/kb. In situ hybridization of root tips from 48 to 72 hr-old maize seedlings or excised quiescent centers (QCs) of roots were carried out following procedures described in Section 6.1.6. , supra .

The results show that ZCR expression in maize primary roots is localized to a file of cells that is identified as the endodermal layer. The expression pattern continues in a single uninterrupted file through the QC which consists of approximately 1000-1500 cells (FIG. 22) .

In two-week old regenerating QCs, ZCR expression is found in a file of cells extending through the newly formed apex. Thus, the regenerated roots exhibits a ZCR expression pattern that is similar to that seen in the primary root, even though the root apex does not contain the normal arrangement of cell files at this stage.

ZCR expression during regeneration of the root apex was also examined. In the initial stages of regeneration, cell proliferation occurs to fill in the removed tissue and begins to regenerate the basic shape of the root tip. All cells on the blunt edge of the root appears to contribute to the new population of cells. The ZCR expression pattern indicates that molecular signals are differentially present in these cells at an early stage in regeneration. The gene appears to be diagnostic of cells that are preparing to undergo asymmetrical division in order to re-establish the normal organization of the root apex from the large undifferentiated cells. The results indicate that ZCR expression is required for pattern formation since it is expressed prior to the generation of any specific anatomical pattern in the newly formed not tissue.

11. EXAMPLE 6. EXPRESSION PATTERN OF ZCR GENE IN SOYBEAN ROOTS AND ROOT NODULES

SCR expression in soybean roots and nodules was examined using in situ hybridization with a SCR probe. The procedure used were as described in Sections 6.1.6. and 11.

In primary roots, SCR is expressed in the endodermis. Expression was also found in cells at the root tip that are located at the distal end of the endodermal cell files. In soybean nodules, expression of SCR was detected in the peripheral tissue at the site of developing vascular strands. At later stages of vascular development within the nodule, SCR expression was found flanking the vascular tissue. These results indicate that SCR is involved in regulating vascularization in the nodule by contributing to the radial organization that is required to generate endodermis. These findings indicate that SCR promoter may be used to express proteins in a highly tissue-specific manner in soybean nodules. One application is to use SCR promoter to engineer nodules through production of components in a tissue-specific manner. Another application is that modification of the expression of SCR could enhance nodule activity by improving vascularization and/or the number of endodermal layers. 12. EXAMPLE 7. SCR EXPRESSION AFFECTS GRAVITROPISM OF AERIAL STRUCTURES

In addition to being defective in specific embryonic and postembryonic meristematic divisions, both the scr and the shr mutants have shoots that exhibit severely defective gravitropism. Complementation analysis showed that scr is allelic to a sgr (shoot gravitropism) mutant, sgrl . Four mutant alleles of SCR (i .e . , scrl , scr2, sgrl-1 and sgr 1-2) have been identified. All four of these mutants have normal root gravitropism and defective shoot gravitropism.

Etiolated hypocotyls of scr mutants placed on their sides do not respond to gravity even after 3 hr. Similar behaviors were observed with the inflorescence stems of sgrl-1 mutant, which do not curve upwards even after two days on their sides. In contrast, the roots of these plants respond rapidly to the change in orientation with the same kinetics as the wild type. Thus, mutations in the SCR gene lead to a radial pattern deficiency in the root but have no effect on root gravitropism.

Comparable results were also obtained for shr roots and for hypocotyls and inflorescence stems, i.e., data indicate that shr shows normal root gravitropism but almost no stem gravitropism.

13. DEPOSIT OF MICROORGANISMS The following microorganisms have been deposited in accordance with the terms of the Budapest Treaty with the American Type Culture Collection; 12301 Parklawn Drive, Rockville, MD 20852, U.S.A., on the dates indicated:

Accession

Microorganism Clone No. Date

DH5α pGEX-2TK* 98031 April 26, 1996

(pLIG 1-3/Sac+MOBlSac)

DH5α pNYHl (Zm-scllb) 98032 April 26, 1996

DH5α pNYH2 (Zm-scll) 98033 April 26, 1996

DH5α pNYH3 (Zm-scl2) 98034 April 26, 1996

DH5α pZCR April 18, 1997 Although the invention is described in detail with reference to specific embodiments thereof, it will be understood that variations which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, each of the disclosures of which is incorporated by reference in its entirety.

International Application No: PCT/

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 86 , lines ₂5-37 of the description

A. IDENTIFICATION OF DEPOSIT '

Further deposits are identified on an additional sheet

Name of depositary institution ' American Type Culture Collection

Address of depositary institution (including postal code and country)

12301 Parklawn Drive Rockville. MD 20852 US

Date of deposit ' April 26, 1996 Accession Number ^• 98031

B. ADDITIONAL INDICATIONS ^• (leave blank if nil applicable) Thu informauon u continued on a separate attached sheet

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE '

D. SEPARATE FURNISHING OF INDICATIONS ' (leave blank if not applicable)

The Indications listed below will be submitted to the International Bureau later * (Specify the general nature ot the Indications e.g., "Accession Number of Deposit")

E. Ki This sheet was received with the Intemationai application when filed (to be checked by the receiving Office)

D The date of receipt (from the applicant) by the International Bureau '

(Authoπzed Officer) Form PCT/RO/134 (January 1981 ) International Application No: PCT/

Form PCT/RO/134 (cont.)

American Type Culture Collection

12301 Parklawn Drive Rockville, MD 20852 US

Accession No. Date of DβDOsit

98032 April 26, 1996

98033 April 26, 1996

98034 April 26, 1996

Aprit 18, 1997

SEQUENCE LISTING

tl) GENERAL INFORMATION:

(i) APPLICANT: Benfey, Phillip N. Di Laurenzio, Laura Wyβocka-Diller, Joanna Malamy, Jocelyn E. Pyβh, Leonard Helaruitta, Yrjo

(ii) TITLE OF INVENTION: SCARECROW GENE, PROMOTER AND USES THEREOF

(iii) NUMBER OF SEQUENCES: 67

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie & Edmonds LLP

(B) STREET: 1155 Avenue of the Americas

(C) CITY: New York

(D) STATE: New York

(E) COUNTRY: USA

(F) ZIP: 10036-2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: Patentln Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/638,617

(B) FILING DATE: 26-APR-1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Coruzzi, Laura A.

(B) REGISTRATION NUMBER: 30,742

(C) REFERENCE/DOCKET NUMBER: 005914-0056-999

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (212) 790-9090

(B) TELEFAX: (212) 869-9741

(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:l:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2163 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CCTTATTTAT AACCATGCAA TCTCACGACC AACAACCCTT CAATCTCCAT GGCGGAATCC 60 GGCGATTTCA ACGGTGGTCA ACCTCCTCCT CATAGTCCTC TGAGAACAAC TTCTTCCGGT 120

AGTAGCAGCA GCAACAACCG TGGTCCTCCT CCTCCTCCTC CTCCTCCTTT AGTGATGGTG 180

AGAAAAAGAT TAGCTTCCGA GATGTCTTCT AACCCTGACT ACAACAACTC CTCTCGTCCT 240

CCTCGCCGTG TCTCTCACCT TCTTGACTCC AACTACAATA CTGTCACACC ACAACAACCA 300

CCGTCTCTTA CGGCGGCGGC TACTGTATCT TCTCAACCAA ACCCACCACT CTCTGTTTGT 360

GGCTTCTCTG GTCTTCCCGT TTTTCCTTCA GACCGTGGTG GTCGGAATGT TATGATGTCC 420

GTACAACCAA TGGATCAAGA CTCTTCATCT TCTTCTGCTT CACCTACTGT ATGGGTTGAC 480

GCCATTATCA GAGACCTTAT CCATTCCTCA ACTTCAGTCT CTATTCCTCA ACTTATCCAA 540

AACGTTAGAG ACATTATCTT CCCTTGTAAC CCAAATCTCG GTGCTCTTCT TGAATACAGG 600

CTCCGATCTC TCATGCTCCT TGATCCTTCC TCTTCCTCTG ACCCTTCTCC TCAAACTTTC 660

GAACCTCTCT ATCAGATCTC CAACAATCCT TCTCCTCCAC AACAGCAACA GCAGCACCAA 720

CAACAACAAC AACAGCATAA GCCTCCTCCT CCTCCGATTC AGCAGCAAGA AAGAGAAAAT 780

TCTTCTACCG ATGCACCACC GCAACCAGAG ACAGTGACGG CCACTGTTCC CGCCGTCCAA 840

ACAAATACGG CGGAGGCTTT AAGAGAGAGG AAGGAAGAGA TTAAGAGGCA GAAGCAAGAC 900

GAAGAAGGAT TACACCTTCT CACATTGCTG CTACAGTGTG CTGAAGCTGT CTCTGCTGAT 960

AATCTCGAAG AAGCAAACAA GCTTCTTCTT GAGATCTCTC AGTTATCAAC TCCTTACGGG 1020

ACCTCAGCGC AGAGAGTAGC TGCTTACTTC TCGGAAGCTA TGTCAGCGAG ATTACTCAAC 1080

TCGTGTCTCG GAATTTACGC GGCTTTGCCT TCACGGTGGA TGCCTCAAAC GCATAGCTTG 1140

AAAATGGTCT CTGCGTTTCA GGTCTTTAAT GGGATAAGCC CTTTAGTGAA ATTCTCACAC 1200

TTTACAGCGA ATCAGGCGAT TCAAGAAGCA TTTGAGAAAG AAGACAGTGT ACACATCATT 1260

GACTTGGACA TCATGCAGGG ACTTCAATGG CCTGGTTTAT TCCACATTCT TGCTTCTAGA 1320

CCTGGAGGAC CTCCACACGT GCGACTCACG GGACTTGGTA CTTCCATGGA AGCTCTTCAG 1380

GCTACAGGGA AACGTCTTTC GGATTTCACA GATAAGCTTG GCCTGCCTTT TGAGTTCTGC 1440

CCTTTAGCTG AGAAAGTTGG AAACTTGGAC ACTGAGAGAC TCAATGTGAG GAAAAGGGAA 1500

GCTGTGGCTG TTCACTGGCT TCAACATTCT CTTTATGATG TCACTGGCTC TGATGCACAC 1560

ACTCTCTGGT TACTCCAAAG GTAAAATAAA CATTACCTTT TAATCACTCT TTATCTATAA 1620

ATTATTTTAA GATTATATAG GAAAGATATG TTCTAAAAAG CTGGCTTTTT TGGTTAATGA 1680

TTGGGGAATG AACAGATTAG CTCCTAAAGT TGTGACAGTA GTGGAGCAAG ATTTGAGCCA 1740

CGCTGGTTCT TTCTTAGGAA GATTTGTAGA GGCAATACAT TACTACTCTG CACTCTTTGA 1800

CTCACTGGGA GCAAGCTACG GCGAAGAGAG TGAAGAGAGA CATGTCGTGG AACAGCAGCT 1860

ATTATCGAAA GAGATACGGA ATGTATTAGC GGTTGGAGGA CCATCGAGAA GCGGTGAAGT 1920

GAAGTTTGAG AGCTGGAGGG AGAAAATGCA ACAATGTGGG TTTAAAGGTA TATCTTTAGC 1980

TGGAAATGCA GCTACACAAG CGACTCTACT GTTGGGAATG TTTCCTTCGG ATGGTTACAC 2040

TTTGGTTGAT GATAATGGTA CACTTAAGCT TGGATGGAAA GATCTTTCGT TACTCACTGC 2100 TTCAGCTTGG ACGCCTCGTT CTTAGTTTTC TTCTCCTTTT TCACAAACAA TGTGCCCATA 2160 AAT 2163

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 653 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Glu Ser Gly Asp Phe Asn Gly Gly Gin Pro Pro Pro His Ser 1 5 10 15

Pro Leu Arg Thr Thr Ser Ser Gly Ser Ser Ser Ser Asn Asn Arg Gly 20 25 30

Pro Pro Pro Pro Pro Pro Pro Pro Leu Val Met Val Arg Lys Arg Leu 35 40 45

Ala Ser Glu Met Ser Ser Asn Pro Asp Tyr Asn Asn Ser Ser Arg Pro 50 55 60

Pro Arg Arg Val Ser His Leu Leu Asp Ser Asn Tyr Asn Thr Val Thr 65 70 75 80

Pro Gin Gin Pro Pro Ser Leu Thr Ala Ala Ala Thr Val Ser Ser Gin 85 90 95

Pro Asn Pro Pro Leu Ser Val Cyβ Gly Phe Ser Gly Leu Pro Val Phe 100 105 110

Pro Ser Aβp Arg Gly Gly Arg Asn Val Met Met Ser Val Gin Pro Met

115 120 125

Asp Gin Asp Ser Ser Ser Ser Ser Ala Ser Pro Thr Val Trp Val Asp 130 135 140

Ala lie lie Arg Asp Leu lie His Ser Ser Thr Ser Val Ser lie Pro 145 150 155 160

Gin Leu He Gin Asn Val Arg Asp He He Phe Pro Cys Asn Pro Asn 165 170 175

Leu Gly Ala Leu Leu Glu Tyr Arg Leu Arg Ser Leu Met Leu Leu Asp 180 185 190

Pro Ser Ser Ser Ser Asp Pro Ser Pro Gin Thr Phe Glu Pro Leu Tyr 195 200 205

Gin He Ser Asn Asn Pro Ser Pro Pro Gin Gin Gin Gin Gin His Gin 210 215 220

Gin Gin Gin Gin Gin His Lys Pro Pro Pro Pro Pro He Gin Gin Gin 225 230 235 240

Glu Arg Glu Asn Ser Ser Thr Asp Ala Pro Pro Gin Pro Glu Thr Val 245 250 255 Thr Ala Thr Val Pro Ala Val Gin Thr Asn Thr Ala Glu Ala Leu Arg 260 265 270

Glu Arg Lys Glu Glu He Lys Arg Gin Lys Gin Asp Glu Glu Gly Leu 275 280 285

His Leu Leu Thr Leu Leu Leu Gin Cys Ala Glu Ala Val Ser Ala Asp 290 295 300

Asn Leu Glu Glu Ala Asn Lys Leu Leu Leu Glu He Ser Gin Leu Ser 305 310 315 320

Thr Pro Tyr Gly Thr Ser Ala Gin Arg Val Ala Ala Tyr Phe Ser Glu 325 330 335

Ala Met Ser Ala Arg Leu Leu Asn Ser Cys Leu Gly He Tyr Ala Ala 340 345 350

Leu Pro Ser Arg Trp Met Pro Gin Thr His Ser Leu Lys Met Val Ser 355 360 365

Ala Phe Gin Val Phe Asn Gly He Ser Pro Leu Val Lys Phe Ser His 370 375 380

Phe Thr Ala Asn Gin Ala He Gin Glu Ala Phe Glu Lys Glu Asp Ser 385 390 395 400

Val His He He Asp Leu Asp He Met Gin Gly Leu Gin Trp Pro Gly 405 410 415

Leu Phe His He Leu Ala Ser Arg Pro Gly Gly Pro Pro His Val Arg 420 425 430

Leu Thr Gly Leu Gly Thr Ser Met Glu Ala Leu Gin Ala Thr Gly Lys 435 440 445

Arg Leu Ser Asp Phe Thr Asp Lys Leu Gly Leu Pro Phe Glu Phe Cys 450 455 460

Pro Leu Ala Glu Lys Val Gly Asn Leu Asp Thr Glu Arg Leu Asn Val 465 470 475 480

Arg Lys Arg Glu Ala Val Ala Val His Trp Leu Gin His Ser Leu Tyr 485 490 495

Asp Val Thr Gly Ser Asp Ala His Thr Leu Trp Leu Leu Gin Arg Leu 500 505 510

Ala Pro Lys Val Val Thr Val Val Glu Gin Asp Leu Ser His Ala Gly 515 520 525

Ser Phe Leu Gly Arg Phe Val Glu Ala He His Tyr Tyr Ser Ala Leu 530 535 540

Phe Asp Ser Leu Gly Ala Ser Tyr Gly Glu Glu Ser Glu Glu Arg His 545 550 555 560

Val Val Glu Gin Gin Leu Leu Ser Lys Glu He Arg Asn Val Leu Ala 565 570 575

Val Gly Gly Pro Ser Arg Ser Gly Glu Val Lys Phe Glu Ser Trp Arg 580 585 590

Glu Lys Met Gin Gin Cys Gly Phe Lys Gly He Ser Leu Ala Gly Asn 595 600 605

Ala Ala Thr Gin Ala Thr Leu Leu Leu Gly Met Phe Pro Ser Asp Gly 610 615 620

Tyr Thr Leu Val Asp Asp Asn Gly Thr Leu Lys Leu Gly Trp Lys Asp 625 630 635 640

Leu Ser Leu Leu Thr Ala Ser Ala Trp Thr Pro Arg Ser 645 650

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Pro Ala Val Gin Thr Asn Thr Ala Glu Ala Leu Arg Glu Arg Lys Glu 1 5 10 15

Glu He Lys Arg Gin Lys Gin 20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Leu Lys Arg Ala Arg Asn Thr Glu Ala Ala Arg Arg Ser Arg Ala Arg 1 5 10 15

Lys Leu Gin Arg Met Lys Gin 20

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Arg Arg Leu Ala Gin Asn Arg Glu Ala Ala Arg Lys Ser Arg Leu Arg 1 5 10 15 Lys Lys Ala Tyr Val Gin Gin 20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

He Arg Arg Glu Arg Asn Lys Met Ala Ala Ala Lys Cys Arg Asn Arg 1 5 10 15

Arg Arg Glu Leu Thr Asp Thr 20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Arg Lys Arg Met Arg Asn Arg He Ala Ala Ser Lys Cys Arg Lys Arg 1 5 10 15

Lys Leu Glu Arg He Ala Arg 20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Val Arg Leu Met Lys Asn Arg Glu Ala Ala Arg Glu Cys Arg Arg Lys 1 5 10 15

Lys Lys Glu Tyr Val Lys Cys 20

(2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys Arg Lys Glu Ser Asn Arg Glu Ser Ala Arg Arg Ser Arg Tyr Arg

1 5 10 15

Lys Ala Ala His Leu Lys Glu 20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

( ii ) MOLECULE TYPE : peptide

( xi ) SEQUENCE DESCRIPTION : SEQ ID NO: 10 :

Met Arg Gin He Arg Asn Arg Asp Ser Ala Met Lys Ser Arg Glu Arg

1 5 10 15

Lys Lys Ser Tyr He Lys Asp 20

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Arg Arg Met Val Ser Asn Arg Glu Ser Ala Arg Arg Ser Arg Lys Lys 1 5 10 15

Lys Gin Ala His Leu Ala Asp 20

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Ala Phe Glu Lys Glu Asp Ser Val His He He Asp Leu Asp He Met 1 5 10 15

Gin Gly Leu Gin Trp Pro Gly Leu Phe His He Leu Ala Ser Arg Pro 20 25 30

Gly Gly Pro Pro His Val Arg Leu Thr Gly Leu 35 40

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Ala Val Lys Asn Glu Ser Phe Val His He He Asp Phe Gin He Ser 1 5 10 15

Gin Gly Gly Gin Trp Val Ser Leu He Arg Ala Leu Gly Ala Arg Pro 20 25 30

Gly Gly Pro Pro Asn Val Arg He Thr Gly He 35 40

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ala Met Glu Gly Glu Lys Met Val His Val He Asp Leu Asp Ala Ser 1 5 10 15

Glu Pro Ala Gin Trp Leu Ala Leu Leu Gin Ala Phe Asn Ser Arg Pro 20 25 30

Glu Gly Pro Pro His Leu Arg He Thr Gly Val 35 40

(2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ala He Lys Gly Glu Glu Glu Val His He He Asp Phe Asp He Asn 1 5 10 15

Gin Gly Asn Gin Tyr Met Thr Leu He Arg Ser He Ala 20 25

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

( ii ) MOLECULE TYPE: peptide

( xi ) SEQUENCE DESCRIPTION : SEQ ID NO: 16 :

He His Val He Asp Phe Xaa Leu Gly Val Gly Gly Gin Trp Ala Ser

1 5 10 15

Phe Leu Gin Glu Leu Ala His Arg Arg Gly 20 25

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

( ii ) MOLECULE TYPE : peptide

( xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 17 :

Val His He He Xaa Phe Xaa Leu Met Gin Gly Leu Gin Trp Pro Ala 1 5 10 15

Leu Met Asp Val Phe Ser Ala Arg Lys Gly Gly Pi Pro Lys Leu Arg 20 25 30

He Thr Gly He 35

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1085 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGCACGAGCC CAACGGGTCC TGAGCTTCTT ACTTATATGC ATATCTTGTA TGAAGCCTGC 60

CCTTATTTCA AATTCGGTTA TGAATCTGCT AATGGAGCTA TAGCTGAAGC TGTGAAGAAC 120

GAAAGTTTTG TGCACATTAT CGATTTCCAG ATTTCTCAAG GTGGTCAATG GGTGAGTTTG 180

ATCCGTGCTC TTGGTGCTAG ACCTGGTGGA CCTCCGAACG TTAGGATAAC GGGAATTGAT 240

GATCCGAGAT CATCGTTTGC TCGTCAAGGA GGACTTGAGT TAGTTGGACA AAGACTTGGG 300

AAGCTAGCTG AAATGTGCGG TGTTCCGTTT GAGTTCCATG GAGCTGCTTT ATGCTGCACG 360

GAAGTCGAAA TCGAGAAGCT AGGAGTTAGA AATGGAGAAG CGCTCGCGGT TAACTTCCCG 420

CTTGTTCTTC ACCACATGCC TGATGAGAGT GTAACTGTGG AGAATCACAG AGATAGATTG 480

TTGAGATTGG TCAAACACTT GTCACCAAAC GTTGTGACTC TGGTTGAGCA AGAAGCGAAT 540

ACAAACACTG CGCCGTTTCT TCCCCGGTTT GTCGAGACAA TGAACCATTA CTTGGCAGTT 600

TTCGAATCAA TAGATGTGAA ACTCGCTAGA GATCACAAGG AAAGGATCAA TGTTGAGCAG 660

CATTGTTTGG CTAGAGAGGT TGTGAATCTT ATAGCTTGTG AAGGTGTTGA AAGAGAAGAG 720

AGGCACGAGC CACTAGGGAA ATGGAGGTCT CGGTTTCACA TGGCGGGATT TAAACCGTAT 780

CCTTTGAGCT CGTATGTGAA CGCAACAATC AAAGGATTGC TTGAGAGTTA TTCAGAGAAG 840

TATACACTTG AAGAAAGAGA TGGAGCATTG TATTTAGGAT GGAAGAATCA ACCTCTTATC 900

ACTTCTTGTG CTTGGAGGTA ACTAATAAAA ACCTTGTTCG GTTTCAGAAG AGATTAGAAA 960

CTTCTTTTAA AGTTTGCAGA ATCTGTTTGT AAAAGTAAAA CTCATGCATG ATCCGNAGGA 1020

ACAAGTTGTC AAATGTTGTA GTAGTAAGTG ATATGTTGAT GACCCAAAAA AAAAAAAAAA 1080

AAAAA 1085 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Gly Thr Ser Pro Thr Gly Pro Glu Leu Leu Thr Tyr Met His He Leu 1 5 10 15 Tyr Glu Ala Cys Pro Tyr Phe Lys Phe Gly Tyr Glu Ser Ala Asn Gly 20 25 30

Ala He Ala Glu Ala Val Lys Asn Glu Ser Phe Val His He He Asp 35 40 45

Phe Gin He Ser Gin Gly Gly Gin Trp Val Ser Leu He Arg Ala Leu 50 55 60

Gly Ala Arg Pro Gly Gly Pro Pro Asn Val Arg He Thr Gly He Asp 65 70 75 80

Asp Pro Arg Ser Ser Phe Ala Arg Gin Gly Gly Leu Glu Leu Val Gly 85 90 95

Gin Arg Leu Gly Lys Leu Ala Glu Met Cys Gly Val Pro Phe Glu Phe 100 105 110

His Gly Ala Ala Leu Phe Cys Thr Glu Val Glu He Glu Lys Leu Gly 115 120 125

Val Arg Asn Gly Glu Ala Leu Ala Val Asn Phe Pro Leu Val Leu His 130 135 140

Hie Met Pro Asp Glu Ser Val Thr Val Glu Asn Hie Arg Aβp Arg Leu 145 150 155 160

Leu Arg Leu Val Lys His Leu Ser Pro Asn Val Val Thr Leu Val Glu 165 170 175

Gin Glu Ala Asn Thr Asn Thr Ala Pro Phe Leu Pro Arg Phe Val Glu 180 185 190

Thr Met Asn His Tyr Leu Ala Val Phe Glu Ser He Asp Val Lys Leu 195 200 205

Ala Arg Asp His Lys Glu Arg He Asn Val Glu Gin His Cys Leu Ala 210 215 220

Arg Glu Val Glu Asn Leu He Ala Cys Glu Gly Val Glu Arg Glu Glu 225 230 235 240

Arg His Glu Pro Leu Gly Lys Trp Arg Ser Arg Phe His Met Ala Gly 245 250 255

Phe Lys Pro Tyr Pro Leu Ser Ser Tyr Val Asn Ala Thr He Lys Gly 260 265 270

Leu Leu Glu Ser Tyr Ser Glu Lys Tyr Thr Leu Glu Glu Arg Asp Gly 275 280 285

Ala Leu Tyr Leu Gly Trp Lys Asn Gin Pro Leu He Thr Ser Cys Ala 290 295 300

Trp Arg 305

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1231 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCTATGGAAG GAGAGAAGAT GGTTCATGTG ATTGATCTCG ATGCTTCTGA GCCAGCTCAA 60

TGGCTTGCTT TGCTTCAAGC TTTTAACTCT AGGCCTGAAG GTCCACCTCA TTTGAGAATC 120

ACTGGTGTTC ATCACCAGAA GGAAGTGCTT GAACAAATGG CTCATAGACT CATTGAGGAA 180

GCAGAGAAAC TCGATATCCC GTTTCAGTTT AATCCCGTTG TGAGTAGGTT AGACTGTTTA 240

AATGTAGAAC AGTTGCGGGT TAAAACAGGA GAGGCCTTAG CCGTTAGCTC GGTTCTTCAA 300

TTGCATACCT TCTTGGCCTC TGATGATGAT CTCATGAGAA AGAACTGCGC TTTACGGTTT 360

CAGAACAACC CTAGTGGAGT TGACTTGCAG AGAGTTCTAA TGATGAGCCA TGGCTCTGCA 420

GCTGAGGCAC GTGAGAATGA TATGAGTAAC AACAATGGGT ATAGCCCTAG CGGTGACTCG 480

GCCTCATCTT TGCCTTTACC AAGTTCAGGA AGGACTGATA GCTTCCTCAA TGCTATTTGG 540

GGTTTGTCTC CAAAGGTCAT GGTGGTCACT GAGCAAGACT CAGACCACAA CGGCTCCACA 600

CTAATGGAGA GGCTATTAGA ATCACTTTAC ACCTACGCAG CATTGTTTGA TTGCTTGGAA 660

ACAAAAGTTC CAAGAACGTC TCAAGATAGG ATCAAAGTGG AGAAGATGCT CTTCGGGGAG 720

GAGATCAAGA ACATCATATC CTGCGAGGGA TTTGAGAGAA GAGAAAGACA CGAGAAGCTT 780

GAGAAATGGA GCCAGAGGAT CGATTTGGCT GGTTTTGGGA ATGTTCCTCT TAGCTATTAT 840

GCGATGTTGC AGGCTAGGAG ATTGCTTCAA GGGTGCGGTT TTGATGGGTA TAGAATCAAG 900

GAAGAGAGCG GGTGCGCAGT AATTTGCTGG CAAGATCGAC CTCTATACTC GGTATCAGCT 960

TGGAGATGCA GGAAGTGAAT GATATATTAC AGTTTGTCTT CTATTTTGGT TATGAGCAGA 1020

GTCCCTTTCT TTTTTGTATA CATGGGGACA CAATCTTAGT TGTTTTGTGA TGGTGACTTT 1080

CTGTCTCTTT ATGCTATTTT GGCTTAAATG CTTCTACTGC CTCTGCATGT AAAGCCTTTG 1140

TGTGTTGGTT CAATTTGGTC TGGTGTGGGT GTAATACCAA ACCAAATCCA ATTTGAGCTG 1200

AAGATAACTA ATTTGATGAT CGGCTCGTGC C 1231 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 325 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Ala Met Glu Gly Glu Lys Met Val His Val He Asp Leu Asp Ala Ser 1 5 10 15

Glu Pro Ala Gin Trp Leu Ala Leu Leu Gin Ala Phe Asn Ser Arg Pro 20 25 30 Glu Gly Pro Pro His Leu Arg He Thr Gly Val His His Gin Lys Glu 35 40 45

Val Leu Glu Gin Met Ala His Arg Leu He Glu Glu Ala Glu Lys Leu 50 55 60

Asp He Pro Phe Gin Phe Asn Pro Val Val Ser Arg Leu Asp Cys Leu 65 70 75 80

Asn Val Glu Gin Leu Arg Val Lys Thr Gly Glu Ala Leu Ala Val Ser 85 90 95

Ser Val Leu Gin Leu His Thr Phe Leu Ala Ser Asp Asp Asp Leu Met 100 105 110

Arg Lys Asn Cys Ala Leu Arg Phe His Asn Asn Pro Ser Gly Val Asp 115 120 125

Leu Gin Arg Val Leu Met Met Ser His Gly Ser Ala Ala Glu Ala Arg

130 135 140

Glu Asn Asp Met Ser Asn Asn Asn Gly Tyr Ser Pro Ser Gly Asp Ser 145 150 155 160

Ala Ser Ser Leu Pro Leu Pro Ser Ser Gly Arg Thr Asp Ser Phe Leu 165 170 175

Asn Ala He Trp Gly Leu Ser Pro Lys Val Met Val Val Thr Glu Gin 180 185 190

Asp Ser Asp His Asn Gly Ser Thr Leu Met Glu Arg Leu Leu Glu Ser 195 200 205

Leu Tyr Thr Tyr Ala Ala Leu Phe Asp Cys Leu Glu Thr Lys Val Pro 210 215 220

Arg Thr Ser Gin Asp Arg He Lys Val Glu Lye Met Leu Phe Gly Glu 225 230 235 240

Glu He Lys Asn He He Ser Cys Glu Gly Phe Glu Arg Arg Glu Arg 245 250 255

His Glu Lys Leu Glu Lys Trp Ser Gin Arg He Asp Leu Ala Gly Phe 260 265 270

Gly Asn Val Pro Leu Ser Tyr Tyr Ala Met Leu Gin Ala Arg Arg Leu 275 280 285

Leu Gin Gly Cys Gly Phe Asp Gly Tyr Arg He Lys Glu Glu Ser Gly 290 295 300

Cys Ala Val He Cys Trp Gin Asp Arg Pro Leu Tyr Ser Val Ser Ala 305 310 315 320

Trp Arg Cys Arg Lys 325

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1368 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CTTTGTCAAT GGTAAATGAG CTGAGGCAGA TAGTTTCTAT CCAAGGAGAC CCTTCTCAGA 60

GAATCGCAGC TTACATGGTG GAAGGTCTAG CTGCAAGAAT GGCCGCTTCA GGAAAATTCA 120

TCTACAGAGC ATTGAAATGC AAAGAGCCTC CTTCGGATGA GAGGCTTGCA GCTATGCAAG 180

TCCTGTTTGA AGTCTGCCCT TGTTTCAAGT TCGGGTTTTT AGCAGCTAAT GGTGCGATAC 240

TTGAAGCAAT CAAAGGTGAA GAAGAAGTTC ACATAATCGA TTTCGATATA AACCAAGGGA 300

ACCAATACAT GACACTGATA CGAAGCATTG CTGAGTTGCC TGGTAAACGA CCTCGCCTGA 360

GGTTAACAGG AATTGATGAC CCTGAATCAG TCCAACGCTC CATTGGAGGG CTAAGAATCA 420

TCGGTCTAAG ACTCGAGCAA CTCGCAGAGG ATAATGGAGT ATCCTTCAAA TTCAAAGCAA 480

TGCCTTCAAA GACTTCGATT GTCTCTCCAT CAACACTCGG TTGCAAACCA GGAGAAACCT 540

TAATAGTGAA CTTTGCATTC CAACTTCACC ACATGCCTGA CGAGAGTGTC ACAACAGTAA 600

ACCAGCGGGA CGAGCTACTT CACATGGTCA AAAGCTTAAA CCCAAAGCTT GTCACGGTCG 660

TTGAACAAGA CGTGAACACA AACACTTCAC CGTTCTTTCC CAGATTCATA GAGGCTTACG 720

AATACTACTC AGCAGTTTTC GAGTCTCTAG ACATGACACT TCCAAGAGAA AGCCAAGAGA 780

GGATGAATGT AGAAAGACAG TGTCTCGCTA GAGACATAGT CAACATTGTT GCTTGCGAAG 840

GAGAAGAACG GATAGAGAGA TACGAGGCTG CGGGAAAATG GAGAGCAAGG ATGATGATGG 900

CTGGATTCAA TCCAAAACCA ATGAGTGCTA AAGTAACCAA CAATATACAA AACCTGATAA 960

AGCAACAATA TTGCAATAAG TACAAGCTTA AAGAAGAAAT GGGTGAGCTC CATTTTTGCT 1020

GGGAGGAGAA AAGCTTAATC GTTGCTTCAG CTTGGAGGTA AGATAAGTGA CAAGAGCATA 1080

TAGTCTTTAT GTTTCATAAA ACATAATTAT GTTTTTACTG TAATCTTGGG TTATTGTGTA 1140

ACTGGTTAAA TCATCTCCAT GTATTATTAC CAGAGGTTAG GGGTGATCAC AGGTACTAAA 1200

AGCTAATCTA ACACTTATGG AAGAATTTTT CTTTCTTTTT TTTCCCTATT ATATAAAAAT 1260

AATTAGAGTT TTGGTTCTAA ACCTATTTGC TAAGTGTGAA TGAGTCTTTA CATGTTCATA 1320

TTTCAGTTCA AATGGTTAAA TTTGTTAAGG TTCTCACTTA AAAAAAAA 1368 (2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

( ii ) MOLECULE TYPE : peptide

(xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 23 :

Leu Ser Met Val Asn Glu Leu Arg Gin He Val Ser He Gin Gly Asp 1 5 10 15 Pro Ser Gin Arg He Ala Ala Tyr Met Val Glu Gly Leu Ala Ala Arg 20 25 30

Met Ala Ala Ser Gly Lys Phe He Tyr Arg Ala Leu Lys Cys Lys Glu 35 40 45

Pro Pro Ser Asp Glu Arg Leύ Ala Ala Met Gin Val Leu Phe Glu Val 50 55 60

Cys Pro Cys Phe Lys Phe Gly Phe Leu Ala Ala Asn Gly Ala He Leu 65 70 75 80

Glu Ala He Lys Gly Glu Glu Glu Val His He He Asp Phe Asp He 85 90 95

Asn Gin Gly Asn Gin Tyr Met Thr Leu He Arg Ser He Ala Glu Leu 100 105 110

Pro Gly Lys Arg Pro Arg Leu Arg Leu Thr Gly He Asp Asp Pro Glu 115 120 125

Ser Val Gin Arg Ser He Gly Gly Leu Arg He He Asn Leu Arg Leu 130 135 140

Glu Gin Leu Ala Glu Asp Asn Gly Val Ser Phe Lys Phe Lys Ala Met

145 150 155 160

Pro Ser Lys Thr Ser He Val Ser Pro Ser Thr Leu Gly Cys Lye Pro 165 170 175

Gly Glu Thr Leu He Val Asn Phe Ala Phe Gin Leu His His Met Pro 180 185 190

Asp Glu Ser Val Thr Thr Val Asn Gin Arg Asp Glu Leu Leu His Met 195 200 205

Val Lys Ser Leu Asn Pro Leu Val Thr Val Val Glu Gin Aβp Val Asn 210 215 220

Thr Asn Thr Ser Pro Phe Phe Pro Arg Phe He Glu Ala Tyr Glu Tyr 225 230 235 240

Tyr Ser Ala Val Phe Glu Ser Leu Asp Met Thr Leu Pro Arg Glu Ser 245 250 255

Gin Glu Arg Met Asn Val Glu Arg Gin Cys Leu Ala Arg Asp He Val 260 265 270

Asn He Val Ala Cys Glu Gly Glu Glu Arg He Glu Arg Tyr Glu Ala 275 280 285

Ala Gly Lys Trp Arg Ala Arg Met Met Met Ala Gly Phe Asn Pro Lys 290 ' 295 300

Pro Met Ser Ala Lys Val Thr Asn Asn He Gin Asn Leu He Lys Gin 305 310 315 320

Gin Tyr Cys Asn Lys Tyr Lys Leu Lys Glu Glu Met Gly Glu Leu His 325 330 335

Phe Cys Trp Glu Glu Lys Ser Leu He Val Ala Ser Ala Trp Arg 340 345 350

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 100 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: CCAGGAGGCG TTCGAGCGGG AGGAGCGTGT GCACATCATC GACCTCGACA TCATGCAGGG 60 GCTGCAGTGG CCGGGCCTCC TCCACATCCT TGCCTCCCGC 100

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Gin Glu Ala Phe Glu Arg Glu Glu Arg Val His He He Asp Leu Asp 1 5 10 15

He Met Gin Gly Leu Gin Trp Pro Gly Leu Phe His He Leu Ala Ser 20 25 30

Arg

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1094 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CCACGCGTCC GTCAAAGGAT ACAACCATGT ACACATAATT GACTTTTCCC TGATGCAAGG 60

TCTCCAGTGG CCGGCACTCA TGGATGTCTT CTCCGCCCGT GAGGGTGGGC CACCAAAGCT 120

CCGAATCACA GGCATTGGCC CGAACCCAAT AGGTGGCCGT GACGAGCTCC ATGAAGTGGG 180

AATTCGCCTC GCCAAGTATG CACACTCGGT GGGTATCGAC TTCACTTTCC AGGGAGTCTG 240

TGTCGATCAA CTTGATAGGT TGTGCGACTG GATGCTTCTC AAACCAATCA AAGGAGAGGC 300

AGTTGCCATA AACTCCATCC TACAACTCCA TCGCCTCCTC GTTGACCCAG ATGCAAACCC 360

AGTGGTGCCC GCACCAATAG ATATCCTCCT CAAATTGGTC ATCAAGATAA ACCCCATGAT 420 CTTCACGGTG GTTGAGCATG AGGCAGATCA CAACAGACCA CCACTACTAG AGAGGTTCAC 480

TAATGCCCTC TTCCACTATG CGACCATGTT TGACTCTTTG GAGGCCATGC ATCGTTGTAC 540

CAGTGGTAGA GACATCACCG ACTCACTCAC AGAGGTGTAC CTTCGAGGTG AGATTTTTGA 600

CATTGTCTGC GGCGAGGGCA GTGCACGCAC CGAACGTCAT GAGTTGTTTG GTCACTGGAG 660

GGAGAGGCTC ACCTATGCTG GGCTAACTCA AGTGTGGTTC GACCCCGATG AGGTTGACAC 720

GCTAAAAGAC CAGTTGATCC ATGTGACATC CTTATCTGGC TCTGGGTTCA ACATCCTAGT 780

GTGTGATGGC AGCCTTGCAC TAGCGTGGCA TAATCGCCCG TTATATGTGG CAACAGCTTG 840

GTGTGTGACA GGAGGAAATG CTGCCAGTTC CATGGTTGGC AACATCTGTA AGGGTACAAA 900

TGATAGTAGA AGAAAGGAAA ACCGTAATGG ACCCATGGAG TAGCAGGAAG AATAACCATG 960

TCATGAGCAA ATCGATCAAG TAATAAAATG CACTGATGAC ATGCATGGTG ATCTAAAGTT 1020

TTTTTGCGTG AATGTGCAAT GACGAATTGT TCAATTTGAA TAACCTAATC ATGAGACTCA 1080

AAAAAAAAAA AAAA 1094 (2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 313 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

His Ala Ser Val Lys Gly Tyr Asn His Val His He He Asp Phe Ser 1 5 10 15

Leu Met Gin Gly Leu Gin Trp Pro Ala Leu Met Asp Val Phe Ser Ala 20 25 30

Arg Glu Gly Gly Pro Pro Lys Leu Arg He Thr Gly He Gly Pro Asn 35 40 45

Pro He Gly Gly Arg Asp Glu Leu His Glu Val Gly He Arg Leu Ala 50 55 60

Lys Tyr Ala His Ser Val Gly He Asp Phe Thr Phe Gin Gly Val Cys 65 70 75 80

Val Asp Gin Leu Asp Arg Leu Cys Asp Trp Met Leu Leu Lys Pro He 85 90 95

Lys Gly Glu Ala Val Ala He Asn Ser He Leu Gin Leu His Arg Leu 100 105 110

Leu Val Asp Pro Asp Ala Asn Pro Val Val Pro Ala Pro He Asp He 115 120 125

Leu Leu Lys Leu Val He Lys He Asn Pro Met He Phe Thr Val Val 130 135 140

Glu His Glu Ala Asp His Asn Arg Pro Pro Leu Leu Glu Arg Phe Thr 145 150 155 160

Asn Ala Leu Phe His Tyr Ala Thr Met Phe Asp Ser Leu Glu Ala Met 165 170 175

His Arg Cys Thr Ser Gly Arg Asp He Thr Asp Ser Leu Thr Glu Val 180 185 190

Tyr Leu Arg Gly Glu He Phe Asp He Val Cyβ Gly Glu Gly Ser Ala 195 200 205

Arg Thr Glu Arg His Glu Leu Phe Gly His Trp Arg Glu Arg Leu Thr 210 215 220

Tyr Ala Gly Leu Thr Gin Val Trp Phe Asp Pro Asp Glu Val Asp Thr 225 230 235 240

Leu Lys Asp Gin Leu He His Val Thr Ser Leu Ser Gly Ser Gly Phe 245 250 255

Asn He Leu Val Cyβ Asp Gly Ser Leu Ala Leu Ala Trp His Asn Arg 260 265 270

Pro Leu Tyr Val Ala Thr Ala Trp Cys Val Thr Gly Gly Asn Ala Ala 275 280 285

Ser Ser Met Val Gly Asn He Cys Lys Gly Thr Asn Asp Ser Arg Arg 290 295 300

Lys Glu Asn Arg Asn Gly Pro Met Glu 305 310

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 611 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CCCAACTTGG GAAGCCCTTC CTCCGCTCCG CCTCCTACCT CAAGGAGGCC CTCCTCCTCG 60

CACTCGCCGA CAGCCACCAT GGCTCCTCCG GCGTCACCTC GCCGCTCGAC GTTGCCCTCA 120

AGCTTGCAGC ATACAAGTCT TTCTCTGACC TGTCACCTGT GCTCCAGTTC ACTAACTTTA 180

CCGCAACAAG GCGCTTCTTG ATGAGATTGG TGGCATGGCA ACTTCCTGCA TCCATGTCAT 240

TGACTTTGAT CTCGGTGTTG GTGGTCAGTG GGCTTCCTTC TTGCAGGAGC TTGCCCACCG 300

CCGGGGAGCT GGAGGTATGG CCTTGCCGTT GTTGAAGCTC ACGGCTTTCA TGTCGACTGC 360

TTCTCACCAT CCACTGGAGC TGCACCTTAC CCAGGATAAC CTCTCTCAGT TTGCCGCAGA 420

GCTCAGAATT CCTTTCGAAT TCAATGCCGT CAGTCTTGAT GCATTCAATC CTGCGGAATC 480

TATTTCTTCC TCTGGTGATG AAGTTGTTGC TGTTAGCCTC CCTGTTGGCT GCTCTGCTCG 540

TGCACCACCG CTGCCAGCGA TTCTTCGGTT GGTGAAACAG CTTTGTCCTA AGGTTGTCGT 600 GGCTATTGAT C 611

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 502 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: CDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TACAGAGCAA CAGCAGTATA ATATTAATTC 60

TGTACCACAC AACCATTTGA TAGGTTAAAT TACCCTCTAG TCTCTACTCA TAAGCAGTGT 120

TTCCAATGAG ATGATCATGG CTAATTGAGC AGAGCATGGC AACAACCTAA AGCAACATCA 180

TTAGCTATAG AGACTGACAC CAATATTCCT AAATCCACTA GGCTAGCTAA TAAGCTGCAA 240

CGAAAAGCAA TATGAAGAGT TCAACAGCTC AAGACAACAA TTTCATTTGC AACATTTAAT 300

TGCAAGAATA AATGGACATT ACTGGAGTGG TCGATGCTTG CAAACGGTGG TGGAACCTTG 360

GTGGAGTGAA GCTTATGGCT GATCAGCACC GCCAAGATGA TATGGATACA AGCTCCCCAC 420

GCTGCCAGTA GAGCGTAAGA GCAGCTCCGC GTTTCTCCAC ATGGAATCCT CGGACCTGCA 480

CCCGCTTCAG GAGGCAGTCT GC 502 (2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 298 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Pro Gin Gin Gin Gin Gin His Gin Gin Gin Gin Gin Gin His Lys Pro 1 5 10 15

Pro Pro Pro Pro He Gin Gin Gin Glu Arg Glu Asn Ser Ser Thr Asp 20 25 30

Ala Pro Pro Gin Pro Glu Thr Val Thr Ala Thr Val Pro Ala Val Gin 35 40 45

Thr Asn Thr Ala Glu Ala Leu Arg Glu Arg Lys Glu Glu He Lys Arg 50 55 60

Gin Lys Gin Asp Glu Glu Gly Leu His Leu Leu Thr Leu Leu Leu Gin 65 70 75 80

Cyβ Ala Glu Ala Val Ser Ala Asp Asn Leu Glu Glu Ala Asn Lys Leu 85 90 95 Leu Leu Glu He Ser Gin Leu Ser Thr Pro Tyr Gly Thr Ser Ala Gin 100 105 110

Arg Val Ala Ala Tyr Phe Ser Glu Ala Met Ser Ala Arg Leu Leu Asn 115 120 125

Ser Cyβ Leu Gly He Tyr Ala Ala Leu Pro Ser Arg Trp Met Pro Gin 130 135 140

Thr His Ser Leu Lys Met Val Ser Ala Phe Gin Val Phe Asn Gly He 145 150 155 160

Ser Pro Leu Val Lys Phe Ser His Phe Thr Ala Asn Gin Ala He Gin 165 170 175

Glu Ala Phe Glu Lys Glu Asp Ser Val His He He Asp Leu Asp He 180 185 190

Met Gin Gly Leu Gin Trp Pro Gly Leu Phe His He Leu Ala Ser Arg 195 200 205

Pro Gly Gly Pro Pro His Val Arg Leu Thr Gly Leu Gly Thr Ser Met 210 215 220

Glu Ala Leu Gin Ala Thr Gly Lys Arg Leu Ser Asp Phe Thr Asp Lys 225 230 235 240

Leu Gly Leu Pro Phe Glu Phe Cys Pro Leu Ala Glu Lys Val Gly Asn 245 250 255

Asp Leu Thr Glu Arg Leu Asn Val Arg Lys Arg Glu Ala Ala Val His 260 265 270

Trp Leu Gin His Ser Leu Tyr Asp Val Thr Gly Ser Asp Ala His Thr 275 280 285

Leu Trp Leu Leu Gin Arg Leu Ala Pro Lys 290 295

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

( ii ) MOLECULE TYPE : peptide

( xi ) SEQUENCE DESCRIPTION : SEQ ID NO: 31 :

Gly Thr Ser Pro Thr Gly Pro Glu Leu Leu Thr Tyr Met Hie He Leu

1 5 10 15

Tyr Glu Ala Cys Pro Tyr Phe Lys Phe Gly Tyr Glu Ser Ala Asn Gly 20 25 30

Ala He Ala Glu Ala Val Lye Asn Glu Ser Phe Val His He He Asp 35 40 45

Phe Gin He Ser Gin Gly Gly Gin Trp Val Ser Leu He Arg Ala Leu 50 55 60

Gly Ala Arg Pro Gly Gly Pro Pro Asn Val Arg He Thr Gly He Asp 65 70 75 80

Asp Pro Arg Ser Ser Phe Ala Arg Gin Gly Gly Leu Glu Leu Val Gly 85 90 95

Gin Arg Leu Gly Lys Leu Ala Glu Met Cys Gly Val Pro Phe Glu Phe 100 105 110

His Gly Ala Ala Leu Cys Cys Thr Glu Val Glu He Glu Lys Leu Gly 115 120 125

Val Arg Asn Gly Glu Ala Leu Ala Val Asn Phe Pro Leu Val Leu His 130 135 140

His Met Pro Asp Glu Ser Val Thr Val Glu Asn His Arg Asp Arg Leu 145 150 155 160

Leu Arg Leu Val Lys His Leu Ser Pro Asn Val Val Thr Leu Val Glu 165 170 175

Gin Glu Ala Aβn Thr Asn Thr Ala Pro Phe Leu Pro Arg Phe Val Glu 180 185 190

Thr Met Asn His Tyr Leu Ala Val Phe Glu Ser He Asp Val Lys Leu 195 200 205

Ala Arg Asp His Lys Glu Arg He Asn Val Glu Gin His Cys Leu Ala 210 215 220

Arg Glu Val Val Asn Leu He Ala Cys Glu Gly Val Glu Arg Glu Glu 225 230 235 240

Arg His Glu Pro Leu Gly Lys Trp Arg Ser Arg Phe His Met Ala Gly 245 250 255

Phe Lys Pro Tyr Pro Leu Ser Ser Tyr Val Asn Ala Thr He Lys Gly 260 265 270

Leu Leu Glu Ser Tyr Ser Glu Lys Tyr Thr Leu Glu Glu Arg Asp Gly 275 280 285

Ala Leu Tyr Leu Gly Trp Lys Asn Gin Pro Leu He Thr Ser Cys Ala 290 295 300

Trp Arg Xaa 305

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 353 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Leu Ser Met Val Asn Glu Leu Arg Gin He Val Ser He Gin Gly Asp 1 5 10 15

Pro Ser Gin Arg He Ala Ala Tyr Met Val Glu Gly Leu Ala Ala Arg 20 25 30 Met Ala Ala Ser Gly Lys Phe He Tyr Arg Ala Leu Lys Cys Lys Glu 35 40 45

Pro Pro Ser Aβp Glu Arg Leu Ala Ala Met Gin Val Leu Phe Glu Val 50 55 60

Cyβ Pro Cyβ Phe Lys Phe Gly Phe Leu Ala Ala Aβn Gly Ala He Leu 65 70 75 80

Glu Ala He Lye Gly Glu Glu Glu Val His He He Asp Phe Aβp He 85 90 95

Asn Gin Gly Asn Gin Tyr Met Thr Leu He Arg Ser He Ala Glu Leu 100 105 110

Pro Gly Lys Arg Pro Arg Leu Arg Leu Thr Gly He Asp Aβp Pro Glu 115 120 125

Ser Val Gin Arg Ser He Gly Gly Leu Arg He He Gly Leu Arg Leu 130 135 140

Glu Gin Leu Ala Glu Asp Aβn Gly Val Ser Phe Lys Phe Lys Ala Met 145 150 155 160

Pro Ser Lys Thr Ser He Val Ser Pro Ser Thr Leu Gly Cys Lys Pro 165 170 175

Gly Glu Thr Leu He Val Asn Phe Ala Phe Gin Leu His His Met Pro 180 185 190

Asp Glu Ser Val Thr Thr Val Asn Gin Arg Asp Glu Leu Leu His Met 195 200 205

Val Lys Ser Leu Asn Pro Lys Leu Val Thr Val Val Glu Gin ABp Val 210 215 220

Asn Thr Aβn Thr Ser Pro Phe Phe Pro Arg Phe He Glu Ala Tyr Glu 225 230 235 240

Tyr Tyr Ser Ala Val Phe Glu Ser Leu Asp Met Thr Leu Pro Arg Glu 245 250 255

Ser Gin Glu Arg Met Aβn Val Glu Arg Gin Cys Leu Ala Arg Asp He 260 265 270

Val Asn He Val Ala Cys Glu Gly Glu Glu Arg He Glu Arg Tyr Glu 275 280 285

Ala Ala Gly Lys Trp Arg Ala Arg Met Met Met Ala Gly Phe Asn Pro 290 295 300

Lys Pro Met Ser Ala Lys Val Thr Aβn Asn He Gin Asn Leu He Lys 305 310 315 320

Gin Gin Tyr Cys Asn Lys Tyr Lys Leu Lys Glu Glu Met Gly Glu Leu 325 330 335

His Phe Cys Trp Glu Glu Lys Ser Leu He Val Ala Ser Ala Trp Arg 340 345 350

Xaa

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 326 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Ala Met Glu Gly Glu Lye Met Val His Val He Aβp Leu Aβp Ala Ser 1 5 10 15

Glu Pro Ala Gin Trp Leu Ala Leu Leu Gin Ala Phe Aβn Ser Arg Pro 20 25 30

Glu Gly Pro Pro Hie Leu Arg He Thr Gly Val Hie Hie Gin Lys Glu 35 40 45

Val Leu Glu Gin Met Ala Hie Arg Leu He Glu Glu Ala Glu Lye Leu 50 55 60

Asp He Pro Phe Gin Phe Asn Pro Val Val Ser Arg Leu Asp Cys Leu 65 70 75 80

Asn Val Glu Gin Leu Arg Val Lys Thr Gly Glu Ala Leu Ala Val Ser 85 90 95

Ser Val Leu Gin Leu His Thr Phe Leu Ala Ser Asp Aβp Aβp Leu Met 100 105 110

Arg Lys Asn Cys Ala Leu Arg Phe Gin Asn Asn Pro Ser Gly Val Asp 115 120 125

Leu Gin Arg Val Leu Met Met Ser His Gly Ser Ala Ala Glu Ala Arg 130 135 140

Glu Asn Asp Met Ser Asn Asn Asn Gly Tyr Ser Pro Ser Gly Asp Ser 145 150 155 160

Ala Ser Ser Leu Pro Leu Pro Ser Ser Gly Arg Thr Asp Ser Phe Leu 165 170 175

Aβn Ala He Trp Gly Leu Ser Pro Lye Val Met Val Val Thr Glu Gin 180 185 190

Asp Ser Asp His Asn Gly Ser Thr Leu Met Glu Arg Leu Leu Glu Ser 195 200 205

Leu Tyr Thr Tyr Ala Ala Leu Phe Asp Cyβ Leu Glu Thr Lys Val Pro 210 215 220

Arg Thr Ser Gin Asp Arg He Lys Val Glu Lys Met Leu Phe Gly Glu 225 230 235 240

Glu He Lye Aβn He He Ser Cyβ Glu Gly Phe Glu Arg Arg Glu Arg 245 250 255

Hie Glu Lye Leu Glu Lye Trp Ser Gin Arg He Aβp Leu Ala Gly Phe 260 265 270

Gly Aβn Val Pro Leu Ser Tyr Tyr Ala Met Leu Gin Ala Arg Arg Leu 275 280 285

Leu Gin Gly Cyβ Gly Phe Asp Gly Tyr Arg He Lys Glu Glu Ser Gly 290 295 300 Cyβ Ala Val He Cyβ Trp Gin Aβp Arg Pro Leu Tyr Ser Val Ser Ala 305 310 315 320

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 277 amino acidβ

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Asn Lys Arg Leu Lys Ser Cys Ser Ser Pro Asp Ser Met Val Thr Ser

1 5 10 15

Thr Ser Thr Gly Thr Gin He Gly Gly Val He Gly Thr Thr Val Thr 20 25 30

Thr Thr Thr Thr Thr Thr Thr Ala Ala Ala Glu Ser Thr Arg Ser Val 35 40 45

He Leu Val Asp Ser Gin Glu Asn Gly Val Arg Leu Val Hie Ala Leu 50 55 60

Met Ala Cys Ala Glu Ala He Gin Gin Asn Aβn Leu Thr Leu Ala Glu 65 70 75 80

Ala Leu Val Lys Gin He Gly Cys Leu Ala Val Ser Gin Ala Gly Ala 85 90 95

Met Arg Lys Val Ala Thr Tyr Phe Ala Glu Ala Leu Ala Arg Arg He 100 105 110

Tyr Arg Leu Ser Pro Pro Gin Asn Gin He Asp His Cys Leu Ser Asp 115 120 125

Thr Leu Gin Met His Phe Tyr Glu Thr Cys Pro Tyr Leu Lys Phe Ala 130 135 140

His Phe Thr Ala Aβn Gin Ala He Leu Glu Ala Phe Glu Gly Lys Lys 145 150 155 160

Arg Val His Val He Asp Phe Ser Met Asn Gin Gly Leu Gin Trp Pro 165 170 175

Ala Leu Met Gin Ala Leu Ala Leu Arg Glu Gly Gly Pro Pro Thr Phe 180 185 190

Arg Leu Thr Gly He Gly Pro Pro Ala Pro Aβp Asn Ser Asp His Leu 195 200 205

His Glu Val Gly Cys Lys Leu Ala Gin Leu Ala Glu Ala He His Val 210 215 220

Glu Phe Glu Tyr Arg Gly Phe Val Ala Asn Ser Leu Ala Asp Leu Asp 225 230 235 240

Ala Ser Met Leu Glu Leu Arg Pro Ser Asp Thr Glu Ala Val Ala Val 245 250 255

Asn Ser Val Phe Glu Leu His Lys Leu Leu Gly Arg Xaa Gly Gly He 260 265 270

Glu Lys Val Leu Gly 275

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 262 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Gly Gly Gly Gly Aβp Thr Tyr Thr Thr Asn Lys Arg Leu Lys Cys Ser 1 5 10 15

Asn Gly Val Val Glu Thr Thr Thr Ala Thr Ala Glu Ser Thr Arg His 20 25 30

Val Val Leu Val Aβp Ser Gin Glu Asn Gly Val Arg Leu Val His Ala 35 40 45

Leu Leu Ala Cyβ Ala Glu Ala Val Gin Lye Glu Asn Leu Thr Val Ala 50 55 60

Glu Ala Leu Val Lys Gin He Gly Phe Leu Ala Val Ser Gin He Gly 65 70 75 80

Ala Met Arg Gin Val Ala Thr Tyr Phe Ala Glu Ala Leu Ala Arg Arg 85 90 95

He Tyr Arg Leu Ser Pro Ser Gin Ser Pro He Asp His Ser Leu Ser 100 105 110

Asp Thr Leu Gin Met Hie Phe Tyr Glu Thr Cyβ Pro Tyr Leu Lys Phe 115 120 125

Ala His Phe Thr Ala Asn Gin Ala He Leu Glu Ala Phe Gin Gly Lye 130 135 140

Lys Arg Val His Val He Asp Phe Ser Met Ser Gin Gly Leu Gin Trp 145 150 155 160

Pro Ala Leu Met Gin Ala Leu Ala Leu Arg Pro Gly Gly Pro Pro Val 165 170 175

Phe Arg Leu Thr Gly He Gly Pro Pro Ala Pro Asp Asn Phe Aβp Tyr 180 185 190

Leu His Glu Val Gly Cyβ Lys Leu Ala His Leu Ala Glu Ala He His 195 200 205

Val Glu Phe Glu Tyr Arg Gly Phe Val Ala Aβn Thr Leu Ala Asp Leu 210 215 220

Aβp Ala Ser Met Leu Glu Leu Arg Pro Ser Glu He Glu Ser Val Ala 225 230 235 240 Val Aβn Ser Val Phe Glu Leu Hie Lye Leu Leu Gly Arg Pro Gly Ala 245 250 255

He Asp Lys Val Leu Gly 260

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 203 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Gin Leu Gly Lys Pro Phe Leu Arg Ser Ala Ser Tyr Leu Lys Glu Ala 1 5 10 15

Leu Leu Leu Ala Leu Ala Asp Ser Hie Hie Gly Ser Ser Gly Val Thr 20 25 30

Ser Pro Leu Asp Val Ala Leu Lys Leu Ala Ala Tyr Lys Ser Phe Ser 35 40 45

Asp Leu Ser Pro Val Leu Gin Phe Thr Asn Phe Thr Ala Asn Lys Ala 50 55 60

Leu Leu Aβp Glu He Gly Gly Met Ala Thr Ser Cys He His Val He 65 70 75 80

Aβp Phe Aβn Leu Gly Val Gly Gly Gin Trp Ala Ser Phe Leu Gin Glu 85 90 95

Leu Ala Hie Arg Arg Gly Ala Gly Gly Met Ala Leu Pro Leu Leu Lys 100 105 110

Leu Thr Ala Phe Met Ser Thr Ala Ser His His Pro Leu Glu Leu His 115 120 125

Leu Thr Gin Aβp Aβn Leu Ser Gin Phe Ala Ala Glu Leu Arg He Pro 130 135 140

Phe Glu Phe Aβn Ala Val Ser Leu Aβp Ala Phe Aβn Pro Ala Glu Ser 145 150 155 160

He Ser Ser Ser Gly Aβp Glu Val Val Ala Val Ser Leu Pro Val Gly 165 170 175

Cyβ Ser Ala Arg Ala Pro Pro Leu Pro Ala He Leu Arg Leu Val Lys 180 185 190

Gin Leu Cys Pro Lys Val Val Val Ala He Asp 195 200

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 131 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

His Ala Ser Val Lys Gly Tyr Asn His Val His He He Asp Phe Ser 1 5 10 15

Leu Met Gin Gly Leu Gin Trp Pro Ala Leu Met Asp Val Phe Ser Ala 20 25 30

Arg Glu Gly Gly Pro Pro Lys Leu Arg He Thr Gly He Gly Pro Aβn 35 40 45

Pro He Gly Gly Arg Aβp Glu Leu Hie Glu Val Gly He Arg Leu Ala 50 55 60

Lye Tyr Ala His Ser Val Gly He Asp Phe Thr Phe Gin Gly Val Cyβ 65 70 75 80

Val Aβp Gin Leu Aβp Arg Leu Cyβ Aβp Trp Met Leu Leu Lye Pro He 85 90 95

Lye Gly Glu Ala Val Ala He Aβn Ser He Leu Gin Leu His Arg Leu 100 105 110

Leu Val Asp Pro Asp Ala Asn Pro Val Val Pro Ala Pro He Asp He 115 120 125

Leu Leu Lys 130

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Gin Glu Ala Phe Glu Arg Glu Glu Arg Val Hie He He Aβp Leu Asp 1 5 10 15

He Met Gin Gly Leu Gin Trp Pro Gly Leu Phe Hie He Leu Ala Ser 20 25 30

Arg

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: βingle

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Phe Ala Gly Cys Arg Arg Val His Val Val Asp Phe Gly He Lys Gin 1 5 10 15

Gly Met Gin Trp Pro Ala Leu Leu Xaa Asp Leu Ala Leu 20 25

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 73 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Gly Arg Aβn Gly Arg Thr Leu Trp Leu Gly Glu Gly His He Asp Leu 1 5 10 15

Trp Pro Leu Gin Gly Leu Leu Ser Gin Gly Leu Gin Arg Ala Leu Cys 20 25 30

Ala Arg Pro Leu Gly Ala Pro His Val Phe Leu Pro Gly Leu His Thr 35 40 45

Leu Ser Leu Gly Leu Gin Xaa Arg Hie Leu Leu Val Hie Met Met Ala 50 55 60

Leu Ser Tyr Ser Tyr Gly Arg Xaa Pro 65 70

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Thr Ser Asp Ser Ala Ser Ser Phe Asn He Pro Thr Ser Ala Gin Asn 1 5 10 15

His Tyr Ala Thr Gly Ser Phe Ser Thr Asn Ser Arg Thr Thr Asn Val 20 25 30

Ala Thr Ala Thr Thr Asn Ser Ala Thr Ala Hie Trp Val Ala Thr Asp 35 40 45

Ala Glu His Thr Asp Thr He He Ala Gin Pro 50 55 (2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 110 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Arg Xaa Phe Aβp Ser Leu Glu His Asp Ala Ser Lys Gly Glu Pro Arg 1 5 10 15

Glu Asp Glu Arg Gly Arg Xaa Cyβ Leu Ala Arg Aβn He Val Asn He 20 25 30

Val Xaa Cys Lys Xaa Glu Glu Arg He Glu Arg Tyr Glu Val Thr Gly 35 40 45

Lys Trp Arg Ala Arg Met Met Met Ala Gly Phe Ser Pro Arg Pro Met 50 55 60

Ser Gly Arg Val Thr Ser Aβn He Glu Ser Leu He Lys Arg Asp Tyr 65 70 75 80

Cys Ser Lys Tyr Lys Val Lys Glu Glu Met Gly Glu Leu His Phe Ser 85 90 95

Trp Glu Glu Lys Ser Leu He Val Ala Ser Ala Trp Ser Xaa 100 105 110

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 137 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Aβn Gly Ser Tyr Aβn Ala Pro Phe Phe Val Thr Arg Phe Arg Glu Ala 1 5 10 15

Leu Phe Hie Tyr Ser Ala He Phe Aβp Met Leu Glu Thr Aβn He Pro 20 25 30

Lye Asp Asn Glu Gin Arg Leu Leu He Glu Ser Ala Leu Phe Ser Arg 35 40 45

Glu Xaa Asn Val He Ser Cyβ Glu Gly Leu Glu Arg Met Glu Arg Pro 50 55 60

Glu Thr Tyr Lye Gin Trp Gin Val Arg Aβn Gin Arg Val Gly Phe Lye 65 70 75 80

Gin Leu Pro Leu Asn Gin Asp Met Met Lye Arg Ala Arg Xaa Glu Gly 85 90 95

Gin Val Leu Pro Thr Arg Thr Phe He He Aβp Glu Aβp Aβn Arg Trp 100 105 110

Leu Leu Gin Gly Trp Lye Gly Arg He Leu Phe Ala Leu Ser Thr Trp 115 120 125

Lye Pro Asp Aβn Arg Ser Ser Ser Xaa

130 135

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 amino acidβ

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Asn Gly Gly Ala Phe Ala Pro Ser Thr Trp Thr Ala Arg Ser Leu Asn 1 5 10 15

Gly Gly Ala Phe Ala Pro Ser Thr Trp Thr Ala Arg Ser Leu Pro Val 20 25 30

Pro Ser Ser Pro Ser Thr Asp Ser Phe 35 40

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1279 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: CDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GCGGCTATCT TCTACGGCCA CCACCACCAT ACACCTCCGC CGGCAAAGCG GCTCAACCCT 60

GGTCCCGTGG GGATAACAGA GCAGCTGGTT AAGGCAGCAG AGGTCATAGA GAGCGACACG 120

TGTCTAGCTC AGGGGATATT GGCGCGGCTC AATCAACAGC TCTCTTCTCC CGTCGGGAAG 180

CCATTAGAAA GAGCAGCTTT TTACTTCAAA GAAGCTCTCA ATAATCTCCT TCACAACGTC 240

TCCCAAACCC TAAACCCTTA TTCCCTCATC TTCAAGATCG CTGCTTACAA ATCCTTCTCA 300

GAGATCTCTC CCGTTCTTCA GTTCGCCAAC TTTACCTCCA ACCAAGCCCT CTTAGAGTCC 360

TTCCATGGCT TCCACCGTCT CCACATCATC GACTTCGATA TCGGCTACGG TGGCCAATGG 420

GCTTCCCTCA TGCAAGAGCT TGTTCTCCGC GACAACGCCG CTCCTCTCTC CCTCAAGATC 480

ACCGTTTTCG CTTCTCCGGC GAACCACGAC CAGCTCGAAC TTGGCTTCAC TCAAGACAAC 540 CTCAAGCACT TCGCCTCTGA GATCAACATC TCCCTTGACA TCCAAGTTTT GAGCTTAGAC 600

CTCCTCGGCT CCATCTCGTG GCCTAACTCG TCGGAGAAAG AAGCTGTCGC CGTTAACATC 660

TCCGCCGCGT CCTTCTCGCA CCTCCCTTTG GTCCTCCGTT TCGTGAAGCA TCTATCTCCG 720

ACGATCATCG TCTGCTCCGA CAGAGGATGC GAGAGGACGG ATCTGCCCTT CTCTCAACAG 780

CTCGCCCACT CGCTGCACTC ACACACCGCT CTCTTCGAAT CCCTCGACGC CGTCAACGCC 840

AACCTCGACG CAATGCAGAA GATCGAGAGG TTTCTTATAC AGCCGGAGAT AGAGAAGCTG 900

GTGTTGGATC GTAGCCGTCC GATAGAAAGG CCGATGATGA CGTGGCAAGC GATGTTTCTA 960

CAGATGGGTT TCTCACCGGT GACGCACAGT AACTTCACGG AGTCTCAAGC CGAGTGTTTA 1020

GTCCAACGGA CGCCAGTGAG AGGCTTTCAC GTCGAGAAGA AACATAACTC ACTTCTCCTA 1080

TGTTGGCAAA GGACAGAACT CGTCGGAGTT TCAGCATGGA GATGTCGCTC CTCCTGATTT 1140

CCACCGGAGT TTCAATTATT AAAAAAATAT TTTCCTTAAT TCAATTTATC TTAAATGACA 1200

AATTTTTAGT TTCTGATTTT ATTTTGCTCA GTGCGATGGA TTTTTAAATT TAAGTTTCAC 1260

ACAAATATAT AAATTTTTG 1279 (2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 379 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Ala Ala He Phe Tyr Gly His His His His Thr Pro Pro Pro Ala Lys 1 5 10 15

Arg Leu Asn Pro Gly Pro Val Gly He Thr Glu Gin Leu Val Lys Ala 20 25 30

Ala Glu Val He Glu Ser Asp Thr Cys Leu Ala Gin Gly He Leu Ala 35 40 45

Arg Leu Aβn Gin Gin Leu Ser Ser Pro Val Gly Lye Pro Leu Glu Arg 50 55 60

Ala Ala Phe Tyr Phe Lye Glu Ala Leu Asn Asn Leu Leu His Asn Val 65 70 75 80

Ser Gin Thr Leu Aβn Pro Tyr Ser Leu He Phe Lye He Ala Ala Tyr 85 90 95

Lye Ser Phe Ser Glu He Ser Pro Val Leu Gin Phe Ala Asn Phe Thr 100 105 110

Ser Aβn Gin Ala Leu Leu Glu Ser Phe His Gly Phe Hie Arg Leu His 115 120 125

He He Asp Phe Aβp He Gly Tyr Gly Gly Gin Trp Ala Ser Leu Met 130 135 140 Gin Glu Leu Val Leu Arg Aβp Aβn Ala Ala Pro Leu Ser Leu Lys He 145 150 155 160

Thr Val Phe Ala Ser Pro Ala Asn Hie Aβp Gin Leu Glu Leu Gly Phe 165 170 175

Thr Gin Aβp Asn Leu Lys His Phe Ala Ser Glu He Asn He Ser Leu 180 185 190

Asp He Gin Val Leu Ser Leu Asp Leu Leu Gly Ser He Ser Trp Pro 195 200 205

Asn Ser Ser Glu Lys Glu Ala Val Ala Val Asn He Ser Ala Ala Ser 210 215 220

Phe Ser His Leu Pro Leu Val Leu Arg Phe Val Lys His Leu Ser Pro 225 230 235 240

Thr He He Val Cys Ser Aβp Arg Gly Cys Glu Arg Thr Asp Leu Pro 245 250 255

Phe Ser Gin Gin Leu Ala Hie Ser Leu His Ser His Thr Ala Leu Phe 260 265 270

Glu Ser Leu Asp Ala Val Asn Ala Asn Leu Asp Ala Met Gin Lys He 275 280 285

Glu Arg Phe Leu He Gin Pro Glu He Glu Lys Leu Val Leu Asp Arg 290 295 300

Ser Arg Pro He Glu Arg Pro Met Met Thr Trp Gin Ala Met Phe Leu 305 310 315 320

Gin Met Gly Phe Ser Pro Val Thr His Ser Asn Phe Thr Glu Ser Gin 325 330 335

Ala Glu Cyβ Leu Val Gin Arg Thr Pro Val Arg Gly Phe His Val Glu 340 345 350

Lys Lys His Aβn Ser Leu Leu Leu Cyβ Trp Gin Arg Thr Glu Leu Val 355 360 365

Gly Val Ser Ala Trp Arg Cyβ Arg Ser Ser Xaa 370 375

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 745 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

TGCATACAAC GCACCGTTTT TCGTAACACG GTTTCGCGAA GCTCTATTTC ATTTCTCCTC 60

GATTTTTGAC ATGCTTGAGA CAATTGTGCC ACGAGAAGAC GAAGAGAGGA TGTTCCTTGA 120

GATGGAGGTC TTTGGGAGAG AGGCACTGAA TGTGATTGCT TGCGAAGGTT GGGAAAGAGT 180

GGAGAGGCCT GAGACATACA AGCAGTGGCA CGTACGGGCT ATGAGGTCAG GGTTGGTGCA 240 GGTTCCATTT GACCCAAGCA TTATGAAGAC ATCGCTGCAT AAGGTCCACA CATTCTACCA 300

CAAGGATTTT GTGATCGATC AAGATAACCG GTGGCTCTTG CAAGGCTGGA AGGGAAGAAC 360

TGTCATGGCT CTTTCTGTTT GGAAACCAGA GTCCAAGGCT TGACCGAGAA ATCCTCGTTG 420

GCATATGAGA GACCATCTCT TGATTTTCTT CCTGTGTAAT TCCCAGAGAC AGAATTACAG 480

ATGTAAGAAG AGAATGCTGC ACAAAGAACT TGTTCAAAGA TAATATTGAT GTAAGTCCTG 540

TTTTATAACT TTCTAGCTGT GTTTTTGTTG TTTCTCAGCT AGATTCTCCT AACGGTATTC 600

TTGTAGCTAG GGTGATCAGA TTGTTTGTAT ATTGCTAGCA GAGTTAGTTT GTCTAGATTG 660

TAACACATAT AAGAGGAAGC TTAGAGTTTC TATGGTTTAA AGAGAAGTTT TTTCCTTCTC 720

CAATGTAAAA AAAAAAAAAA AAAAA 745 (2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 134 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Ala Tyr Asn Ala Pro Phe Phe Val Thr Arg Phe Arg Glu Ala Leu Phe 1 5 10 15

His Phe Ser Ser He Phe Asp Met Leu Glu Thr He Val Pro Arg Glu 20 25 30

Asp Glu Glu Arg Met Phe Leu Glu Met Glu Val Phe Gly Arg Glu Ala 35 40 45

Leu Asn Val He Ala Cys Glu Gly Trp Glu Arg Val Glu Arg Pro Glu 50 55 60

Thr Tyr Lys Gin Trp His Val Arg Ala Met Arg Ser Gly Leu Val Gin 65 70 75 80

Val Pro Phe Asp Pro Ser He Met Lys Thr Ser Leu His Lys Val His 85 90 95

Thr Phe Tyr His Lye Aβp Phe Val He Asp Gin Asp Asn Arg Trp Leu 100 105 110

Leu Gin Gly Trp Lys Gly Arg Thr Val Met Ala Leu Ser Val Trp Lys 115 120 125

Pro Glu Ser Lys Ala Xaa 130

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 775 base pairβ

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

AAAAAATGGG AAACCATCAC TCTTGATGAA CTTATGATCA ATCCAGGAGA GACAACGGTC 60

GTCAACTGCA TTCATCGGTT ACAATACACT CCTGATGAAA CTGTGTCATT AGACTCTCCA 120

AGAGACACGG TTCTGAAGCT ATTCAGAGAT ATCAATCCTG ACCTCTTTGT GTTTGCAGAG 180

ATTAACGGAA TGTACAACTC TCCTTTCTTC ATGACGAGGT TCCGAGAAGC GCTTTTTCAT 240

TACTCTTCAC TCTTTGACAT GTTTGACACC ACAATACACG CAGAGGATGA GTACAAAAAC 300

AGGTCACTGT TGGAGAGAGA GTTACTTGTG AGAGACGCGA TGAGCGTGAT TTCCTGCGAG 360

GGTGCAGAGC GGTTTGCGAG GCCTGAAACC TACAAGCAAT GGCGAGTTAG GATTTTGAGA 420

GCCGGGTTTA AGCCAGCAAC TATTAGCAAA CAGATCATGA AGGAGGCTAA GGAAATTGTG 480

AGGAAACGTT ACCATAGAGA TTTTGTGATC GATAGCGATA ACAATTGGAT GCTTCAAGGA 540

TGGAAAGGAA GAGTCATCTA TGCTTTTTCT TGCTGGAAAC CTGCTGAGAA GTTCACAAAC 600

AATAATTTAA ACATCTGAAA AATGTTACTT CTCAATTACA TCATTTTTGT TTCCCAATGG 660

TTTTGTAGAA TATGTTTGAT CCCGTGAGTG GATGCAACTC TTTTTTCCTG CAAGTACATA 720

TTGTATTCAA ATCCTTGTGG AAATGATAAA TTGTTTAATC AAAAAAAAAA AAAAA 775 (2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 206 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Lys Lys Trp Glu Thr He Thr Leu Asp Glu Leu Met He Asn Pro Gly 1 5 10 15

Glu Thr Thr Val Val Asn Cyβ He His Arg Leu Gin Tyr Thr Pro Aβp 20 25 30

Glu Thr Val Ser Leu Asp Ser Pro Arg Asp Thr Val Leu Lys Leu Phe 35 40 45

Arg Asp He Asn Pro Aβp Leu Phe Val Phe Ala Glu He Asn Gly Met 50 55 60

Tyr Asn Ser Pro Phe Phe Met Thr Arg Phe Arg Glu Ala Leu Phe His 65 70 75 80

Tyr Ser Ser Leu Phe Asp Met Phe Aβp Thr Thr He Hie Ala Glu Aβp 85 90 95

Glu Tyr Lye Asn Arg Ser Leu Leu Glu Arg Glu Leu Leu Val Arg Asp 100 105 110

Ala Met Ser Val He Ser Cys Glu Gly Ala Glu Arg Phe Ala Arg Pro 115 120 125

Glu Thr Tyr Lys Gin Trp Arg Val Arg He Leu Arg Ala Gly Phe Lye 130 135 140

Pro Ala Thr He Ser Lye Gin He Met Lye Glu Ala Lye Glu He Val 145 150 155 160

Arg Lye Arg Tyr Hie Arg Aβp Phe Val He Aβp Ser Aβp Aβn Aβn Trp 165 170 175

Met Leu Gin Gly Trp Lye Gly Arg Val He Tyr Ala Phe Ser Cyβ Trp 180 185 190

Lys Pro Ala Glu Lye Phe Thr Aβn Aβn Aβn Leu Aβn He Xaa 195 200 205

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 548 baβe pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

AATCGCTTGA ACCGAATTTG GATCGAGATT CGAAAGAAAG GCTGAGAGTG GAGAGAGTGC 60

TGTTCGGTAG GAGGATTATG GATTTGGTCC GATCAGATGA TGATAATAAT AAACCGGGAA 120

CCCGGTTTGG GTTAATGGAG GAGAAAGAAC AATGGAGAGT GTTGATGGAG AAAGCTGGAT 180

TTGAGCCGGT TAAACCGAGT AATTACGCGG TTAGCCAAGC GAAGCTGCTA CTATGGAACT 240

ACAATTATAG TACATTGTAT TCACTTGTTG AATCGGAGCC AGGTTTCATC TCCTTGGCTT 300

GGAACAATGT GCCTCTCCTC ACCGTTTCCT CTTGGCGTTG ACTACTTGGT CCGATAAGTT 360

AATCTAGTAT TTTGAGTTAG CTTTTAGAAT TGAATTGTTT GGGGTTAGAT TTGGATGTTT 420

AATTAGTCTC TAGCCTATTC TCTTACTCTT TTTTGTCTAG TGCTTGGAGT GATGATGGTT 480

TGTCGTTTAT GTTCATTTGT AATATATATT GTATGTAACA TTTGACTAAA AAAAAAAAAA 540

AAAAAAAA 548 (2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 113 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Ser Leu Glu Pro Asn Leu Asp Arg Asp Ser Lys Glu Arg Leu Arg Val 1 5 10 15

Glu Arg Val Leu Phe Gly Arg Arg He Met Aβp Leu Val Arg Ser Asp 20 25 30

Aβp Aβp Aβn Aβn Lye Pro Gly Thr Arg Phe Gly Leu Met Glu Glu Lye 35 40 45

Glu Gin Trp Arg Val Leu Met Glu Lye Ala Gly Phe Glu Pro Val Lye 50 55 60

Pro Ser Aβn Tyr Ala Val Ser Gin Ala Lye Leu Leu Leu Trp Asn Tyr 65 70 75 80

Asn Tyr Ser Thr Leu Tyr Ser Leu Val Glu Ser Glu Pro Gly Phe He 85 90 95

Ser Leu Ala Trp Asn Asn Val Pro Leu Leu Thr Val Ser Ser Trp Arg 100 105 110

Xaa

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1093 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GCGAATGTTG AGATCTTGGA AGCAATAGCT GGGGAAACCA GAGTCCACAT TATCGATTTT 60

CAGATTGCAC AGGGATCACA ATACATGTTT TTGATTCAGG AGCTTGCGAA ACGCCCTGGT 120

GGGCCGCCGT TGCTGCGTGT GACGGGTGTG GATGATTCAC AGTCCACCTA TGCTCGTGGG 180

GGAGGACTCA GCTTGGTAGG TGAGAGGCTT GCAACTTTGG CGCAGTCATG TGGTGTCCCG 240

TTTGAGTTTC ACGATGCCAT CATGTCTGGG TGCAAGGTGC AGCGGGAACA TCTCGGGTTG 300

GAACCTGGCT TTGCTGTTGT TGTGAACTTC CCATATGTAT TACACCACAT GCCAGACGAG 360

AGCGTAAGTG TTGAAAAATA CAGAGACAGG CTGCTGCATC TGATCAAGAG CCTCTCCCCA 420

AAACTGGTTA CTCTAGTAGA GCAAGAATCC AACACAAACA CCTCGCCATT GGTGTCACGG 480

TTTGTGGAAA CACTGGATTA CTACACAGCG ATGTTTGAGT CGATAGATGC AGCACGGCCA 540

CGGGATGATA AGCAGAGAAT CAGCGCAGAA CAACACTGTG TAGCAAGAGA CATAGTGAAC 600

ATGATAGCAT GTGAGGAGTC AGAGAGAGTA GAGAGACACG AGGTACTGGG GAAATGGAGG 660

GTCAGAATGA TGATGGCTGG GTTCACGGGT TGGCCGGTCA GCACATCTGC AGCGTTTGCA 720

GCGAGTGAGA TGCTGAAAGC TTATGACAAA AACTACAAAC TGGGAGGCCA TGAAGGAGCG 780 CTCTACCTCT TCTGGAAGAG ACGACCCATG GCTACATGTT CCGTGTGGAA GCCAAACCCA 840

AACTATATTG GGTAAGTTAT AGTGATGATG GTTACTTGAG TGGATAAAGA AGAGCACAAC 900

AAAAACACAT CTGTCGCTGT AAATTTTTTA GGATGTGCAA TGATGTTTTA AGTTGTAACA 960

CAACCTAAGT TATATATGTA TACAAACCAA ACCTGGTGGT TGTTTTTCTC TTGTAAATTG 1020

TCATGTGGTT GTGGGTGGGA AGCTAGTAAT GAAATATAAC CAAAACATTG ATTAGGTCAA 1080

AAAAAAAAAA AAA 1093 (2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 285 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Ala Aβn Val Glu He Leu Glu Ala He Ala Gly Glu Thr Arg Val His 1 5 10 15

He He Aβp Phe Gin He Ala Gin Gly Ser Gin Tyr Met Phe Leu He 20 25 30

Gin Glu Leu Ala Lys Arg Pro Gly Gly Pro Pro Leu Leu Arg Val Thr 35 40 45

Gly Val Asp Aβp Ser Gin Ser Thr Tyr Ala Arg Gly Gly Gly Leu Ser 50 55 60

Leu Val Gly Glu Arg Leu Ala Thr Leu Ala Gin Ser Cys Gly Val Pro 65 70 75 80

Phe Glu Phe His Aβp Ala He Met Ser Gly Cys Lys Val Gin Arg Glu 85 90 95

His Leu Gly Leu Glu Pro Gly Phe Ala Val Val Val Asn Phe Pro Tyr 100 105 110

Val Leu Hie Hie Met Pro Asp Glu Ser Val Ser Val Glu Lys Tyr Arg 115 120 125

Asp Arg Leu Leu Hie Leu He Lys Ser Leu Ser Pro Lys Leu Val Thr 130 135 140

Leu Val Glu Gin Glu Ser Aβn Thr Aβn Thr Ser Pro Leu Val Ser Arg 145 150 155 160

Phe Val Glu Thr Leu Asp Tyr Tyr Thr Ala Met Phe Glu Ser He Aep 165 170 175

Ala Ala Arg Pro Arg Asp Asp Lye Gin Arg He Ser Ala Glu Gin Hie 180 185 190

Cyβ Val Ala Arg Aβp He Val Aβn Met He Ala Cys Glu Glu Ser Glu 195 200 205

Arg Val Glu Arg His Glu Val Leu Gly Lys Trp Arg Val Arg Met Met 210 215 220

Met Ala Gly Phe Thr Gly Trp Pro Val Ser Thr Ser Ala Ala Phe Ala 225 230 235 240

Ala Ser Glu Met Leu Lys Ala Tyr Asp Lys Aβn Tyr Lye Leu Gly Gly 245 250 255

Hie Glu Gly Ala Leu Tyr Leu Phe Trp Lye Arg Arg Pro Met Ala Thr 260 265 270

Cyβ Ser Val Trp Lys Pro Asn Pro Aβn Tyr He Gly Xaa 275 280 285

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1928 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

AAAGACTTTA GCAGATTTTC AAGCGGCTCA GAACATCAAC AACAACAACA ACAACAACCG 60

TTTTATAGTC AAGCAGCTCT CAACGCTTTT CTTTCAAGGT CTGTGAAGCC TCGAAATTAT 120

CAGAATTTTC AATCTCCGTC GGCCGATGAT TGATCTCACG TCGGTGAATG ATATGAGTTT 180

GTTTGGTGGT TCTGGTTCAT CTCAGCGTTA CGGTTTACCG GTTCCCAGGT CTCAGACGCA 240

ACAGCAACAA TCGGATTACG GTTTATTTGG TGGGATCCGA ATGGGAATCG GGTCGGGTAT 300

TAATAATTAT CCAACATTAA CCGGCGTTCC GTGTATTGAA CCGGTTCAAA ACCGGGTTCA 360

TGAATCGGAG AACATGTTGA ATAGTTTAAG AGAGCTTGAG AAACAGCTTT TAGATGATGA 420

CGATGAGAGT GGTGGTGATG ATGACGTGTC AGTTATAACA AATTCAAATT CCGATTGGAT 480

TCAAAATCTC GTGACTCCGA ACCCGAACCC GAACCCGGTT TTGTCTTTTT CACCGAGCTC 540

TTCTTCTTCG TCTTCTTCGC CTTCTACAGC TTCGACGACG ACATCGGTAT GTTCTAGGCA 600

AACGGTTATG GAAATCGCGA CGGCGATCGC GGAAGGGAAA ACAGAGATAG CGACGGAGAT 660

TTTGGCGCGT GTTTCTCAAA CGCCTAATCT TGAGAGGAAT TCAGAGGAGA AGCTTGTTGA 720

TTTCATGGTG GCTGCGCTTC GATCGAGGAT AGCTTCTCCA GTGACGGAAT TGTATGGGAA 780

GGAGCATTTA ATCTCGACTC AATTGCTCTA CGAGCTCTCT CCTTGTTTCA AACTCGGTTT 840

CGAGGCCGCG AATCTCGCCA TTCTCGACGC CGCCGATAAC AACGACGGTG GAATGATGAT 900

ACCGCACGTT ATCGATTTCG ATATCGGAGA AGGTGGACAA TACGTTAACC TTCTCCGTAC 960

ATTATCCACG CGCCGGAATG GTAAAAGTCA GAGTCAGAAT TCTCCGGTGG TTAAGATCAC 1020

CGCCGTGGCG AACAACGTTT ACGGATGTTT AGTCGATGAC GGTGGAGAAG AGAGGTTAAA 1080

AGCCGTCGGA GATTTGTTGA GCCAACTCGG TGATCGACTC GGTATCTCCG TAAGTTTCAA 1140 CGTGGTGACG AGTTTACGAC TCGGTGATCT GAATCGTGAA TCTCTCGGGT GTGATCCCGA 1200

CGAGACTTTG GCTGTGAACT TAGCTTTCAA GCTTTATCGT GTTCCCGACG AAAGCGTATG 1260

CACGGAGAAT CCAAGAGACG AACTTCTCCG GCGCGTGAAG GGACTTAAAC CGCGCGTGGT 1320

TACTCTAGTG GAGCAAGAAA TGAATTCGAA TACGGCGCCG TTTTTAGGGA GAGTGAGTGA 1380

GTCATGCGCG TGTTACGGTG CGTTGCTTGA GTCGGTCGAG TCTACGGTTC CTAGTACGAA 1440

TTCCGACCGT GCCAAAGTTG AGGAAGGAAT TGGCCGGAAG CTAGTAAACG CGGTGGCGTG 1500

CGAAGGAATC GATCGTATAG AGCGGTGCGA GGTGTTCGGG AAATGGCGAA TGCGGATGAG 1560

CATGGCTGGG TTTGAGTTAA TGCCATTGAG TGAGAAGATA GCGGAGTCGA TGAAGAGTCG 1620

TGGAAACCGA GTCCACCCGG GCTTTACCGT TAAAGAAGAT AACGGAGGTG TGTGCTTTGG 1680

TTGGATGGGA CGGGCACTCA CTGTCGCATC CGCTTGGCGT TAACTTCACA CACTCTTTTT 1740

TTTCTTCTTA TTATTACCAT ATTATTATTA ATTTTCGAGA TTATTCTGAT ATTATTATCA 1800

TTGTGATTTT CCGTTTCGAA AAGTGTAGGA ATCTTATGTA ACAAAGAAAA AAAAAAGACT 1860

TTTATGTTTT TCTAATAATA AAAGAAAGAG TGATTGGGTT CAAAAAAAAA AAAAAAAAAA 1920

AAAAAAAA 1928 (2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 524 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Asp Leu Thr Ser Val Asn Asp Met Ser Leu Phe Gly Gly Ser Gly Ser

1 5 10 15

Ser Gin Arg Tyr Gly Leu Pro Val Pro Arg Ser Gin Thr Gin Gin Gin 20 25 30

Gin Ser Aβp Tyr Gly Leu Phe Gly Gly He Arg Met Gly He Gly Ser 35 40 45

Gly He Aβn Aβn Tyr Pro Thr Leu Thr Gly Val Pro Cyβ He Glu Pro 50 55 60

Val Gin Asn Arg Val His Glu Ser Glu Aβn Met Leu Aβn Ser Leu Arg 65 70 75 80

Glu Leu Glu Lye Gin Leu Leu Asp Asp Asp Asp Glu Ser Gly Gly Aβp 85 90 95

Asp Asp Val Ser Val He Thr Aβn Ser Aβn Ser Asp Trp He Gin Asn 100 105 110

Leu Val Thr Pro Asn Pro Asn Pro Asn Pro Val Leu Ser Phe Ser Pro 115 120 125 Ser Ser Ser Ser Ser Ser Ser Ser Pro Ser Thr Ala Ser Thr Thr Thr 130 135 140

Ser Val Cyβ Ser Arg Gin Thr Val Met Glu He Ala Thr Ala He Ala 145 150 155 160

Glu Gly Lye Thr Glu He Ala Thr Glu He Leu Ala Arg Val Ser Gin 165 170 175

Thr Pro Aβn Leu Glu Arg Aβn Ser Glu Glu Lye Leu Val Asp Phe Met 180 185 190

Val Ala Ala Leu Arg Ser Arg He Ala Ser Pro Val Thr Glu Leu Tyr 195 200 205

Gly Lys Glu Hie Leu He Ser Thr Gin Leu Leu Tyr Glu Leu Ser Pro 210 215 220

Cyβ Phe Lye Leu Gly Phe Glu Ala Ala Aβn Leu Ala He Leu Aβp Ala 225 230 235 240

Ala Aβp Asn Asn Asp Gly Gly Met Met He Pro His Val He Asp Phe 245 250 255

Asp He Gly Glu Gly Gly Gin Tyr Val Aβn Leu Leu Arg Thr Leu Ser 260 265 270

Thr Arg Arg Asn Gly Lys Ser Gin Ser Gin Asn Ser Pro Val Val Lys 275 280 285

He Thr Ala Val Ala Asn Aβn Val Tyr Gly Cys Leu Val Asp Asp Gly 290 295 300

Gly Glu Glu Arg Leu Lys Ala Val Gly Aβp Leu Leu Ser Gin Leu Gly 305 310 315 320

Asp Arg Leu Gly He Ser Val Ser Phe Asn Val Val Thr Ser Leu Arg 325 330 335

Leu Gly Aβp Leu Asn Arg Glu Ser Leu Gly Cys Asp Pro Asp Glu Thr 340 345 350

Leu Ala Val Asn Leu Ala Phe Lys Leu Tyr Arg Val Pro Asp Glu Ser 355 360 365

Val Cys Thr Glu Asn Pro Arg Asp Glu Leu Leu Arg Arg Val Lys Gly 370 375 380

Leu Lys Pro Arg Val Val Thr Leu Val Glu Gin Glu Met Asn Ser Asn 385 390 395 400

Thr Ala Pro Phe Leu Gly Arg Val Ser Glu Ser Cyβ Ala Cyβ Tyr Gly 405 410 415

Ala Leu Leu Glu Ser Val Glu Ser Thr Val Pro Ser Thr Aβn Ser Asp 420 425 430

Arg Ala Lys Val Glu Glu Gly He Gly Arg Lys Leu Val Aβn Ala Val 435 440 445

Ala Cyβ Glu Gly He Aβp Arg He Glu Arg Cys Glu Val Phe Gly Lys 450 455 460

Trp Arg Met Arg Met Ser Met Ala Gly Phe Glu Leu Met Pro Leu Ser 465 470 475 480

Glu Lys He Ala Glu Ser Met Lys Ser Arg Gly Asn Arg Val His Pro 485 490 495

Gly Phe Thr Val Lys Glu Aβp Aβn Gly Gly Val Cyβ Phe Gly Trp Met 500 505 510

Gly Arg Ala Leu Thr Val Ala Ser Ala Trp Arg Xaa 515 520

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2635 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

TCTTACTCAA GGTTCTTCTT TGTCATCTTG TTGCCGAATC CACAAAGAGG AGAATAAAGA 60

TTCGACCTTT ATTAGATATT AACGACTCTG GATTTTTGGG TTTTTGGAGT TGGATCCACA 120

TGGGTTCTTA TCCGGATGGA TTCCCTGGAT CCATGGACGA GTTGGATTTC AATAAGGACT 180

TTGATTTGCC TCCCTCCTCA AACCAAACCT TAGGTTTAGC TAATGGGTTC TATTTAGATG 240

ACTTAGATTT CTCATCCTTG GATCCTCCAG AGGCATATCC CTCCCAGAAC AACAACAACA 300

ACAACATCAA CAACAAAGCT GTAGCAGGAG ATCTGTTATC ATCTTCATCT GATGACGCTG 360

ATTTCTCTGA TTCTGTTTTG AAGTATATAA GCCAAGTTCT TATGGAAGAG GATATGGAAG 420

AGAAGCCTTG TATGTTTCAT GATGCTTTGG CTCTTCAAGC TGCTGAGAAA TCTCTCTATG 480

AGGCTCTTGG TGAGAAAGAC CCTTCTTCGT CTTCTGCTTC TTCTGTGGAT CATCCTGAGA 540

GATTGGCTAG TCATAGCCCT GACGGTTCTT GTTCAGGTGG TGCTTTTAGT GATTACGCTA 600

GCACCACTAC CACTACTTCC TCTGATTCTC ACTGGAGTGT TGATGGTTTG GAGAATAGAC 660

CTTCTTGGTT ACATACACCT ATGCCGAGTA ATTTTGTTTT CCAGTCTACT TCTAGGTCCA 720

ACAGTGTCAC CGGTGGTGGT GGTGGTGGTA ATAGTGCGGT TTACGGTTCA GGTTTTGGCG 780

ATGATTTGGT TTCGAATATG TTTAAAGATG ATGAATTGGC TATGCAGTTC AAGAAAGGGG 840

TTGAGGAAGC TAGTAAGTTC CTTCCTAAGT CTTCTCAGCT CTTTATTGAT GTGGATAGTT 900

ACATCCCTAT GAATTCTGGT TCCAAGGAAA ATGGTTCTGA GGTTTTTGTT AAGACGGAGA 960

AGAAAGATGA GACAGAGCAT CATCATCATC ATAGCTATGC ACCACCACCC AACAGATTAA 1020

CTGGTAAGAA AAGCCATTGG CGCGACGAAG ATGAAGATTT CGTTGAAGAA AGAAGTAACA 1080

AGCAATCAGC TGTTTATGTT GAGGAAAGCG AGCTTTCTGA AATGTTTGAT AACATGTTCC 1140

TATGTGGCCC TGGGAAACCT GTATGCATTC TTAACCAGAA CTTTCCTACA GAATCCGCTA 1200

AAGTCGTGAC CGCACAGTCA AATGGAGCAA AGATTCGTGG GAAGAAATCA ACTTCTACTA 1260

GTCATAGTAA CGATTCTAAG AAAGAAACTG CTGATTTGAG GACTCTTTTG GTGTTATGTG 1320 CACAAGCTGT ATCAGTGGAT GATCGTAGAA CCGCCAACGT TTAGCTAAGG CAGATACGAG 1380

AGCATTCTTC GCCTCTAGGC AATGGTTCAG AGCGGTTGGC TCATTATTTT GCAAATAGTC 1440

TTGAAGCACG CTTAGCTGGG ACCGGTACAC AGATCTACAC CGCTTTATCT TCGAAGAAAA 1500

CGTCTGCAGC AGACATGTTG AAGGCTTACC AGACATACAT GTCGGTCTGC CCTTTCAAGA 1560

AAGCTGCTAT CATATTTGCT AACCACAGCA TGATGCGTTT CACTGCAAAC GCCAACACGA 1620

TCCACATAAT AGATTTCGGA ATATCTTACG GTTTTCAGTG GCCTGCTCTG ATTCATCGCC 1680

TCTCGCTCAG CAGACCTGGT GGTTCGCCTA AGCTTCGAAT TACCGGTNNN NNNNNNNNNN 1740

NNNNNNNNNN NNNNNNNNNN NNNGAGTTCA GGAGACAGGT CATCGCTTGG CTCGATACTG 1800

TCAGCGACAC AATGTTCCGT TTGAGTACAA CGCAATTGCT CAGAAATGGG GAAACGATCC 1860

AAGTCGAAGA CTTAAAGCTT CGACAAGGAG AGTATGTGGT TGTGAACTCT TTGTTCCGTT 1920

TCAGGAACCT TCTAGATGAG ACCGTTCTGG TAAACAGCCC GAGAGATGCA GTTTTGAAGC 1980

TGATAAGAAA AATAAACCCG AATGTCTTCA TTCCAGCGAT CTTAAGCGGG AATTACAACG 2040

CGCCATTCTT TGTCACGAGG TTCAGAGAAG CGTTGTTTCA TTACTCGGCT GTGTTTGATA 2100

TGTGTGACTC GAAGCTAGCT AGGGAAGACG AGATGAGGCT GATGTATGTG TTTGAGTTTT 2160

ATGGGAGAGA GATTGTGAAT GTTGTGGCTT CTGAAGGAAC AGAGAGAGTG GAGAGCCGAG 2220

AGACATATAA GCAGTGGCAG GCGAGACTGA TCCGAGCCGG ATTTAGACAG CTTCCGCTTG 2280

AGAAGGAACT GATGCAGAAT CTGAAGTTGA AAATCGAAAA CGGGTACGAT AAAAACTTCG 2340

ATGTTGATCA AAACGGTAAC TGGTTACTTC AAGGGTGGAA AGGTAGAATC GTGTATGCTT 2400

CATCTCTATG GGTTCCTTCG TCTTCATAGA TGTTGTTTCT TACGTTCTAA GCGACTGGGA 2460

TTTATGTAGG GCTTTTCTGT TGATAGTCTC TCGCCAACAC GAGTGGATTA AGTTCAGAGT 2520

TAGGGTTCTT GAACACTAGA ATGTTGTTAT ATTATGCTTG TGACATAGCG TGTGTAAGAG 2580

TGTAGCCTAA GAGATATAGT ACTCATTGCA TGATCTTTTG CTATATGTTN CATGT 2635 (2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 809 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Leu Leu Lys Val Leu Leu Cys His Leu Val Ala Glu Ser Thr Lys Arg 1 5 10 15

Arg He Lys He Arg Pro Leu Leu Asp He Asn Asp Ser Gly Phe Leu 20 25 30

Gly Phe Trp Ser Trp He Hie Met Gly Ser Tyr Pro Aβp Gly Phe Pro 35 40 45 Gly Ser Met Asp Glu Leu Asp Phe Aβn Lye Asp Phe Asp Leu Pro Pro 50 55 60

Ser Ser Aβn Gin Thr Leu Gly Leu Ala Aβn Gly Phe Tyr Leu Aβp Aβp 65 70 75 80

Leu Aβp Phe Ser Ser Leu Aβp Pro Pro Glu Ala Tyr Pro Ser Gin Aβn 85 90 95

Asn Aβn Aβn Aβn Aβn He Asn Asn Lye Ala Val Ala Gly Asp Leu Leu 100 105 110

Ser Ser Ser Ser Asp Aβp Ala Aβp Phe Ser Aβp Ser Val Leu Lye Tyr 115 120 125

He Ser Gin Val Leu Met Glu Glu Asp Met Glu Glu Lys Pro Cys Met 130 135 140

Phe His Asp Ala Leu Ala Leu Gin Ala Ala Glu Lys Ser Leu Tyr Glu 145 150 155 160

Ala Leu Gly Glu Lys Asp Pro Ser Ser Ser Ser Ala Ser Ser Val Asp 165 170 175

His Pro Glu Arg Leu Ala Ser His Ser Pro Asp Gly Ser Cys Ser Gly 180 185 190

Gly Ala Phe Ser Asp Tyr Ala Ser Thr Thr Thr Thr Thr Ser Ser Asp 195 200 205

Ser His Trp Ser Val Asp Gly Leu Glu Asn Arg Pro Ser Trp Leu His 210 215 220

Thr Pro Met Pro Ser Asn Phe Val Phe Gin Ser Thr Ser Arg Ser Asn 225 230 235 240

Ser Val Thr Gly Gly Gly Gly Gly Gly Asn Ser Ala Val Tyr Gly Ser 245 250 255

Gly Phe Gly Asp Asp Leu Val Ser Asn Met Phe Lys Asp Asp Glu Leu 260 265 270

Ala Met Gin Phe Lys Lys Gly Val Glu Glu Ala Ser Lys Phe Leu Pro 275 280 285

Lys Ser Ser Gin Leu Phe He Asp Val Asp Ser Tyr He Pro Met Asn 290 295 300

Ser Gly Ser Lys Glu Asn Gly Ser Glu Val Phe Val Lys Thr Glu Lys 305 310 315 320

Lys Asp Glu Thr Glu His His His His Hie Ser Tyr Ala Pro Pro Pro 325 330 335

Asn Arg Leu Thr Gly Lys Lys Ser Hie Trp Arg Asp Glu Asp Glu Asp 340 345 350

Phe Val Glu Glu Arg Ser Asn Lys Gin Ser Ala Val Tyr Val Glu Glu 355 360 365

Ser Glu Leu Ser Glu Met Phe Asp Asn Met Phe Leu Cys Gly Pro Gly 370 375 380

Lys Pro Val Cys He Leu Asn Gin Asn Phe Pro Thr Glu Ser Ala Lys 385 390 395 400

Val Val Thr Ala Gin Ser Asn Gly Ala Lys He Arg Gly Lys Lys Ser 405 410 415

Thr Ser Thr Ser His Ser Asn Aβp Ser Lye Lys Glu Thr Ala Asp Leu 420 425 430

Arg Thr Leu Leu Val Leu Cyβ Ala Gin Ala Val Ser Val Asp Aβp Arg 435 440 445

Arg Thr Ala Aβn Val Xaa Leu Arg Gin He Arg Glu His Ser Ser Pro 450 455 460

Leu Gly Asn Gly Ser Glu Arg Leu Ala His Tyr Phe Ala Asn Ser Leu 465 470 475 480

Glu Ala Arg Leu Ala Gly Thr Gly Thr Gin He Tyr Thr Ala Leu Ser 485 490 495

Ser Lys Lys Thr Ser Ala Ala Aβp Met Leu Lye Ala Tyr Gin Thr Tyr 500 505 510

Met Ser Val Cyβ Pro Phe Lys Lys Ala Ala He He Phe Ala Asn His 515 520 525

Ser Met Met Arg Phe Thr Ala Asn Ala Asn Thr He His He He Asp 530 535 540

Phe Gly He Ser Tyr Gly Phe Gin Trp Pro Ala Leu He His Arg Leu 545 550 555 560

Ser Leu Ser Arg Pro Gly Gly Ser Pro Lye Leu Arg He Thr Gly Xaa 565 570 575

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu Phe Arg Arg Gin 580 585 590

Val He Ala Trp Leu Asp Thr Val Ser Asp Thr Met Phe Arg Leu Ser 595 600 605

Thr Thr Gin Leu Leu Arg Asn Gly Glu Thr He Gin Val Glu Aβp Leu 610 615 620

Lys Leu Arg Gin Gly Glu Tyr Val Val Val Asn Ser Leu Phe Arg Phe 625 630 635 640

Arg Asn Leu Leu Asp Glu Thr Val Leu Val Asn Ser Pro Arg Aβp Ala 645 650 655

Val Leu Lye Leu He Arg Lys He Asn Pro Asn Val Phe He Pro Ala 660 665 670

He Leu Ser Gly Asn Tyr Asn Ala Pro Phe Phe Val Thr Arg Phe Arg 675 680 685

Glu Ala Leu Phe His Tyr Ser Ala Val Phe Asp Met Cys Aβp Ser Lys 690 695 700

Leu Ala Arg Glu Asp Glu Met Arg Leu Met Tyr Val Phe Glu Phe Tyr 705 710 715 720

Gly Arg Glu He Val Asn Val Val Ala Ser Glu Gly Thr Glu Arg Val 725 730 735

Glu Ser Arg Glu Thr Tyr Lys Gin Trp Gin Ala Arg Leu He Arg Ala 740 745 750

Gly Phe Arg Gin Leu Pro Leu Glu Lye Glu Leu Met Gin Asn Leu Lys 755 760 765 Leu Lys He Glu Aβn Gly Tyr Aβp Lye Aβn Phe Aβp Val Asp Gin Asn 770 775 780

Gly Asn Trp Leu Leu Gin Gly Trp Lys Gly Arg He Val Tyr Ala Ser 785 790 795 800

Ser Leu Trp Val Pro Ser Ser Ser Xaa

805

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: βingle

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Gin Glu Ala Asp His Asn Lys Thr Gly Phe Leu Asp Arg Phe Thr Glu 1 5 10 15

Ala Leu Phe Tyr Tyr Ser Ala Val Phe Asp Ser Leu Asp Ala Ala Asn 20 25 30

Aβn Asn Asn Asn Asn Asn Asn Gin Arg Met Glu Ala Glu Tyr Leu Gin 35 40 45

Arg Glu He Cys Asp He Val Cys Gly Glu Gly Ala Ala Arg Xaa Glu 50 55 60

Arg His Glu Pro Leu Ser Arg Trp Arg Asp Arg Leu Thr Arg Ala Gly 65 70 75 80

Leu Ser Ala Val Pro Leu Gly Ser Asn Ala 85 90

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 199 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Daucus carota

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

TCTGCAGACA ATTTTNAGGA GGCCAATACC ATGCTATTGG AAATTTCAGA ACTGTCCACA 60

CCTNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNGTACTTC TCAGAGGNAA TGTCGGNNAG 120

ATTAGTTAGC TCCTGCTTAG GAATCTATGC TTCTCTTCCN GCAACAGTGG TGCCTCCTCA 180

TGGTCAGAAA GTGGCCTCA 199 (2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 66 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Daucus carota

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Ser Ala Aβp Aβn Phe Xaa Glu Ala Aβn Thr Met Leu Leu Glu He Ser 1 5 10 15

Glu Leu Ser Thr Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr 20 25 30

Phe Ser Glu Xaa Met Ser Xaa Arg Leu Val Ser Ser Cyβ Leu Gly He

35 40 45

Tyr Ala Ser Leu Pro Ala Thr Val Val Pro Pro His Gly Gin Lys Val 50 55 60

Ala Ser 65

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 321 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(Vi) ORIGINAL SOURCE:

(A) ORGANISM: Glycine max

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

TCAACTGAGA ATCTAGAAGA TGCCAACAAG ATGCTTCTGG AGATTTCTCA GTTATCAACA 60

CCGTTCNNCA CTTCAGCACA GCGTGTGGCA GCATATTTCT CAGAAGCCAT ATCAGCAAGG 120

TTGGTGAGTT CATGTCTAGG GATATACGCA ACTTTGCCAC ACACACACCA AAGCCACAAG 180

GTAGCTTCAG CTTTTCAAGT GTTCAATGGT ATTAGTCCTT TAGTGGAGTT CTCACACTTC 240

ACAGCAAACC AAGCAATTCA AGAAGCCTTC GAAAGAGAAG AGAGGGTGCA CATCATAGAT 300

CTTGATATAA TGCAAGGGTT G 321 (2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 107 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: βingle (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Glycine max

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Ser Thr Glu Aβn Leu Glu Aβp Ala Aβn Lye Met Leu Leu Glu He Ser 1 5 10 15

Gin Leu Ser Thr Pro Phe Xaa Thr Ser Ala Gin Arg Val Ala Ala Tyr 20 25 30

Phe Ser Glu Ala He Ser Ala Arg Leu Val Ser Ser Cyβ Leu Gly He 35 40 45

Tyr Ala Thr Leu Pro Hie Thr His Gin Ser His Lye Val Ala Ser Ala 50 55 60

Phe Gin Val Phe Asn Gly He Ser Pro Leu Val Glu Phe Ser His Phe 65 70 75 80

Thr Ala Asn Gin Ala He Gin Glu Ala Phe Glu Arg Glu Glu Arg Val 85 90 95

His He He Asp Leu Asp He Met Gin Gly Leu 100 105

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Picea

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

TCTGCAGACA ACTTTGAAGA AGCCAATACA ATACTGCCTC AGATCACAGA ACTCTCCACC 60

CCCTATNGCA ACTCGGTGCA ACGAGTGGCT GCCTATNNNN NNNNNNNNNN NNNNNNNNNN 120

NNNNNNNNNN NNTGCATAGG AATGTATTCT CCTCTCCCTC CTATTCACAT GTCCCAGAGC 180

CAGAAAATTG TGAAT 195 (2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 65 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE:

(A) ORGANISM: Picea

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Ser Ala Asp Asn Phe Glu Glu Ala Asn Thr He Leu Pro Gin He Thr 1 5 10 15

Glu Leu Ser Thr Pro Tyr Xaa Aβn Ser Val Gin Arg Val Ala Ala Tyr 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys He Gly Met 35 40 45

Tyr Ser Pro Leu Pro Pro He Hie Met Ser Gin Ser Gin Lys He Val 50 55 60

Asn 65

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2151 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GATATCAGCA TCATCAATTT TAAATGTAAG TTGGCAAAAG ATCATGAGGG TTCTCATAGT 60

AATTTGGCCA CAAGGTATGA CACTGTCTCA ATTGAGCAAT CTAGTAGAGA AACTGATCCA 120

TCATATATTG CTCATATTGA AAGTGAAAAA GATATGCTCA AGAACCTAGT AGAGAAGCTA 180

AAAATTGAAA AATCTAGCTC TACTAGAAAA ATATGATAGG TTGCCTGTTT CTCATGAAAA 240

TTTATTAGAT AATCATATCA TGGCTAGATG TCGCTCATGA GGTTGTTCTT GCTAGTTTAG 300

ATTCCTGTGG GCATTCATCT CTTTTAGATG CACTAACATG ATAGGAAGTT TCTAATCTGG 360

TGCTTCACAA TTCTGGTGAT TCATGCTTCC TTCATTGCAA TTGATATTGA TGCTTGATTC 420

ATGCTTCAGT CACTTTGTGC GTTTAATTGG TATTGTATGT ATCACTAGAT TGTAGGGTGT 480

CTGCAACTAG TGTTTCACCA TGTGGTTTTT TAGTATCATT CGTATTAGTT TCTAACTTTC 540

TATTGATATA TTAAAGTGAT AACTAGTTTT AGAAATATTC TCTTGTGCCA TTAATGCTAC 600

AACTTGTTTT TAGCGTGTAC GTTAGCATTA TAATATTTCC TTATTATGAA AGCGGAAGAG 660

AAACGCGCCC AACCAGAGCA TCCACGTCGT CTCATTTCAC CTTCATCGTT GGATCATAGA 720

TGAGCGGTCC ACGGTGAACT CCGTTTGCCT GCAAAACCAC GTCCTCTACG CGCTGTTAAG 780

TAGCTTCTAG AAACATCACG ATGTGTCCCG TCCATTCCTT TAGGAGGAGC CGGATCCGGC 840

GCCGCAGTCG CCCAAGGTCC CGACCGCCGC GGCCTCGGCC GCCGCCGCCA AGGAGCGGAA 900 GGAGGTGCAG CGGCGGAAGC AGCGCGACGA GGAGGGCCTC CACCTGCTGA GTGCTGACGC 960

TGCTGCTGCA GTGCGCGGAG GCCGTGAACG CGGACAACCT CGACGACGCG CACCAGACGC 1020

TGCTGGAGAT CGCGGAGCTG GCCACGCCGT TCGGCACCTC GACCCAGCGC GTGGCCGCCT 1080

ACTTCGCGGA GGCCATGTCG GCGCGCGTCG TCAGCTCCTG CCTAGGCCTG TACGCGCCGC 1140

TGCCGCCGGG CTCCCCCGCC GCGGCGCGCC TCCACGGCCG CGTGGCCGCC GCGTTCCAGG 1200

TGTTCAACGG CATCAGCCCC TTCGTCAAGT TCTCGCACTT CACCGCCAAC CAGGCCATCC 1260

AGGAGGCGTT CGAGCGGGAG GAGCGTGTGC ACATCATCGA CCTCGACATC ATGCAGGGGC 1320

TGCAGTGGCC GGGCCTCTTC CACATCCTTG TCTCCCGCCC CGGCGGCCCG CCCAGGGTCA 1380

GGCTCACCGG CCTGGGGGCG TCCATGGACG CGCTCGAGGC GACGGGGAAG CGCCTCTCCG 1440

ACTTCGCCGA CACGCTCGGC CTGCCCTTCG AGTTCTGCGC CGTCGCCGAG AAGGCCGGCA 1500

ACGTTGACCC GCAGAAGCTG GGCGTCACGC GGCGGGAGGC CGTCGCCGTC CACTGGCCGC 1560

ACCACTCGCT TTACGACGTC ATCGGCTCCG ACTCCAACAC GCTCTGGCTC ATCCAAAGGT 1620

CCTCCATTTT CCTTCTCTGC CTTTCTTCCA TGTCAAATCT TGATGCAATC ATGACCACTT 1680

TTCAGCTGCT GACATTGGAT AATGTGAGCT TTACGGCAAG CATCAAGTCG TGGTAGTACA 1740

TCCATTACAG CTATTTCTAA AATATTCTTC GGAGGTTTCC TGCTCATAGT AAAAAAAAAT 1800

CGCGTTTTGA AGCTCAAAAG GCGATTTCTT CCGAGGTTTG CTGTTGAGCG CTATTTTGGA 1860

AACCCCATTT TCTCAATTGA TTTTTATTTT TTAAAGAAAA ATTAGTTCAT TTTTCTCTTG 1920

TGAAATGGAG TCCCAAACTA ACCCTAATAT TAAAAAAAAC GCGCTTTGGA GCTCAAAACG 1980

CTCGTTGTTA TGACCAACCA GCTTTATAGG TTTAAAAAGG TTGAATCTTG ACAATGCTTT 2040

TGAAAAGGTT GAATCTTGAC AATGCTTTTG AGATGATACT GTAGTGTAGT CTGTAGTGGA 2100

GCATCCTCCA TGGTCTTTGG TGATCGAGAA TTCCTGCAGC CCGGGGGATC C 2151 (2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 716 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Tyr Gin His His Gin Phe Xaa Met Xaa Val Gly Lys Arg Ser Xaa Gly

1 5 10 15

Phe Ser Xaa Xaa Phe Gly His Lye Val Xaa His Cys Leu Asn Xaa Ala 20 25 30

He Xaa Xaa Arg Asn Xaa Ser He He Tyr Cyβ Ser Tyr Xaa Lye Xaa 35 40 45

Lye Arg Tyr Ala Gin Glu Pro Ser Arg Glu Ala Lys Asn Xaa Lys He 50 55 60

Xaa Leu Tyr Xaa Lys Aβn Met He Gly Cyβ Leu Phe Leu Met Lys He 65 70 75 80

Tyr Xaa He He He Ser Trp Leu Aβp Val Ala His Glu Val Val Leu 85 90 95

Ala Ser Leu Aβp Ser Cyβ Gly His Ser Ser Leu Leu Aβp Ala Leu Thr 100 105 110

Xaa Xaa Glu Val Ser Aβn Leu Val Leu Hie Asn Ser Gly Asp Ser Cys 115 120 125

Phe Leu Hie Cyβ Asn Xaa Tyr Xaa Cyβ Leu He His Ala Ser Val Thr 130 135 140

Leu Cys Val Xaa Leu Val Leu Tyr Val Ser Leu Asp Cys Arg Val Ser 145 150 155 160

Ala Thr Ser Val Ser Pro Cyβ Gly Phe Leu Val Ser Phe Val Leu Val 165 170 175

Ser Asn Phe Leu Leu He Tyr Xaa Ser Asp Asn Xaa Phe Xaa Lys Tyr 180 185 190

Ser Leu Val Pro Leu Met Leu Gin Leu Val Phe Ser Val Tyr Val Ser 195 200 205

He He He Phe Pro Tyr Tyr Glu Ser Gly Arg Glu Thr Arg Pro Thr 210 215 220

Arg Ala Ser Thr Ser Ser His Phe Thr Phe He Val Gly Ser Xaa Met 225 230 235 240

Ser Gly Pro Arg Xaa Thr Pro Phe Ala Cys Lys Thr Thr Ser Ser Thr 245 250 255

Arg Cys Xaa Val Ala Ser Arg Aβn He Thr Met Cys Pro Val His Ser 260 265 270

Phe Arg Arg Ser Arg He Arg Arg Arg Ser Arg Pro Arg Ser Arg Pro 275 280 285

Pro Arg Pro Arg Pro Pro Pro Pro Arg Ser Gly Arg Arg Cyβ Ser Gly 290 295 300

Gly Ser Ser Ala Thr Arg Arg Ala Ser Thr Cys Xaa Val Leu Thr Leu 305 310 315 320

Leu Leu Gin Cyβ Ala Glu Ala Val Aβn Ala Asp Asn Leu Asp Asp Ala 325 330 335

His Gin Thr Leu Leu Glu He Ala Glu Leu Ala Thr Pro Phe Gly Thr 340 345 350

Ser Thr Gin Arg Val Ala Ala Tyr Phe Ala Glu Ala Met Ser Ala Arg 355 360 365

Val Val Ser Ser Cys Leu Gly Leu Tyr Ala Pro Leu Pro Pro Gly Ser 370 375 380

Pro Ala Ala Ala Arg Leu His Gly Arg Val Ala Ala Ala Phe Gin Val 385 390 395 400

Phe Aβn Gly He Ser Pro Phe Val Lys Phe Ser His Phe Thr Ala Aβn 405 410 415 Gin Ala He Gin Glu Ala Phe Glu Arg Glu Glu Arg Val His He He 420 425 430

Asp Leu Asp He Met Gin Gly Leu Gin Trp Pro Gly Leu Phe Hie He 435 440 445

Leu Val Ser Arg Pro Gly Gly Pro Pro Arg Val Arg Leu Thr Gly Leu 450 455 460

Gly Ala Ser Met Asp Ala Leu Glu Ala Thr Gly Lys Arg Leu Ser Asp 465 470 475 480

Phe Ala Asp Thr Leu Gly Leu Pro Phe Glu Phe Cyβ Ala Val Ala Glu 485 490 495

Lys Ala Gly Aβn Val Aβp Pro Gin Lye Leu Gly Val Thr Arg Arg Glu 500 505 510

Ala Val Ala Val His Trp Pro His His Ser Leu Tyr Aβp Val He Gly 515 520 525

Ser Aβp Ser Asn Thr Leu Trp Leu He Gin Arg Ser Ser He Phe Leu 530 535 540

Leu Cyβ Leu Ser Ser Met Ser Aβn Leu Aβp Ala He Met Thr Thr Phe 545 550 555 560

Gin Leu Leu Thr Leu Aβp Aβn Val Ser Phe Thr Ala Ser He Lye Ser 565 570 575

Trp Xaa Tyr He His Tyr Ser Tyr Phe Xaa Asn He Leu Arg Arg Phe 580 585 590

Pro Ala His Ser Lys Lys Lys Ser Arg Phe Glu Ala Gin Lys Ala He 595 600 605

Ser Ser Glu Val Cys Cys Xaa Ala Leu Phe Trp Lye Pro Hie Phe Leu 610 615 620

Asn Xaa Phe Leu Phe Phe Lys Glu Lye Leu Val Hie Phe Ser Leu Val 625 630 635 640

Lye Trp Ser Pro Lys Leu Thr Leu He Leu Lys Lys Thr Arg Phe Gly 645 650 655

Ala Gin Asn Ala Arg Cys Tyr Aβp Gin Pro Ala Leu Xaa Val Xaa Lys 660 665 670

Gly Xaa He Leu Thr Met Leu Leu Lys Arg Leu Asn Leu Asp Asn Ala 675 680 685

Phe Glu Met He Leu Xaa Cys Ser Leu Xaa Trp Ser He Leu His Gly 690 695 700

Leu Trp Xaa Ser Arg He Pro Ala Ala Arg Gly He 705 710 715

Claims

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a SCARECROW protein containing an amino acid sequence substantially similar to the sequence of MOTIF III (VHIID) of Arabidopsis SCR protein shown in FIGS. 13A-F.

2. An isolated nucleic acid molecule comprising a nucleotide sequence that (a) encodes a scarecrow protein having the amino acid sequence shown of any one of SEQ ID NO:2, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID N0:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67; or (b) is the complement of the nucleotide sequence of (a) .

3. An isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes to the nucleic acid of Claim 2 and encodes a naturally occurring SCR gene product.

4. A nucleic acid molecule comprising a nucleotide sequence that (a) encodes a SCJ? protein lacking one to four of the following motifs delineated in FIGS. 13A-F: MOTIF I, MOTIF II, MOTIF III, MOTIF IV, MOTIF V, or MOTIF VI; or (b) is the complement of the nucleotide sequence of (a) .

5. A nucleic acid molecule comprising a nucleotide sequence that (a) encodes a polypeptide corresponding to MOTIF I, MOTIF II, MOTIF IV, MOTIF V or MOTIF VI of the SCARECROW protein delineated in FIGS. 13A-F; or (b) is the complement of the nucleotide sequence of (a) .

6. The isolated nucleic acid molecule of Claim 1 comprising the nucleic acid sequence of any one of SEQ ID NO:l, SEQ ID N0:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 or SEQ ID NO:66. 5

7. A DNA vector containing the nucleotide sequence of Claim

I, 2, 3, 4, 5, or 6.

0 8. An expression vector containing the nucleotide sequence of Claim 1, 2, 3, A , 5, or 6 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the nucleotide sequence in a host cell. 5

9. A genetically engineered host cell containing the nucleotide sequence of Claim 1, 2, 3, 4, 5, or 6.

10. A genetically engineered host cell containing the 0 nucleotide sequence of Claim 1, 2, 3, 4, 5, or 6 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the nucleotide sequence in a host cell. 5

II, An isolated SCARECROW protein.

12. The protein of Claim 11 having the amino acid sequence shown in FIG. 5E (SEQ ID NO:2).

30

13. A SCARECROW protein lacking one to four of the following motifs delineated in FIGS. 13A-F: MOTIF I, MOTIF II, MOTIF

III, MOTIF VI, MOTIF V, or MOTIF VI.

35 14. A polypeptide corresponding to MOTIF I, MOTIF II, MOTIF

IV, MOTIF V or MOTIF VI of the SCARECROW protein as delineated in FIGS. 13A-F.

15. An antibody that immunospecifically binds the protein or polypeptide of Claim 11, 12, 13 or 14.

16. An anti-idiotypic antibody that mimics an epitope of the SCARECROW protein.

17. A plant engineered to overexpress or underexpress the SCARECROW protein, so that cell division is modified and root development is altered

18. A plant engineered to overexpress the SCARECROW protein, so that cell division is increased in roots, resulting in thicker root development.

19. A transgenic plant containing a transgene having the nucleotide sequence of Claim 1, 2, 3, 4, 5, or 6.

20. A transgenic plant containing a transgene having the nucleotide sequence of Claim 1, 2, 3, 4, 5, or 6 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the nucleotide sequence in a transgenic plant cell.

21. The transgenic plant of Claim 19, in which the transgene encodes an antisense molecule that suppresses expression of endogenous SCARECROW gene product, so that cell division is decreased in roots, resulting in thinner root development.

22. A genetically engineered plant in which the endogenous SCARECROW gene is disrupted or inactivated so that cell division is decreased in roots, resulting in thinner root development.

23. A transgenic plant containing a transgene encoding a gene of interest operatively associated with a SCARECROW promoter, so that the gene of interest is expressed in roots.

24. The transgenic plant of Claim 23, in which the gene of interest encodes a gene product that confers herbicide, salt, pathogen, or insect resistance.

25. A transgenic plant containing a transgene encoding a gene of interest operatively associated with a SCARECROW promoter, so that the gene of interest is expressed in stems.

26. The transgenic plant of Claim 25, in which the gene of interest encodes a gene product that increases starch, lignin or cellulose biosynthesis.

27. A plant engineered to overexpress or underexpress the SCARECROW protein so that the stem or hypocotyl gravitropism is altered.

28. The plant of Claim 28, which is less susceptible to lodging than a wild-type plant.